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Abstract
Chemoselective reactions enable the transformation of distinct functional groups in the
presence of others. As such, these transformations are a powerful class of chemical re-
actions avoiding cumbersome protecting group manipulations in organic molecules and
importantly, facilitate the modification of complex biomolecules at predefined sites, yiel-
ding homogenous products. The latter is essential for a wide range of applications in life
sciences, in particular for the investigation of protein function and for the development
of biopharmaceuticals.
In this thesis, a chemoselective transformation for the synthesis of unsaturated vinyl-
and ethynylphosphonothiolates was developed. We were able to show that these types of
compounds are efficiently synthesised from unsaturated phosphonites and electrophilic
disulfides in the presence of other functional groups. A key step in the development of
this chemoselective transformation was to prevent formation of an unwanted addition
product, which resulted from the nucleophilic attack of a thiolate leaving group to the
desired unsaturated phosphonothiolates. Efficient suppression of this side reaction was
achieved when the disulfide-phosphonite reaction was performed under acidic conditions.
We demonstrated the scope and chemoselectivity of the disulfide-phosphonite reaction
for the synthesis of a number of small molecule derivatives as well as for the installation of
vinylphosphonothiolates on unprotected peptides and small proteins, with ubiquitin as
the most complex substrate. Furthermore, we showed that vinyl- and ethynylphospho-
nothiolates react chemoselectively with thiols and in particular with cysteine residues
on proteins to form thiol-phosphonothiolate conjugates. Comparing the reactivity of
vinyl- and ethynylphosphonothiolates in thiol additions with glutathione, we found that
ethynyl-derivatives are significantly more reactive with a bimolecular rate constant of
1.32M-1s-1 at pH 7.4, as opposed to 2.0mM-1s-1 for the glutathione addition to the
respective vinyl-derivatives. However, the enhanced reactivity of ethynylphosphonoth-
iolates is compromised by the stability of these reagents and their thiol-conjugates.
The versatility of the herein developed method was demonstrated in three applications.
First, site-selectively ubiquitinated protein conjugates were generated by employing the
vinylphosphonothiolate-ubiquitin probe for conjugation with proteins carrying a single
cysteine. In particular, this strategy was used to generate a non-hydrolysable diubiqui-
tin as well as a ubiquitin-α-Synuclein conjugate. This study emphasises the conceptual
value of the disulfide-phosphonite reaction, as it enables the chemoselective installation
of electrophilic groups onto proteins, inducing thereby reactivity towards nucleophilic
additions and consequently allowing protein-protein conjugations via canonical nucle-
ophilic amino acids.
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In a second application, unsaturated phosphonothiolates were evaluated as cysteine-
selective linkers for the generation of antibody-drug conjugates (ADCs). Using
ethynylphosphonothiolates, the efficient generation of brentuximab-MMAE ADCs
with high average drug to antibody ratios (DARs) was possible, however these
ADCs were not stable at neutral pH. On the other hand, using the less reactive
vinylphosphonothiolate derivatives, the generation of ADCs with decent DARs was
more challenging but the resulting ADCs proved to be more stable. In fact, the ADCs
generated with vinylphosphonothiolates appeared to be more stable in rat serum than
the maleimide-linked, clinically approved ADC Adcetris R©.
In a last application, vinylphosphonothiolates were used as linkers to equip distinct
proteins with photo-reactive crosslinkers to study dynamic protein-protein interactions.
To this end, specific antibodies against molecular chaperones as well as deubiquitinat-
ing enzymes were chosen as model substrates. While the attempt to identify specific
interaction partners of chaperones was not fruitful, promising preliminary results for
the covalent crosslinking between DUB-photocrosslinker conjugates and ubiquitin
substrates were obtained.
Taken together, the herein developed method enables the chemoselective transforma-
tion of electrophilic disulfides into electrophilic vinyl- and ethynylphosphonothiolates,
thereby inducing reactivity for subsequent cysteine-selective thiol additions. This
formal conjugation of two complex thiol-containing molecules forms a promising
platform for the generation of homogenous peptide and protein conjugates without the
need for non-canonical amino acids.
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Zusammenfassung
Chemoselektive Reaktionen ermöglichen die selektive Umwandlung einer bestimmten
funktionellen Gruppe innerhalb eines Moleküls in Gegenwart anderer funktioneller
Gruppen und sind somit eine wichtige Klasse von Reaktionen für die Herstellung von
homogen modifizierten Biomolekülen. Letztere sind für eine Reihe von Anwendungen
in den Biowissenschaften wichtig, insbesondere für die Untersuchung von Proteinfunk-
tionen, sowie für die Herstellung von Biopharmazeutika.
In der vorliegenden Arbeit wurde eine chemoselektive Synthese für die Herstellung von
ungesättigten Vinyl- und Ethynylphosphonothiolaten entwickelt. Es konnte gezeigt wer-
den, dass diese Verbindungen effizient aus ungesättigten Phosphoniten und elektrophilen
Disulfiden in Gegenwart anderer funktioneller Gruppen synthetisiert werden können.
Ein wichtiger Schritt dabei war die Unterdrückung eines Nebenprodukts, welches aus
der Addition einer Thiolat-Abgangsgruppe an die ungesättigten Phosphonothiolate
resultierte. Die effiziente Unterdrückung dieser Nebenreaktion konnte erreicht werden,
indem die Disulfid-Phosphonit-Reaktion unter sauren Bedingungen durchgeführt
wurde. Die hohe Chemoselektivität der Disulfid-Phosphonit-Reaktion wurde anhand
der Einführung von Vinylphosphonothiolaten auf ungeschützten Modellpeptiden und
dem Protein Ubiquitin demonstriert. Ungesättigte Phosphonothiolate reagieren in
einer zweiten, ebenfalls chemoselektiven Reaktion mit Thiolen und insbesondere mit
Cysteinen von Proteinen unter Bildung von Thiol-Phosphonothiolat-Konjugaten. Beim
Vergleich von Vinyl- und Ethynylphosphonothiolaten hinsichtlich ihrer Reaktivität
mit Thiolen wurde festgestellt, dass Ethynylderivate Geschwindigkeitskonstanten
zweiter Ordnung im niedrigen M-1s-1 aufweisen und somit signifikant reaktiver sind
als die Vinylphosphonothiolate mit Geschwindigkeitskonstanten im mM-1s-1 Bereich.
Der hohen Reaktivität von Ethynylphosphonothiolaten steht jedoch die suboptimale
Stabilität dieser Reagenzien an sich als auch ihrer Thiolkonjugate gegenüber.
Die Vielseitigkeit des hier entwickelten Verfahrens wurde in drei Anwendungen de-
monstriert. Ausgehend von einem elektrophilen Vinylphoshonothiolat-modifizierten
Ubiquitin gelang es uns, homogene Ubiquitin-Protein-Konjugate zu erzeugen, insbeson-
dere ein nicht hydrolysierbares Diubiqutin-Konjugat und ein Ubiquitin-α–Synuclein-
Konjugat. In einer zweiten Anwendung wurden ungesättigte Phosphonothiolate als
Linker in Antikörper-Wirkstoff-Konjugaten (ADCs) untersucht. Unter Verwendung von
Ethynylphosphonothiolaten konnten Brentuximab-MMAE-ADCs mit hohen Antikörper
zu Wirkstoff Verhältnissen (DARs) hergestellt werden, doch diese ADCs waren selbst
unter neutralen Bedingungen nicht stabil. Im Gegenzug dazu war es schwieriger, ADCs
mit hohen DARs herzustellen, wenn die weniger reaktiven Vinylphosphonothiolat-
Derivate verwendet wurden. Diese ADCs erwiesen sich jedoch als deutlich stabiler
und wiesen sogar eine höhere Serumstabilität auf als das klinisch zugelassene ADC
Adcetris R©.
Schliesslich wurden Vinylphosphonothiolate als Linker verwendet, um sowohl spezi-
fische Antikörper gegen molekulare Chaperone als auch Deubiquitinasen (DUB) mit
photoreaktiven Crosslinkern auszustatten, um mit diesen Konjugaten dynamische
Protein-Protein Interaktionen zu untersuchen. Versuche, mit Hilfe von Antikörper-
Photocrosslinker Konjugaten spezifische Interaktionspartner von Chaperonen zu
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identifizieren, waren nicht erfolgreich. Hingegen konnten vielversprechende Ergebnis-
se für die kovalente Verknüpfung zwischen DUB-Photocrosslinker-Konjugaten und
Ubiquitin-Substraten erzielt werden.
Insgesamt ermöglicht das hier entwickelte Verfahren die chemoselektive Umwandlung
von elektrophilen Disulfiden in elektrophile Vinyl- und Ethynylphosphonothiolate,
wodurch Reaktivität für Cystein-selektive Thioladditionen induziert wird. Wir glauben,
dass diese formale Konjugation von zwei komplexen thiolhaltigen Molekülen beruhend
auf kanonischen Aminosäuren Anwendung finden wird, um homogen modifizierte
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“The need still exists for additional orthogonal functional groups and
improvements in the kinetics and selectivities of the reactions
already at hand. Mining of the periodic table and classic organic
literature are two avenues that are likely to bear interesting fruit.
Group 15 has been particularly lucrative in terms of bioorthogonal
reactions, and perhaps the larger elements within this group,
bismuth and antimony, could be similarly beneficial. In addition,
novel combinations of phosphorus and sulfur have yet to be
explored.”
Ellen M. Sletten and Carolyn R. Bertozzi, Bioorthogonal Chemistry: Fishing for
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1 Introduction
1.1 Motivation: The need for protein modification methods
Proteins are among the most abundant biomolecules within a cell and are involved in
all cellular processes ranging from the maintenance of metabolism to the control of sig-
nalling pathways, allowing differentiation and cell-cell communication. Gaining insight
into these processes, both in health and disease, is tightly connected to the under-
standing of the function and interactions of the involved proteins on a molecular level.
Consequently, the investigation of proteins is a major goal in natural life sciences. To
this end, modifying proteins with functional moieties provides a powerful tool to study
and manipulate their function (Fig. 1) [1, 2, 3, 4, 5]. For instance, cellular localisa-
tion of a protein can be visualised through fluorescent labelling. Alternatively, proteins
can be equipped with reactive crosslinkers to study protein-protein interactions [6] or
with cell-penetrating peptides (CPPs) to facilitate intracellular delivery [7]. Further-
more, proteins can be converted into therapeutic agents by attaching pharmacophores
as exemplified with antibody-drug conjugates (ADCs) [8]. Moreover, the installation of
post-translational modifications (PTMs) allows to study their effects on protein func-
tion.
Given the molecular complexity of proteins, the selective modification with functional
handles is a challenging endeavour. Despite tremendous advances in the last years and



























X, Y: reactive counterparts
protein of interest (POI)
fluorophores
visualization
Fig. 1 The controlled modification of proteins with functional handles can be achieved by means
of selective conjugation strategies. The resulting protein conjugates find application in
basic research, diagnostics and therapy.
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1.2 Protein modification strategies
Tackling the challenge of modifying proteins in a selective manner, a number of strategies
have been developed as depicted in Fig. 2.
Addressing peptide tags
= natural amino acid residue
= unnatural amino acid residue
= peptide tag
= fusion protein








Fig. 2 Strategies for the selective modification of proteins with functional handles.
1.2.1 Protein modification via fusion proteins
For the selective modification of proteins within complex environments such as living
cells, the use of genetically fused proteins has proven a particularly powerful strategy.
For example, fluorescent fusion proteins have become indispensable tools to study the
localisation and interactions of proteins inside living cells by fluorescent microscopy or
FRET-based assays [9]. The best known example of a fluorescent protein is the green
fluorescent protein (GFP) from the jellyfish Aequorea victoria [10]. Genetic engineering
of the amino acids that contribute to its chromophore, along with the discovery of new
fluorescent protein scaffolds has produced an array of available fluorescent proteins with
different colours [9]. Fluorescently labelled proteins can be generated by genetically fus-
ing the gene of the protein of interest and the fluorescent protein (Fig. 3A). To minimise
interference with protein function, the modifier protein is usually fused at either the
N- or the C-terminus. Nevertheless, since GFP and its derivatives are relatively large
proteins (27 kDa), their attachment can still cause perturbations of the structure and
function of the protein of interest.
In a different strategy, so-called self-labelling proteins are fused to the protein of interest
and can subsequently be covalently modified with functional handles equipped with spe-
cific recognition substrates (Fig. 3B) [11]. Well-known examples following this strategy
include the self-labelling enzymes SNAP- and CLIP-tag, which can be selectively mod-
ified at their active site cysteine with nucleobase-derivatives carrying fluorophores or
other reporter compounds [12, 13, 14]. Another example is the HaloTag, an engineered
variant of the bacterial enzyme haloalkane dehalogenase, which recognises functionalised
alkyl halides as substrates and thereby gets labelled at a nucleophilic aspartate residue
[15, 16]. All of these tags are well suited for the specific labelling of proteins within
2
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cells. Given their orthogonality, they can also be used in combination, allowing for the
versatile multi-labelling of proteins within the same system [13]. Nevertheless, also these












































Fig. 3 Selective protein labelling via fusion proteins. A) The fusion protein itself can be the
reporter tag, such as the green fluorescent proteins (GFP). B) The self-labelling pro-
teins SNAP-, CLIP- and Halo-tag recognise O-6-benzylguanine, O-6-benzylcytosine or
1-chloro-hexyl derivatives, respectively, thereby getting covalently modified at either cys-
teine residues (SNAP- and CLIP-tag) or at a nucleophilic aspartate residue (Halo-tag).
1.2.2 Protein modification via peptide tags
An attractive alternative to the large protein tags described above are short peptide-
based recognition tags [17]. These tags, which are only a few amino acids long, are
genetically fused to a protein of interest and can for instance recognise and bind a
small-molecule probe (Fig. 4). One of the shortest peptide-tag employed for this la-
belling strategy is a tetra-cysteine motif (Fig. 4A). As shown by Tsien and co-workers in
1998, this tag exploits the high affinity of the CCxxCC sequence (xx are most commonly
the amino acids Gly, Pro) towards organobiarsenical compounds [18]. The latter can be
derivatised with fluorescent dyes, such as fluorescein and other dyes with the xanthene
backbone [19, 20, 21]. The resulting masked dye-arsenical-helix-binders enable the intra-
cellular labelling of proteins containing the CCxxCC motif. Upon thiol-exchange with
the cysteines of the peptide tag, the fluorescence drastically increases. Drawbacks of
this labelling method are the cytotoxicity of arsenic-containing compounds as well as the
need for extensive washing steps to remove hydrophobic dyes that are non-specifically
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bound to membranes or off-target cellular proteins. Furthermore, micromolar concen-
trations of 1,2-ethanediol have to be added to the cells in order to reduce non-specific




























































Fig. 4 Examples for methods making use of peptide tags to enable site-selective protein la-
belling. A) Biarsenical-functionalised fluorescent dyes react selectively with a tetra-
cysteine motif. B) The DBCO-tag increases the rate of thiol-yne reactions. C) The π-
clamp tag promotes nucleophilic aromatic substitution of perfluoroaromatic compounds
with cysteine.
A further limitation of this method can be that the introduced tetra-cysteine tag gives
rise to the formation of incorrect disulfide bonds within the protein of interest. Some
of these problems were overcome by the development of the tetraserine motif SSPGSS,
which can be labelled with bisboronic acid dyes instead [22]. Nevertheless, a limitation to
this strategy is the relative high abundance of the SSPGSS sequence in human proteins,
giving rise to background labelling.
Pentelute and co-workers developed two other short peptide sequences, which can be
used for site-selective protein labelling. The DBCO-tag, a seven residue peptide tag,
increases the rate of the thiol-yne reaction between a cysteine in the tag sequence and
cyclooctyne derivatives more than 200-fold, thereby enabling regioselective labelling of
the tag in the presence of other cysteines (Fig. 4B) [23]. Similarly, they found that
the nucleophilic aromatic substitution between cysteine residues and perfluoroaromatic
molecules can be promoted efficiently in aqueous solutions by the π-clamp, a four-residue
peptide sequence (Fig. 4C) [24].
In order to further improve the binding affinity of a peptide tag for a given labelling
agent, peptide-binding peptide tags have been employed [17]. High-affinity peptide-
pairs characterised by nM binding affinities are for instance found in coiled-coil motifs
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[25]. In 2008, Matsuzaki and co-workers have used such a high-affinity coiled-coil
peptide-pair for the labelling of cell surface receptors of living cells [26]. Those systems
have been refined further to drive covalent bond formation between a protein and
a labelling tag of interest. Thereby, reactive groups on both peptide tags (e.g. a
nucleophilic amino acid on one peptide tag and an electrophilic moiety on the other
peptide tag) are brought in proximity, inducing reactivity for covalent bond formation.
For example, the Seitz group made use of a system relying on transthioesterification
of a cysteine-containing a peptide tag and a thioester-containing functional handle,






















Fig. 5 Example for peptide-peptide interaction-mediated protein labelling.
Next to the above described systems, the inherent chemoselectivity of enzymes has
been used a lot for the site-selective labelling of proteins at short peptide recognition
sequences1. These enzymes recognise a specific peptide sequence and selectively transfer
the desired label onto a specific amino acid within the peptide tag (Fig. 6).
For instance, the Wells group introduced the enzyme subtiligase, which is an engineered
peptide ligase derived from the bacterial serine protease subtilisin (BPN) [29, 30]. The
two point mutations S221C P225A alter the mechanism of BPN to favour aminolysis
over peptidase activity, thereby facilitating the ligation of a C-terminal ester-containing
peptide to an acceptor peptide containing an amine. Subtiligase accepts a wide scope
of substrate amino acid sequences on both peptide ends, including non-natural amino
acids, which can be further reacted with orthogonal groups to introduce functional
handles site-selectively. To overcome the initial restriction of this labelling method to
proteins C-termini, Weeks and Wells recently reported a library of subtiligase variants
with defined specificities that allow for site-specific modification of proteins also at
their N-termini [31]. These recent findings, along with the high efficiency of subtiligase
and the mild reaction conditions make subtiligase-catalysed ligation a very powerful
tool for peptide ligation.
























































General concept of enzyme-mediated protein modification
Fig. 6 Examples for enzyme-mediated protein labelling methods.
Another enzyme widely used for protein labelling is sortase A, a transpeptidase naturally
catalysing the ligation of surface proteins to the cell wall of Gram-positive bacteria
[32]. Sortase A recognises the C-terminal amino acid sequence LPXTG and cleaves
it at the threonine residue. The resulting enzyme-substrate intermediate can then be
conjugated to a second peptide fragment, bearing at least one glycine residue at the
N-terminus [33, 34]. Recently, the Lang group developed a sortase-mediated ligation of
an engineered ubiquitin to a protein of interest, giving rise to non-hydrolysable, site-
specifically ubiquitinated proteins in living cells [35].
Butelase 1, another peptide ligase, was recently discovered by Nguyen et al. [36]. This
enzyme was isolated from C. ternatea, a tropical cyclotide-producing plant. Butelase
1 recognises a C-terminal tripeptide motif Asn/Asp-His-Val and cleaves after Asn/Asp
to ligate it to the N-terminal residue of a substrate peptide. Catalytic efficiencies are
as high as 1.34 x 106M−1s−1 [37]. Consequently, butelase 1 mediated ligation reactions
are generally completed within minutes and give excellent yields. Moreover, butelase 1
is particularly useful for the efficient cyclisation of peptides [38].
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In our group, yet a different enzymatic method has been developed, employing the
enzyme tubulin tyrosine ligase (TTL). In nature, TTL recognises a 14-mer amino
acid C-terminal sequence of a protein and attaches the amino acid tyrosine to it
[39]. TTL also tolerates tyrosine-derivatives, e.g. equipped with an azide or an
aldehyde functionality. This allows for the subsequent, chemoselective modification
with functional handles containing alkyne or hydroxylamine groups [40, 41].
Given the size of the peptide and protein tags discussed above, the general challenge
with these strategies is to maintain the integrity of the engineered protein with respect to
correct folding and activity. Introducing extra amino acids into a protein can influence
the correct three dimensional fold by disrupting covalent or non-covalent interactions
between amino acids. Also the solubility of the protein of interest can be changed
upon adding amino acids to the sequence. Furthermore, attached polypeptide tags may
hamper protein-protein interactions by blocking substrate recognition sites. In order
to minimise disruptions in the protein folding and activity, the polypeptide recognition
tags are commonly attached at the N- or C-termini. Site-selective labelling at other sites
is often prohibited or limited to unstructured areas of the protein. Further reducing the
size of the recognition tag is thus a valuable strategy toward low-invasive labelling of
proteins also at other sites than the termini.
1.2.3 Protein modification via unnatural amino acids
A strategy to reduce the size of the introduced tag in proteins is the incorporation
of non-canonical amino acids. The power of this approach lies in the ability to site-
selectively introduce unnatural functional groups into proteins, which can then be ad-
dressed with excellent chemoselectivity by orthogonal counterparts, also within complex
environments (Fig. 7) [42].






















































































Fig. 7 The site-selective incorporation of unnatural amino acids into proteins allows for
bioorthogonal labelling in biological systems.
Suitable chemical reactions for such selective labelling in biological environments
have to fulfil several criteria [2]. Most importantly, bioorthognal reactions should not
cross-react with any functional groups present in biomolecules to avoid background
labelling and ensure specific labelling of the protein of interest. Furthermore, these
reactions have to proceed under physiological conditions (ambient temperatures, pH
around 6-8). Moreover, it is often desirable that the generated product as well as the
reaction partners are stable under these physiological conditions and non-toxic to living
systems. In recent years, considerable effort has driven the development of bioorthognal
reactions that fulfil most of these criteria.
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Ketones and aldehydes were among the first functionalities explored for bioorthogonal
labelling of proteins [43] (scheme 1A). Their carbonyl group can be addressed with strong
nucleophiles such as alkoxyamines [44], hydrazides [45] or hydrazines [46] under slightly
acidic conditions (pH 4-6). However, with bimolecular rate constants in the range of
10−4 to 10−3 M−1s−1, these types of reactions are rather slow and must thus typically
be carried out at high concentrations [47]. With the need for acidic conditions as
well as observed cross-reactivity with other carbonyl-bearing metabolites [48], these




























































Scheme 1 Examples for bioorthogonal reactions.
Azides on the other hand are absent in biological systems and have therefore been
widely employed for bioorthogonal labelling reactions [47]. Azides are relatively stable
under physiological conditions and they are small and thus easy to incorporate into
various biomolecules. They can undergo [3+2]-cycloadditions with alkynes to form
stable triazoles [48, 49, 50] (scheme 1B). This reaction can be catalysed by copper
(I) [51, 52], which made it applicable for bioorthogonal labelling. To avoid cell-toxic
Cu(I)-salts [53], strain-promoted alkyne-azide-cycloadditions (typically using strained
cyclooctynes) have been developed [54, 55] (scheme 1C). Limitations of these types
of molecules can be their hydrophobicity [56] as well as cross-reactivity with thiols
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of cysteines in thiol-yne reactions [57]. In addition to alkyne substrates, azides can
also undergo chemoselective reactions in complex mixtures with triarylphosphines in
the so-called Staudinger ligation, which is discussed in detail in chapter 1.4 (scheme 1D).
A major limitation of the bioorthogonal reactions discussed above are their slow
reaction rates, necessitating long reaction times or high excess of reagents to achieve
sufficient labelling [47]. In contrast, the bioorthogonal inverse-electron demand Diels-
Alder (IEDDA) reaction between tetrazines and strained alkenes or alkynes exhibits
extraordinary fast reaction rates [58]. Gaseous nitrogen is the only by-product in these
irreversible reactions. Based on earlier work by Boger and others [59, 60], the groups
of Fox and Hilderbrand simultaneously reported the application of IEDDA reactions
for bioorthogonal labelling [61, 62]. The rates of IEDDA reactions have been further
increased by introducing ring strain to the dienophile or by changing the electron
deficiency of the tetrazines. For bioorthogonal reactions, the Fox group developed
trans-cyclooctenes (TCO) (scheme 1E) as highly reactive dienophiles with bimolecular
rate constants in the range of 106M−1s−1 [63]. Even more reactive dienophiles could
be generated by further increasing the ring-strain of TCOs [64, 65]. High selectivity
and rapid kinetics of IEDDA reactions makes them one of the most promising class of
reactions for bioorthognal protein modification in biological systems.
One way to incorporate the unnatural amino acid into a protein is to employ an
enzymatic ligation method (compare chapter 1.2.2). Alternatively, unnatural amino
acids can be incorporated by means of protein semi-synthesis [66, 28]. A further,
more straight-forward, strategy is to supplement the medium of expressing cells with
an unnatural amino acid structurally similar to a canonical amino acid. Given the
translational machinery and in particular the aminoacyl-tRNA synthetase tolerates the
unnatural amino acid, the latter gets incorporated in place of its structural natural
analogue. In a seminal study by Cowie and Cohen in 1957, this concept has been
demonstrated for the incorporation of selenomethionine in methionine-depleted growth-
medium [67]. Increased yields can be obtained using auxotrophic expression systems,
meaning cells or bacteria, which themselves are unable to synthesise the natural amino
acid to be replaced. This method has been expanded for the incorporation of several
bioorthogonal functional groups like homopropargylglycine, homoallylglycine [68] and
azidohomoalanine [69], which can be further functionalised by means of bioorthogonal
chemistry. In a very recent report, Lauster et al. have used this strategy to introduce
homopropargylglycine into Qβ-phage capsids for subsequent functionalisation with
azide-containing sialic acid derivatives by means of copper-catalysed azide-alkyne
cycloadditions (CuAAC) [70]. Thereby, they generated a multivalent binder for the
viral spike protein haemagglutinin of the influenza A virus, shown to inhibit influenza
virus entry. While auxotrophic expression usually gives high yields, drawbacks of this
method are the limited scope of amino acids tolerated by the translational machinery
as well as the residue-specific, global incorporation of the non-canonical amino acid.
Genetic code expansion on the other hand enables the incorporation of non-canonical
amino acids in a site-selective manner, while at the same time offers more structural
diversity [71]. In this concept, aminoacyl-tRNA synthetase/tRNA-pairs are employed,
which are orthogonal to natural occurring pairs. The promiscous synthetase transfers
the non-canonical amino acid onto a tRNA complementary to a blank codon. For
example, in the amber suppression technique, the stop codon UAG is repurposed for the
incorporation of the desired unnatural amino acid [72]. The catalogue of non-canonical
amino acids that can be incorporated into proteins by this method has been steadily
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expanded over the last years by the evolution of several orthogonal aminoacyl-tRNA
synthetases [73, 74]. Out of these, the pyrrolysyl-tRNA synthetase (PylRS)/tRNACUA
pairs have proven particularly useful as they are orthogonal not only in bacteria but
also in eukaryotic cells [75, 76, 77] and in animals [78, 79, 80, 81]. Examples for
unnatural functional groups that were incorporated into proteins by means of genetic
code expansion include azides and alkynes [82, 83], tetrazines [84], bicyclononynes and
trans-cyclooctenes [85] (Fig. 7). Despite its excellent site-specificity, a drawback of
amber suppression is the competition with the termination of the protein, which gives
rise to truncated proteins at the modification side [86].
1.2.4 Protein modification via natural amino acids
Although the protein modification strategies outlined in the three previous chapters
are undoubtedly indispensable for the selective labelling of proteins in complex envi-
ronments, they all rely on genetical engineering, which may perturb protein function
or result in low yields of the expressed proteins. Therefore, whenever possible, di-
rectly addressing the natural amino acids with chemoselective methods is often more
straight-forward. This strategy mainly finds application for the modification of puri-
fied proteins in vitro, although in certain cases, there are also ways to achieve selective
modification of natural amino acids within complex mixtures, as discussed below. To
date, a plethora of methods exist for the selective modification of many of the natural
amino acids [3]. The primary amine groups of lysines can for instance be selectively
addressed with N -hydroxysuccinimide esters (NHS), isocyanates and isothiocyanates or
via reductive amination [3]. Given though that proteins are large and usually contain
multiple addressable lysines, these strategies typically lead to a heterogeneous mixture
of modified proteins carrying different numbers of modifications. For applications, in
which the site of modifications is important, other labelling strategies must be pursued.
One strategy to improve site-selective labelling of natural amino acids relies on affinity-
induced labelling [87]. Here, high-affinity ligands are employed, which direct a latent
electrophile to a distinct area of a protein, thereby inducing reactivity to nucleophilic
residues in proximity. Electrophilic warheads that have been employed in this strategy
include phenyl esters [88], tosyl groups [89] and acyl imidazoles [90]. Impressively, this
strategy enabled the selective labelling of endogenous proteins even in vivo [91, 92].
Nevertheless, the scope of this methods is limited to proteins with an identified ligand.
Furthermore, within the binding region of the ligand, it is difficult to steer which exact
residue is getting labelled when several nuleophilic functional groups are in close prox-
imity.
Another, more general strategy towards homogenous protein labelling is to target low-
abundant natural amino acids, such as cysteine (see chapter 1.3). This approach is
complemented by site-directed mutagenesis, which provides a means to either remove
amino acids that should not be labelled or introduce a single addressable copy of a given
amino acid to ensure site-selectivity.
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1.3 Methods for selective protein modification via cysteine
Within the natural amino acids, cysteine has seen the most attention for selective
protein modification [93, 94]. This is partly due to its low natural abundance, which
facilitates site-selective labelling. Depending on the literature source, the natural
abundance of cysteine is approximately 1.1% [95]. For comparison, lysine is much
more abundant with about 6.3% (Fig. 8B). Furthermore, cysteines are often bound
in disulfide bridges, which reduce their abundance as addressable nucleophiles even
further. Thus often only one free cysteine is available for functionalisation or can be
introduced by means of site-directed mutagenesis, allowing site-selective functionali-
sation. Alternatively, disulfide bridges can be reduced to two free cysteines, thereby
making them accessible for modification with electrophiles.
The other reason why cysteine is an attractive target for selective protein modification
lies in its distinct, yet diverse reactivity profile. Compared to other nucleophilic amino
acids, cysteine has a unique nucleophilicity. With a pKa value of around2 8 it has a
high tendency to form the nucleophilic thiolate under physiological conditions and can
thus be addressed with various electrophiles. For comparison, lysine has a pKa value
of approximately 10 and is thus mainly protonated under physiological conditions.
Consequently, at neutral or slightly basic pH (ca. 7-8.5), cysteine can usually be
addressed with high selectivity over lysine. However, cross-reactivity is sometimes


























105 pm 120 pm




Fig. 8 Comparison of the nucleophilic amino acids lysine (Lys), cysteine (Cys) and selenocys-
teine (Sec).
A close analogue to cysteine is selenocysteine (Sec), also referred to as the 21st pro-
teinogenic amino acid [98]. Sec is very low abundant in proteins, nevertheless plays an
important role in several enzymes with redox functions [99]. Cys and Sec only differ
by one atom, sulphur versus selenium. This seemingly small difference distinguishes
though the properties of cysteine and selenocysteine distinctly. The pKa value of Sec
(around 5) is much lower than that of Cys. As a consequence, under physiological con-
ditions, most of the selenol (R-SeH) side chains in Sec are present in the deprotonated
selenolate (R-Se-) form. Compared to thiolates, the negative charge on selenolates is
better stabilized due to the larger size of selenium versus sulphur [100] and its lower
2The pKa value of amino acids varies depending on the local environment with respect to buffer
exposure and the neighbouring residues [96, 97].
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redox potential (Fig. 8B) [98]. This makes selenolates much better nucleophiles than
the respective thiolates of deprotonated cysteines. However, the larger atomic size and
higher polarisability of selenium also make the chemical bonds with selenium generally
weaker than the corresponding bonds with sulphur. This feature of selenium has been
employed in the development of rapid ligation methods using peptide selenoesters [66].
Although selenocysteine is a better nucleophile at physiological pH than cysteine and
could thus interfere when addressing cysteine, this is mostly not a problem given the
very low abundance of cysteine in natural proteins. The distinct chemical properties of
cysteine has been an inspiration for researchers for decades, illustrated by the plethora
of cysteine-selective methods available to date [93, 94]. The bulk of existing methods
rely on addressing cysteine with electrophilic reagents (Fig. 2A), while others engage
cysteine in radical reactions (Fig. 2B). Some methods also make use of the high affinity
of cysteine to metals [101, 102, 103, 104]. Yet another approach to employ cysteine for
protein modification is by selectively transforming it first selectively into an electrophilic
















Scheme 2 Different strategies to selectively modify cysteine on proteins: A) With electrophiles
(El), B) through radical transformations, C) via intermediary conversion into an
electrophile, inducing reactivity for subsequent labelling with nucleophiles (Nu).
1.3.1 Selective modification of cysteine with electrophiles
The majority of cysteine-selective labelling methods rely on electrophilic reagents
(Fig. 9). Next to their synthetic accessibility and their selectivity for cysteine-labelling,
other important aspects are high reactivity to allow labelling under dilute conditions
as well as good stability of the labelling reagents as well as the conjugation products.
S SEl
δ
Fig. 9 Cysteines can selectively be addressed with a variety of electrophilic reagents (El).
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Maleimides and related compounds
In the toolbox for cysteine-selective modification, maleimides stand out owing to their
excellent reactivity. Thiol-Michael additions to maleimides are characterised by bi-
molecular rate constants in the range from 102-104 M−1s−1 dependent on the pH and
the reagent structure [105, 106]. Due to their excellent reactivity, maleimides have
been widely applied in various bioconjugation applications. Also most of the currently
approved antibody-drug conjugates were generated using maleimides [8]. Nonetheless,
there are several drawbacks for classical maleimides like the observed cross-reactivity
with lysine and histidine, particularly under basic conditions when using the maleimide
reagent in excess [107]. Another drawback of classical maleimides is the reactivity of the
thiosuccinimide adducts towards retro-Michael addition and subsequent thiol-exchange
reactions (scheme 3A) [108, 109]. The latter ones are particularly critical in the con-
text of ADC therapeutics, in which premature release of the cytotoxic payload can
compromise efficacy or lead to off-target toxicity. To overcome this issue, Lyon et al.
developed self-hydrolysing maleimides that accelerate the hydrolysis of the thiosuccin-
imide adducts to succinamic acid thioethers by installing an adjacent basic amino group,









































































Scheme 3 A) Problems associated with classical maleimides. B) Structures of next-generation
maleimide-derivatives and related compounds.
In a different approach, Kalia and co-workers tackled retro-Michael degradation using 3-
substituted exocyclic maleimides, which give rise to more stable thiosuccinimide adducts
[111]. Other next-generation maleimides include mono- and dihalogen- or thioaryl-
substituted derivatives that possess advanced reactivity allowing multiple thiol addi-
tions. For example, monobromomaleimides, developed by Tedaldi et al. rapidly react
with cysteines [112], and allow a second Michael addition to the resulting thiomaleimide
[113]. Alternatively, the first addition reaction can be reverted by the addition of TCEP
[112]. Similarly to this approach, dibromomaleimides introduced by Smith et al. [114]
allow for the addition of two thiols to a maleimide scaffold, thus enabling the rebridging
of disulfides in a protein of interest [115]. The resulting bioconjugates can further be
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stabilised by hydrolysis or are reversible by the addition of external thiols [116]. As
an alternative to dibromomaleimides, diarylthiomaleimides (scheme 3B), which do not
show cross-reactivity with TCEP allow for one-pot TCEP reduction and rebridging of
disulfides [117]. Yet other reagents for disulfide double functionalisation of cysteine-
peptides and disulfide rebridging are 3-bromo-5-methylene-pyrrolones, recently intro-
duced by Zhang et al. [118]. Thiol additions to these reagents are however reversible
and the thiol-conjugates must be stabilised by reduction-mediated ring-openings. As
a last example of maleimide-related reagents for cysteine-labelling, dibromopyridazine-
diones developed by Chudasama et al. are to be mentioned [119]. Thiol-conjugates to
these reagents employ excellent hydrolytic stability but are reversible in the presence of
excess thiols.
While the development of next-generation maleimides and maleimide-related com-
pounds has led to significant improvements of classical maleimides, another important
aspect for cysteine-labelling reagents is their synthetic accessibility. From a users per-
spective, the question of how easily these cysteine-reactive handles can be synthesised
and incorporated into a certain functional moiety for labelling is highly relevant.
As for the synthesis of N -functionalised maleimides, there are two routes that prevail in










































3) oligonucleotide deprotection (NH3, r.t.)
4) maleimide deprotection (toluene, 90 °C)











































































Scheme 4 Synthesis of maleimide derivatives. A) Commonly used synthetic route to gener-
ate N -functionalised maleimides from the condensation of succinic anhydride with
amines. B) Alternative, mild route to acces maleimide derivatives via the Mit-
sunobu reaction with maleic anhydrides. Both routes can be used to generate bi-
functional linkers. C) Mild synthetic route to access substituted maleimide deriva-
tives. PPh3=triphenylphosphine, DIPEA=N,N -diisopropylethylamine, ClCO2Me=
methyl chloroformate, NMM=N -methylmorpholine.
In the first route, the amine opens the succinic anhydride and the resulting maleic acid
condensates under elevated temperatures and acidic conditions (scheme 4A) [120]. In
the second route, direct N -alkylation of maleimides can be accomplished under milder
conditions by means of a Mitsunobu reaction, using alcohols as alkyl group donors
(scheme 4B) [121]. Another mild approach for the synthesis of N -derivatised substi-
tuted maleimides and bromopyridazinediones has been reported by Castañeda et al.
using N -methoxycarbonyl activate maleimide i termediates (scheme 4C) [122]. All of
these synthetic routes enable the synthesis of general building blocks [123, 124] (e.g.
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the SMCC linker, scheme 4A), which can be used in subsequent amide couplings for
further functionalisation. To date, a wide selection of such bifunctional maleimide link-
ers are commercially available, which still promotes the use of classical maleimides for
bioconjugations, despite suboptimal selectivity and stability of these compounds.
While the site-selective incorporation of maleimides using bifunctional linkers is straight-
forward for functional handles that contain only one reactive group (e.g. an amine
or carboxylic acid), more complex biomolecules like peptides or oligonucleotides often
require more selective chemistry or protecting group manipulations. Even though in-
stalling a maleimide group on an unprotected peptide can in principle be accomplished
with the SMCC linker, this process would lead to a mixture of products when several
amino groups are present in the sequence. Thus, the site-selective incorporation of a
maleimide group into a peptide or a protein requires either the installation of an un-
natural amino acid, which can be addressed with an orthogonal bifunctional linker, or
a suitable protecting-group strategy. The latter approach has been used for instance
by Marburg et al. [125] as depicted in scheme 5A. They employed an orthogonally-
removable lysine-protecting group and introduced the maleimide functionality via an
N -hydroxysuccinimide ester in the last step of a standard Fmoc-SPPS. An example
for the incorporation of a maleimide group into oligonucleotides has been accomplished
by Sanchez et al. (scheme 5B) [126]. They incorporated a 2,5-dimethylfuran protected
maleimide at the 5′-end through a phosphoramidite building block, which is inert against
the ammonia treatment during oligonucleotide synthesis. Deprotection is achieved in











3) oligonucleotide deprotection (NH3, r.t.)
4) maleimide deprotection (toluene, 90 °C)






































Scheme 5 A) Example for the incorporation of a maleimide group into a protected peptide





Next to maleimides, α-halocarbonyl reagents have been used to functionalise cysteines
(scheme 6A) [127]. Owing to the excellent stability of the formed thioether bond, these
reagents are extensively used in MS sample preparation of digested proteins [128] and
have also been applied for the construction of stable immunoconjugates [129]. The reac-
tivity of α-halocarbonyl reagents increases in the order of chlorine, bromine and iodine
derivatives. Reported rate constants for thiol-additions to chloroacetamides at physio-
logical pH are in the low M−1s−1 range [130]. Cysteine-selectivity in turn is best for the
least reactive chlorines derivatives [131].
α-halocarbonyl reagents are often synthesised from substitution of activated carbonyls
with amines (scheme 6B). Chloro- and bromoacetamides can be accessed from chloro-
and bromo-acetylchlorides/bromides with amines under cooled conditions by the aid of a
base. Thereby, selective substitution occurs at the more electrophilic carbonyl position.
This conversion tolerates alcohols [132], carboxyclic acids and Boc-protected amines,
thus allowing the synthesis of bifunctional linkers (scheme 6D) that for instance have
been used to conjugate cytotoxins to antibodies [133, 129]. Treatment of chloro- or
bromoacetamides with potassium- or sodiumiodide gives rise to N -derivatised iodoac-
etamides (scheme 6B). Alternatively, α-haloacetamides can be accessed from haloacetic
anhydrides (scheme 6C). The latter strategy was used to synthesise a diazirine iodoac-
etamide derivative for photocrosslinking studies [134]. The incorporation of haloac-
etamides into biomolecules like peptides and oligonucleotides has not seen a lot atten-


















































































reactivity: I > Br > Cl




Scheme 6 A) Modification of cysteine with α-halocarbonyl reagents. B/C) Synthetic ap-
proaches for the synthesis of α-halocarbonyl reagents. D) Example for the synthesis
of a bifunctional linker.
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α/β-unsaturated carbonyl reagents
Another class of cysteine-selective, electrophilic reagents are α/β-unsaturated car-
bonyls, some of which are depicted in scheme 7. Bernardes and co-workers introduced
carbonyl-acrylic reagents as Michael-acceptors for thiol-addition, with benzoyl acry-
lamide as the best-performing derivative (scheme 7A) [135]. They were able to show
that cysteine addition to these compounds is highly selective and proceeds with
rapid kinetics (k2= 10.9M−1s−1 at pH 8.0), enabling the labelling of various proteins
under stoichiometric conditions, including the therapeutic antibody trastuzumab.
N -derivatised benzoyl acrylamides are easily accessible from amide couplings between
amines and the commercially available 3-benzoylacrylic acid [136, 135].
2-azidoacrylates, which were introduced by Ariyasu et al. are reactive, cysteine-
selective Michael-acceptors (k2 (for glutathione addition) of about 0.51M−1s−1) at pH
7.4 (scheme 7B) [137]. Furthermore, these reagents allow for dual functionalisation
through successive alkyne-azide cycloadditions. The authors synthesised the amino
2-azidoacrylate precursors, which are amenable for couplings at the amino group, from
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Scheme 7 Cysteine-selective α/β-unsaturated carbonyl reagents and examples for their syn-
thesis: A) Carbonylacrylic reagents, B) 2-azidoacrylates.
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Based on unsaturated bissulfones [138], Wang et al. introduced water-soluble α,β-
unsaturated ketones for cysteine-selective bioconjugation (scheme 8) [139]. These
reagents allow for disulfide-rebridging, while at the same time introducing a functional
handle at the bridged site. A PEG amine allyl sulfone derivative, which serves as
substrate to introduce functional handles via amide couplings, was synthesised in a









































Scheme 8 Cysteine-selective α,β-unsaturated ketones and an example for their synthesis.
Finally, Fox and co-workers introduced cyclopropenyl ketones as a new class of irre-
versible cysteine alkylators (scheme 9) [140]. Thiol additions to the strained cyclo-
propenyl exhibit extraordinary fast kinetics (k2= 595 M−1s−1 for glutathione addition
in PBS at pH 7.4), thus allowing excellent conversions at low protein concentrations
in short time. As opposed to maleimides, here the products are stable towards retro-
Michael addition in the presence of excess external thiol in PBS and human plasma. The
authors synthesised amide-derivatised cyclopropenyl ketones from 2-methylcycloprop-2-
enecarboxylic acid and propanal, followed by NHS-mediated amide coupling and oxida-
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Scheme 9 Reaction of cyclopropenyl ketones with cysteine and synthetic route to access these
reagents.
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Other unsaturated electrophiles
Next to the above discussed Michael-acceptors, other unsaturated electrophiles serve
as good cysteine-selective reagents. Luo et al. for instance have recently introduced
1,4-dinitroimidazoles (1,4-DNIms) as highly efficient cysteine-selective bioconjugation
reagents (scheme 10) [142]. Under aqueous acidic or neutral conditions, 1,4-DNIms react
exclusively with thiols and modify cysteine on proteins quantitatively in seconds. The
authors used a carboxylic acid derivative to install the 1,4-dinitroimidazole group on a
fluorophore and peptides via amide couplings. The synthesis of this general building
block required several steps including protecting group manipulations (scheme 10), thus
the direct formation of the 1,4-dinitroimidazole group on complex biomolecules is not





















































































































































































































































Scheme 10 Reaction of 1,4-dinitroimidazole with cysteine and synthetic route to access these
unsaturated electrophiles. PMB= para-methoxybenzyl.
Another class of unsaturated electrophiles, azabicyclic vinyl sulfones, has been de-
veloped by Bernardes and co-workers (scheme 11) [143]. Excellent conversions were
obtained for the modification of a cysteine-ubiquitin mutant at pH 7.0 with as little
as 1-5 eq. after only 30min. The formed thiol conjugates proved to be stable against
thiol exchange and retro-Michael addition but can undergo slow cleavage through a
rDA reaction. However, the introduced azabicyclic dienophile can be stabilised against
this pathway via a second bioorthogonal derivatisation by means of an inverse electron
demand Diels-Alder reaction (IEDDA) with tetrazines. This system was further refined
by introduction of norbornadiene bromovinyl sulfones that also react selectively with
cysteines on proteins [144]. Subsequent modification with tetrazines, followed by
a double rDA gives rise to pyrrole-linked protein conjugates that are stable in the
presence of high amounts of glutathione. N -derivatisation of these reagents can be
achieved via amide coupling to the bridging nitrogen, as demonstrated in the coupling
















































Scheme 11 Top: Reaction of azabicyclic vinyl sulfones with cysteine and further derivatisations
with tetrazine. Bottom: Synthetic route to access azabicyclic vinyl sulfones.
Ts=4-toluenesulfonyl.
Yet another thiol-reactive motif are unsaturated phosphonates. On a small molecule
level, thiol-addition to unsaturated phosphonates has for instance been demonstrated
by Khusainova et al. (scheme 12) [145]. As reagents for protein modification however,
those compounds have not seen a lot of attention, likely due to their low reactivity.
Nevertheless, Gao et al. have installed electrophilic vinylphosphonates on aminoglyco-
sides for the conjugation to coenzyme A (CoA) via a sulfhydril group [146]. They have
synthesised the vinylphosphonate from a phosphonochloridate intermediate, adapting





















































































































































































































































Scheme 12 Reaction of vinylphosphonates with cysteine and synthetic route to access these
unsaturated electrophiles.
While most of the cysteine-reactive reagents described in this chapter feature good reac-
tivity and cysteine-selectivity and often show very good product stabilities, the synthetic
accessibility of these reagents is predominantly not straight-forward. Furthermore, the
direct installation of these reagents on unprotected biomolecules is usually prohibited
due to the lack of chemoselectivity of the synthetic routes or due to harsh reaction
conditions. Tackling this issue, our group has recently reported unsaturated phospho-
namidates as reagents for cysteine-selective protein labelling. These reagents can be
synthesised from azides and unsaturated phosphonites by means of the chemoselective
Staudinger-phosphonite reaction (SPhR), which is described in detail in chapter 1.4.
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1.3.2 Selective modification of cysteine via radical reactions
All examples described in the previous chapter rely on the reactivity of the thiolate
anion with electrophilic reagents. In a different concept, as cysteine thiyl radical, cys-
teine can also engage in reactions with electron-rich alkenes [149] and alkynes [150].
These radicals can be generated under photo-irradiation (typically at 365 nm), often
promoted by radical-initiators (RI). Upon reaction with alkenes, a carbon radical is
formed and the chain reaction can propagate via hydrogen abstraction from another
sulfhydril group, leading to a new thiyl radical (Fig. 10A). Disulfide formation between
two thiyl radicals eventually terminates the process. The thiol-ene reaction can be
performed under aqueous conditions, features rapid kinetics (in chain reactions, the
propagation kinetic constants range from 105-106M−1s−1, depending on the monomer
structures [151, 152]) and is compatible with diverse functional groups. Next to appli-
cations in material science, these properties made the thiol-ene reaction also attractive


























































































































































































































Fig. 10 Thiol-ene reaction: A) Reaction mechanism, B-E) application examples for the modi-
fication of proteins with the thiol-ene reaction. RI= radical initiator.
For example, Li et al. have employed the thiol-ene reaction on cysteine mutants of
ubiquitin and histones H3 and H4 to generate mimics of the post-translational modifi-
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cation Lys(Ac) (Fig. 10B). Thereby, they reacted the proteins with N -vinyl-acetamide
under photo-irradiation in the presence of the radical initiator VA-044 obtaining ex-
cellent conversions above 90% [153]. In another example, the Strieter group used the
thiol-ene reaction to generate diubiquitins and branched triubiquitins connected via
unnatural isopeptide bonds Fig. 10C. To this end, they subjected cysteine mutants of
ubiquitin to photo-irradiation in the presence of the radical initiator lithium acyl phos-
phinate (LAP) and a C-terminal allyl amide modified ubiquitin variant. When applied
to proteins, the photo-irradiation-induced thiol-ene reaction can induce damage of the
protein as like disulfide cleavage observed by Dondoni et al. [154]. In this study, BSA
carrying a single free cysteine was subjected to the thiol-ene reaction with allyl α-C-
galactoside, however the modification was not only found at the desired cysteine but
also at two additional cysteines naturally engaged in a disulfife bridge (Fig. 10D). The
authors hypothesise that photo-excited aromatic residues promoted electron transfer to
the proximal disulfide bond, causing the cleavage of the latter. The thiol-ene reaction
can also be performed the other way round, by introducing the ene-reagent into the
protein and addressing it with an external thiol. Floyd et al. have for instance incor-
porated L-homoallylglycine into self-assembled, multimeric virus-like particle Qβ and
modified it with glycosyl thiols (Fig. 10E) [155], giving rise to Qβ particles displaying
180 sugar modifications. In this case, structurally important intramolecular disulfide
bonds were not affected, perhaps because no aromatic residues were in close proximity
to promote damaging electron-tansfer. Next to the reactions with alkenes, thiyl radi-
cals have also been employed with alkynes, mainly for applications in polymer synthesis
[150, 156]. Thereby, two thiol groups add to a single alkyne, which has for instance been
used for the synthesis of dendrimers [157]. In the context of protein modification, the
thiol-yne reaction has only been applied in a handful of examples, for instance for the
dual-modification of BSA with a fluorophore and a sugar moiety [158].
1.3.3 Transformation of cysteine into electrophilic handles
Compared to the wealth of nucleophilic functional groups in proteins, electrophilic moi-
eties are rare. The most prominent example are disulfide bonds between two cysteine
residues, which are important for the correct folding of proteins [159]. Cysteine disul-
fide bonds can be attacked by external nucleophilic thiols such as glutathione or by
other cysteine residues to undergo disulfide shuffling. Nevertheless, the overall abun-
dance of reactive electrophilic moieties in proteins is low. The installation of reactive
electrophilic motifs thus provides a strategy for subsequent selective modification with
nucleophiles, including the nucleophilic, natural amino acid residues. The latter con-
cept is particularly attractive for the generation of site-selectively linked protein-protein
conjugates. Such homogenous protein-protein conjugates are gaining increasing atten-
tion in pharmaceutical research (e.g. bispecific antibodies [160]) as well as in basic
research, for example in the generation of site-selectively ubiquitinated proteins (e.g.
Ref. [161, 162, 163]). Different electrophilic moieties have been incorporated into pro-
teins as part of unnatural amino acids through genetical engineering methods [164].
For instance, the incorporation of an alkyl-bromide amino acid enabled protein stapling
through nucleophilic lysine and histidine residues [165]. In a different example, Li et
al. incorporated alkene-bearing amino acids into proteins for subsequent modification
through the thiol-ene reaction [166]. Alternatively, natural amino acids can be trans-
formed into electrophilic handles by means of chemical or enzymatic methods, thereby
inducing reactivity for the subsequent modification with nucleophilic handles (Fig. 11).
Several methods thereby make use of cysteine.
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Fig. 11 General concept for the modification of cysteine with nucleophilic handles via interme-
diately installed electrophiles.
One possibility to install electrophilic handles on cysteine residue relies on the reac-
tion with bis-electrophilic linkers (Fig. 12). Lee et al. for instance used a 3-bromo-2-
bromomethyl-1-propene linker to construct several protein-small molecule conjugates
[167]. They installed the homobifunctional linker on solvent-exposed cysteine residues,
thereby inducing reactivity for the addition of small molecule thiol or amine nucle-
ophiles. Following a similar approach, Holm et al. attached a homobifunctional N,N -
ethylene bis(acrylamide) linker to a cysteine mutant of an affibody, enabling subsequent
covalent capture of its antigen by affinity-induced nucleophilic addition to the weak
acrylamide electrophile [168]. Moreover, Singh et al. employed chloroacetaldehyde as
a bis-electrophilic linker for the conjugation of a cysteine mutant of α-globin and an
amino-oxy ubiquitin derivative [169]. In order to avoid the formation of homo-dimers,
it is necessary to use the linkers in excess, which necessitates a subsequent purification
step before the addition of the nucleophilic modifier.
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Fig. 12 Examples of bis-electrophilic linkers to install an electrophilic motif on cysteine.
Alternatively, rather than attaching a pre-existing electrophilic functional group to
cysteine, a few approaches have been described to install an electrophilic motif on
cysteine by means of chemoselective transformations. For instance, a formyl-glycine
generating enzyme converts the cysteine within the peptide sequence CxPxR into
electrophilic formyl-glycine (scheme 13). The aldehyde can then be addressed with a
nucleophilic amino-oxy reagent to form a stable oxime. Hudak et al. have used this
approach to install an azide and a dibenzoazacyclooctyne on human growth hormone
and a full length human IgG antibody, which enabled subsequent site-selective chemical
protein fusion via copper-free click reaction [170]. A nice feature of this method is
that it enables the site-selective incorporation of the electrophilic aldehyde also in the
presence of other cysteine residues. Nevertheless, the incorporation of the peptide
recognition tag requires genetical engineering of the protein. Another disadvantage is
the lability of the introduced aldehyde. As described by Hudak et al., reducing agents
had to be added to the buffer during protein purification in order to protect the protein
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from oxidation. Furthermore, aldehydes are prone to react with amines from lysine
residues to form imines, which can be another limitation of this method.
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Scheme 13 The FGE-enzyme converts cysteine into an aldehyde, making it thereby amenable
for subsequent modification with nucleophilic aminooxy reagents.
In addition to this tag-based chemoenzymatic conversion, there are chemical protocols
that can deliver electrophiles from unpaired cysteines, which can then subsequently
react selectively with canonical nucleophilic amino acids. A straight-forward protocol
following this concept is the formation of electrophilic disulfides using the Ellman’s
reagent, which facilitates the formation of disulfide-linked protein-protein conjugates
(scheme 14A). This strategy has been applied to various protein substrates, especially in
the field of chemical ubiquitylation to construct ubiquitinated histones [161], ubiquitin-
PCNA [162] and ubiquitin-α-Synuclein conjugates [163]. Notably, the applicability of
this approach is limited due to the inherent lability of disulfides in reducing environments
[171]. Also the thiolate leaving group can potentially re-open the disulfide conjugate
by means of thiol-exchange. Nevertheless, this method is highly attractive as it allows
the straight-forward conjugation of two proteins via natural amino acids in a selective
manner. Moreover, site-selective conjugation can easily be achieved by placing the


































































































































Scheme 14 Cysteine can be converted A) into electrophilic disulfides with Ellman’s reagent
or B) into electrophilic selenylsulfide with PhSeBr. These electrophiles undergo
selective substitution with external thiols or cysteines from a second protein to
give disulfides.
A similar strategy, introduced by Davis and co-workers makes use of electrophilic selenyl-
sulfides, which can be efficiently converted to the respective disulfides with thiols [172]
(scheme 14B). Using thiol derivatives of mono- and oligosaccharides, they have applied
this approach for the site-selective generation of glycosylated proteins. The installation
of the electrophilic selenylsulfide could be easily achieved by treating cysteine-containing
proteins with phenylselenenyl bromide (PhSeBr) [173]. The resulting sulphur-selenium
bond is highly polarised, which is the reason for its excellent reactivity towards nucle-
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ophilic attack by other thiol nucleophiles [174]. As described in Ref. [172], quantitative
conversions of selenylsulfide proteins with thiols could be achieved in under one hour
with low excess of thiol modifiers. Nevertheless, a limitation of this method is that
PhSeBr is a highly hazardous chemical, which makes it unattractive to work with.
In another approach, the Davis group and others converted cysteine residues chemos-
electively into the electrophile dehydroalanine (Dha) [175, 176] (scheme 15). Dha is
susceptible to thia- [177], selena- [178] and aza-Michael-additions [179], as well as to
carbon-based free radical chemistry [180]. There are several methods that enable the
conversion of cysteine into Dha [176]. In 2008, an oxidative amidation/Cope-type elimi-
nation protocol using O-mesitylenesulfonylhydroxylamine (MSH) was reported for Dha
formation on the model protein subtilisin [181]. Given however that MSH is a reactive
oxidizing and aminating reagent, side-reactions with nucleophilic amino acids (Met, Lys,
His, Asp and Glu) were observed in some cases [175]. Thus, alternative methods were
developed employing milder and more selective reagents to convert cysteine into Dha
via bis-alkylation-elimination protocols [175]. The reagents 2,5-dibromohexanediamide
(DBHDA) and 2,5-dibromopentanoate (MDBP) [179] proved to be particularly useful,
given that they are water-soluble and easy to handle. Alternatively, selenocysteine
(Sec) has been used as precursor to generate Dha on proteins. This naturally very
low-abundant amino acid can be incorporated into proteins either cotranslationally
[182], by native chemical ligation [183, 66] or in the form of PhSec by amber stop codon
suppression [184]. Originally, generation of Dha from Sec has been achieved through
oxidation of PhSec using hydrogen peroxide or sodium periodate [184, 185]. Here,
intermediary formed selenoxides undergo a Cope-type elimination to give Dha. These
protocols led to undesired oxidations of amino acids such as methionine and cysteine.
A milder protocol to convert Sec into Dha makes use of DBHDA, which allows some
selectivity over cysteine [183].
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Scheme 15 Methods to generate dehydroalanine from cysteine or selenocysteine precursors
and subsequent modification with nucleophiles or through radical addition.
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Dha has been used for various protein modifications including the synthesis of
protein-protein conjugates. Brik and co-workers for instance employed thiol addition
of a Cys-peptide to Dha in combination with a subsequent native chemical ligation to
construct protein-ubiquitin conjugates [186]. Furthermore, the same group used Dha
on ubiquitin as activity-based probes to identify deubiquitinating enzymes (DUBs)
[187, 188, 189]. To the best of our knowledge, no direct protein-protein conjugation
using Dha derivatised proteins has however been reported for systems that are not
based on affinity- induced reactivity. Furthermore, Dha has seen attention as precursor
for the chemical synthesis of post-translational modifications [176]. Addition of sodium
thiophosphate to Dha for instance gives rise to phospho-cysteine [181]. A general
drawback of Dha modification is the generation of a mixture of diastereoisomers in
the protein backbone [186], which can particularly be a problem when studying PTMs
introduced with this method.
Despite the attractive possibilities for protein-protein conjugations that arise from the
ability to introduce electrophilic moieties into proteins, there are still only few methods
available that allow subsequent conjugations with canonical amino acids. Furthermore,
the existing methods described above sometimes have disadvantages with regard to
stability or selectivity.
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1.4 Chemoselective bioconjugation with P(III) and P(V)
reagents
1.4.1 Reactions of P(III) reagents with azides
A versatile family of chemoselective reactions for the modification of peptides and pro-
teins employ the reactivity between azides and phosphorus(III) reagents. Historically,
the development of these methods dates back to 1919, when Staudinger and Meyer de-
scribed the reaction between organic azides and phosphines for the first time [190]. They
noticed a spontaneous reaction between phenylazide and triphenylphosphine, resulting
in an iminophosphorane. The latter could be hydrolysed to give triphenylphosphinoxide
and aniline as products. The proposed mechanism of this Staudinger reaction is depicted
in scheme 16. In the first step, the phosphine attacks the azide to form a phosphazide,
which undergoes cyclisation. Upon release of gaseous nitrogen, an iminophosphorane
is formed, which can also be described as the reactive aza-ylide form. Under aqueous
conditions, the latter rapidly hydrolyses to the respective amine. Alternatively, the aza-
ylide can be trapped with various electrophiles such as aldehydes to generate imines or
with cyanates to give carbodiimides [191].
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Scheme 16 Mechanism of Staudinger reduction and examples for reactions with electrophiles.
Given the absence of both the azide and the triphenylphosphine functional groups
in natural systems, Bertozzi and co-workers recognised the potential to develop the
Staudinger reaction further into a chemoselective ligation method. They found that
the hydrolysis of the iminophosphorane intermediate could be circumvented in the pres-
ence of an intramolecular, electrophilic trap. By placing an ester into the phosphine
reagent, intramolecular attack is favoured over hydrolysis, giving rise to an amide bond
(scheme 17A). In this ground-breaking study, they applied the Staudinger ligation for the
bioorthogonal cell-surface labelling of azido-containing sugars (incorporated by means
of metabolic glyco-engineering). As a further refinement of the classical Staudinger
ligation, the Bertozzi and the Raines group came up with a solution to eliminate the
unnatural phosphine oxide residue, which is left back in the amide product [192, 193].
In the so-called traceless Staudinger ligation, the phosphine reagent is modified with
an acylated leaving group as for instance phenol, thiophenol or the highly reactive
methanethiol (scheme 17B). With these derivatives, a native amide bond is generated
in the ligation product as a result of an acyl transfer to the nucleophilic iminophos-
phorane and liberation of the phosphine oxide after hydrolysis [194]. Generally, the
traceless Staudinger reaction proceeds with excellent selectivity, nevertheless sometimes
phosphine oxidation can be a limitation [195]. These positive features have prompted
the use of the traceless Staudinger ligation in various applications [191], for instance









































































Scheme 17 A) Classical Staudinger ligation. B) Traceless Staudinger ligation.
Next to the phosphines described above, P-O bond containing phosphorus(III) species
like phosphinites, phosphonites and phosphites [199, 200] can also undergo Staudinger-
type reactions with azides, resulting in phosphinimidates, phosphonimidates and phos-





























































ROH H2O ROH H2O ROH
N2 N2 N2
Scheme 18 Variations of the classical Staudinger reaction.
Owing to the more polarized P-O bonds, these derivatives are generally more labile
than iminophosphoranes (containing all P-C bonds) [201]. As shown by our group and
others, phosphinimidates and phosphorimidates can undergo rearrangements, catalysed
by Lewis acids or alkyl halides, to yield N,N -disubstituted phosphinamidates and phos-
phoramidates [202, 203, 204, 205, 206]. Alternatively, the P=N species can be subjected
to hydrolysis giving rise to phosphinic acids, phosphonamidates and phosphoramidates,
respectively [200, 199, 207, 208, 209]. As opposed to the classical Staudinger reduction
described above, here the P-N bond (as well as the P-C bonds) are preserved in the
hydrolysis products. The reason for this is that alcoholates are generally better leaving
groups compared to amines and thus get liberated preferentially. Nevertheless, reduc-
tion to the amine remains a side-reaction. The Staudinger-phosphite reaction has for
instance been applied for the synthesis of DNA oligomers in organic solvents [210, 211].
In our group, the chemoselective Staudinger-phosphite reaction has been developed
further as a tool for the site-selective modification of azide-containing biomolecules in
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aqueous buffer conditions. In 2009, Serwa et al. succeeded to apply the Staudinger-
phosphite reaction on azide-containing unprotected peptides and the model protein SecB
[207]. In the latter case, an unnatural azido-phenylalanine amino acid was incorporated
into the protein by means of the amber suppression technology. This was then treated
with a water-soluble, light-cleavable phosphite in aqueous buffer at pH 8.0 to result in
the respective phosphoramidate (scheme 19A). Subsequent photo-deprotection yielded
a mimic of phospho-tyrosine, a post-translational modification found in proteins. Along
these lines, Bertran-Vicente et al. were able to generate site-specifically phosphorylated
lysine peptides from ε-azido lysine-containing peptides and either light- or base-cleavable
phosphites (scheme 19B) [212]. Hence, the Staudinger-phosphite reaction enables the
generation of homogenous phospho-peptides, thereby facilitating the investigation of
these post-translational modifications. In a different direction, the Staudinger-phosphite
reaction has been used to incorporate stabilising polyethylene-glycol (PEG) groups into
peptides and proteins [213, 214], for instance into azido-containing analogues of erythro-
poietin (EPO) (scheme 19C) [215]. In another application, the Staudinger-phosphite re-





















































































Scheme 19 Application examples for the Staudinger-phosphite reaction for peptide and protein
modification: A) Site-selective installation of a phospho-tyrosine analogue on the
protein SecB, B) Synthesis of phospho-lysine peptides, C) incorporation of water-
soluble PEG chains into the protein erythropoietin (EPO).
In the above examples, symmetrical phosphites were used. Those were typically syn-
thesised from phosphorus trichloride (PCl3) through base-mediated nucleophilic substi-
tutions with the desired alcohols or by treating the alcohols with hexamethylphophor-
triamide (scheme 20A). Alternatively, using dichloro-N,N -diisopropylaminophosphane
[218] enables for the controlled, stepwise substitution with different alcohols, resulting
in unsymmetrical phosphites (scheme 20B). These types of phosphites can be used to
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Scheme 20 Synthesis routes for A) symmetrical and B) unsymmetrical phosphites.
As depicted in scheme 18, azides can also be converted with phosphonites in the so-called
Staudinger-phosphonite (SPhR) reaction, giving rise to phosphonamidates. However,
compared to phosphites, phosphonites are more prone to auto-oxidation [221], which
complicates their use in modifications of biomolecules. Nevertheless, as described by
Vallee et al., using an sp2-hybridised aryl- rather than an alkyl-substituent at phosphorus
led to increased stability of phosphonites when exposed to air [222]. To further avoid
oxidation, they protected the phosphonites with borane, a process that can be reverted
adding the base DABCO and gentle heating (scheme 21). Moreover, in order to increase
water-solubility, they introduced oligoethylene units at the O-substituents. With these
phosphonites, they could successfully modify azido-containing peptides and the protein
calmodulin under buffer conditions in high conversions. Importantly, these reactions









































OTris buffer pH 8.2,
10% DMSO, 2 h, 70%
Scheme 21 First application of the Staudinger-phosphonite reaction for the site-selective modi-
fication of a protein.
Vallee et al. further expanded the scope of the Staudinger-phosphonite reaction to
borane protected ethynylphosphonites [223]. With these substrates, a stepwise conju-
gation of two different azides could be achieved (scheme 22). In this study, borane-
protected diethyl-ethynylphosphonites were used, which could be easily generated from
diethylchlorophosphite and ethynylmagnesium bromide followed by the addition of BH3,
similar to a published protocol from Montchamp and co-workers [224]. This borane
protected phosphonite was then first subjected to a copper-catalysed azide-alkyne cy-
cloaddition (CuAAC), forming a triazole. In this step, the Staudinger reaction with
the phosphorus is prevented due to the borane-adduct. Only subsequent deprotection
by means of DABCO liberates the reactive triazole phosphonite, making it thereby
amenable to react with a second azide. Similar as for the Staudinger-phosphite reaction
described above, this system was made applicable to peptide and protein modification
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in buffer conditions by the incorporation of stabilising oligo-ethylene glycol through
the O-substituent [225]. Furthermore, as described by Siebertz et al., the use of phos-
phites with O-ortho-nitrobenzyl-substituents enabled the UV-light-induced cleavage of
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Scheme 22 Borane-protected ethynylphosphonites enable the modular coupling of two azides.
When reacting unprotected ethynylphosphonites directly with azides in the Staudinger-
phosphonite reaction, ethynylphosphonamidates are being generated (scheme 23A)
[208]. Our group discovered that this transformation induces reactivity for a subse-
quent thiol-addition to the alkyne group yielding stable thiol conjugates. The fact
that thiol addition is only observed once the phosphonamidate has formed but not
on the phosphonite stage could be explained by the electron-withdrawing nature of
the P=O bond in the phosphonamidate. This likely renders the alkyne moiety more
electron-poor and thus activates it toward nucleophilic attack by thiols. Importantly,
both steps, the Staudinger-phosphonite reaction to make the phosphonamidate as well
as the subsequent addition of thiols, proceed with excellent chemoselectivity. This
feature is distinct from most other thiol/cysteine-selective methods, where the synthesis
of the thiol-reactive reagent often requires several steps including protecting group
manipulations (compare introduction, chapter 1.3.1).
As shown by Kasper et al., O-ethyl-ethynylphosphonamidates could be efficiently syn-
thesised in DMF from the respective azide-precursors and diethyl-ethynylphosphonite.
As probed with reduced glutathione, the thiol-addition to an O-ethyl, N -aryl-EDANS-
ethynylphosphonamidate proceeded with a bimolecular rate constant of 0.62 M−1s−1
at pH 8.5 [208]. Notably, the Z -isomer is thereby formed preferentially, which is in line
with literature reports on the thiol-addition to other electron-deficient alkynes [227].
Next to small molecule derivatives, the Staudinger-phosphonite reaction was applied
to install ethynylphosphonamidates on cyclic peptides, which could subsequently be
conjugated to a cysteine-mutant of eGFP to enable intracellular delivery [208]. In the
same study, the excellent cysteine-selectivity could further be demonstrated by labelling
IgG antibodies. LC-MS/MS analysis of the trypsinated antibody revealed exclusive
cysteine modification, while the other nucleophilic amino acids were not modified,
even when using ethynylphosphonamidate in excess. Moreover, thiol-phosphonamidate
conjugates exhibit high stability under physiological conditions; no thiol exchange or
P-N bond hydrolysis was observed in the presence of excess free thiols or in cell lysate or
human serum. These findings prompted the investigation of ethynylphosphonamidates
as linkers for the generation of stable antibody-drug conjugates (see chapter 5 for back-
ground) [228]. Therefore, an ethynylphosphonite with an O-diethylenglycol substituent
was synthesised starting from bis(diisopropylamino)-chlorophosphine with diethylene
glycol (based on Ref. [224, 223, 226]) (scheme 23B). This phosphonite was subsequently
subjected to the Staudinger-phosphonite reaction with an azide-containing NHS-ester
to generate the respective ethynylphosphonamidate, which could further be coupled
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to a toxin via a free amine. This derivative was then conjugated to a therapeutic
antibody, giving rise to a stable and efficacious ADC.
Notably, the Staudinger-phosphonite reaction generates phosphonamidates as a
racemic mixture, whereby the two enantiomers differ at the substituent configuration
around the phosphorus atom. Consequently, cysteine addition leads to a mixture of
diastereoisomers, which in some cases might be a limitation. However, Kasper et
al. succeeded to separate the two enantiomers of an ethynylphosphonamidate-NHS
building block by means of chiral HPLC [229]. Using these enantiomerically pure


































































O 14 °C, 16 h, pH 8.5
Scheme 23 A) Ethynylphosphonamidates can be accessed by the chemoselective Staudinger-
phosphonite reaction (SPhR) from azides and ethynylphosphonites. Ethynylphos-
phonamidates react selectively with cysteines on proteins, giving the Z -isomer
preferentially. The * marks a chiral center. B) Example for the synthesis of
an ethynylphosphonamidate-toxin derivative, which was used to generate stable
antibody-drug conjugates.
In a different study, Kasper and Glanz employed the Staudinger-phosphonite reac-
tion to make vinylphosphonamidates using vinylphosphonites as the starting materi-
als (scheme 24A) [209]. Analogously to ethynylphosphonamidates, vinylphosphonami-
dates could be used for cysteine-selective bioconjugations such as antibody labelling
at cysteines. However, it was observed that vinylphosphonamidates are less reactive
in thiol-additions compared to ethynylphosphonamidates owing to the less electrophilic
sp2-hybridised vinyl-carbon. Nevertheless, the reactivity of vinylphosphonamidates can
be enhanced by varying the N - and O-substituents (scheme 24B). Generally speaking,
the more electron-withdrawing these substituents are, the more reactive the vinyl bond
gets towards nucleophilic attack by thiols. With two equivalents of glutathione at pH
8.5, an N -phenyl vinylphosphonamidate (10mM) showed 80% conversion after 24 hours,
while a comparable N -alkyl derivative was only converted 20% under the same condi-
tions. The electron-withdrawing sp2-aryl substituent thus increased the reactivity. The
reactivity of the N -phenyl derivative could be further enhanced by replacing the O-ethyl
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residue by a more electron-withdrawing O-trifluoroethyl substituent. This derivative re-






















































































Scheme 24 A) Vinylphosphonamidates can be accessed by the chemoselective Staudinger-
phosphonite reaction from azides and vinylphosphonites. Vinylphosphonamidates
react selectively with cysteines on proteins. The * marks a chiral center. B) The
reactivity of vinylphosphonamidates with thiols (e.g. glutathione, GSH) depends
on the N - and O-substituents.
As depicted in scheme 25, the vinylphosphonites used in the above described studies
were accessed via different routes (again based on Ref. [224, 223, 226]). In one route,
phosphorus trichloride was first reacted with the desired alcohol and then treated with
vinylmagnesium bromide to give the respective vinylphosphonite (route A). Alterna-
tively, bis(diisopropylamino)-chlorophosphine was first alkylated with vinylmagnesium
bromide and then subjected to tetrazole-mediated substitution with the desired alcohol
(route B). Attempts to isolate unprotected vinylphosphonites failed in many cases due to
product decomposition, hence they were protected with borane for isolation and storage.
Before use in the Staudinger-phosphonite reaction, the borane protection was removed
by treatment with DABCO. The diethyl-vinylphosphonite could be accessed from com-
mercially available diethyl chlorophosphite and vinylmagnesium bromide (route C) and
was used as crude mixture in the reaction with azides. Notably, a significant increase in
thiol addition efficiency was observed when the SPhR was carried out in the presence
of a thiol in a one-pot reaction. This variant of the SPhR enabled the facile stapling of





















































































Scheme 25 Different synthetic routes to access vinylphosphonites.
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1 Introduction
1.4.2 Reactions of P(III) reagents with other electrophiles
Next to azides, the reactivity of phosphorus(III) reagents has also been explored with
other electrophiles. In 1898, Michaelis described the reaction of phosphites with alkyl
halides to generate phosphonates [230]. This reaction has further been elaborated by
Arbuzov [231] (and several other investigators [232]), giving it the name Michaelis-
Arbuzov reaction. The proposed mechanism of the classical Michaelis-Arbuzov reaction
between phosphites and alkyl halides is depicted in scheme 26A. First, the lone pair elec-
trons of the phosphite attack the electrophilic alkyl group of the alkyl halide, thereby
substituting a halide anion. In the formed phosphonium salt intermediate, the alkyl
group originating from the alkyl halide is attached at the phosphorus. Then, the dis-
placed halide ion promotes the dissociation of an alkyl group of the phosphite from
the reactive phosphonium intermediate, a process that is facilitated by the tendency of
the phosphorus atom to withdraw electrons to expand its valency by forming a P=O
bond. Overall, a trivalent phosphorus species (phosphite) is converted into pentavalent
phosphorus species (phosphonate). In this process, a new alkyl halide is generated as a
by-product. Typically, this transformation is carried out at elevated temperature.
Next to phosphites, the Michaelis-Arbuzov reaction can also be applied to phospho-














































































































































































































































































































































































































Scheme 26 A) Mechanism of the classical Michaelis-Arbuzov reaction between phosphites and
alkyl halides for the generation of phosphonates. B) Variations with other P(III)
reagents.
Moreover, it has been recognised early that besides alkyl halides, trialkyl phosphites
are also reactive towards various other electrophiles [232], some of which are depicted
in scheme 27. The reaction with β-halo-esters for instance gives rise to β-ester phos-
phonates, which serve as starting materials in the HWE reaction [233]. Similarly, phos-
phonates can be accessed using quaternary salts of Mannich bases [234] or alkyl p-
toluenesulfonate esters [235]. While the latter substrate class requires elevated temper-
atures to convert effectively, more reactive starting materials such as sulfenyl chlorides
have been shown to react readily at temperatures as low as –60 ◦C [236]. Notably, us-
ing sulfenyl chlorides as starting materials, thiophosphonates are formed, containing a
phosphorus-sulphur bond.
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Scheme 27 Various electrophiles react with trialkyl phosphites in Arbuzov-type reactions.
Reactions of P(III) reagents with disulfides
Another well-known substrate class to readily react with phosphorus(III) reagents
are disulfides. Treating them for instance with phosphines leads to the reduction
of the disulfide bond to thiols. The water-soluble phosphine derivative tris(2-
carboxyethyl)phosphine (TCEP) is widely used for the mild reduction of disulfide















Scheme 28 Disulfide reduction by TCEP.
In 1955, Jacobson et al. reasoned that disulfides might as well be good substrates to
react with phosphites, just like the other electrophiles described in scheme 27. Indeed,
when they reacted diethyldisulfide and triethylphosphite together at 90 ◦C for 10 hours,
they were able to obtain the desired ethylthiophosphonate in 77% yield (scheme 29A)
[237]. Moreover, they found near quantitative amounts of diethyl sulfide as a by-product,
indicating that the reaction followed an Arbuzov-like mechanism (compare scheme 26).
A similar outcome was observed by Poshkus et al. when they treated triethylphosphite
with a symmetrical, aromatic disulfide in boiling benzene (scheme 29B) [238]. However,
here the product could be obtained in similar yield after significant shorter amount of
time (ca. 2.5 h as reported in Ref. [239]). This circumstance can be explained by the
fact that the disulfide bond in the aryl derivative is more polarised and hence more
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symmetrical disulfide phosphorothioate sulfide
Scheme 29 Examples for the generation of phosphorothioates from the reaction of triethylphos-
phite with a symmetrical A) dialkyl- and B) diaryldisulfide as described in Ref.
[237] and [238], resp ctively.
Along these lines, Harvey et al. thought that the reactivity of phosphites towards
disulfides could be further enhanced by using unsymmetrical disulfides, reasoning
that the sulphur-sulphur bond in the latter are yet more polarised and thus more
electrophilic than in symmetrical disulfides [239]. Indeed, as demonstrated with a
handful of unsymmetrical disulfides, they noticed striking enhancement of reactivity
in the reaction with triethylphosphite (scheme 30B). In fact, those substrates reacted
exothermically at room temperature and the desired phosphorothioates could be
obtained in good yields next to the expected sulfides (by-products of the thiolate











































































Scheme 30 A) Proposed mechanism of the reaction between triethylphosphite with unsym-
metrical disulfides. B) First examples of this reaction reported by Harvey et al.
[239].
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Also other synthetic routes exist to generate phosphorothioates, for instance via nucle-
ophilic substitution of (RO)2P(O)Cl halides with thiols (e.g. Ref. [240]). An alterna-
tive method, described by Zhu et al., relies on the palladium-catalysed dehydrogena-
tive coupling of H-phosphonates with thiols [241]. Moreover, phosphorothioates were
synthesised in NHC-catalysed coupling reactions between H-phosphonates and disul-
fides [242]. Nevertheless, for the installation of phosphorothioates on biomolecules, the
above described route relying on phosphites and activated disulfides seems most suit-
able, as it is independent of catalysts and proceeds efficiently under mild conditions.
The applicability of the phosphite-disulfide reaction on biomolecules has for instance
been demonstrated by Higson et al. for the synthesis of a diribonucleotide with a 3′-S -
phosphorothiolate linkage, as depicted in scheme 31 [243]. They used a para-nitro-
pyridine activated disulfide, which readily reacted with a ribonucleotide-substituted




































Scheme 31 Example for the reaction between a trialkylphosphite and an unsymmetrical disul-
fide to generate a phosphorothiolate-linked diribonucleotide as shown by Higson et
al. [243].
In a different example, Bertran-Vicente et al. have made use of the chemoselective
phosphite-disulfide reaction to generate site-specifically phosphorylated cysteine pep-
tides (pCys) [244] (scheme 32). To this end, they activated cysteine peptides with the
Ellman’s reagent, which readily reacted with a photo-cleavable phosphite to the corre-
sponding phosphorothiolate ester. Excellent conversion was observed when the reaction
was run in DMF and the product could be isolated in 55% yield. Under aqueous
conditions however, only 27% of the phosphorothiolate ester could be obtained and free
cysteine peptide was observed as a side-product. A likely explanation of this observation
is that water attacked the electrophilic phosphorus in the intermediary formed triester
thiophosphonium cation, thereby substituting the cysteine residue (scheme 32). Never-
theless, with the intact phosphorothiolate ester in hand, pCys peptides could be obtained
after UV-light mediated cleavage of the O-substituents. pCys is a post-translational
modification of cysteine and is for instance known to function as an intermediate in the
phosphoenolpyruvate-dependent phosphotransferase system [245] or in dephosphoryla-
tion of phosphotyrosine residues by protein tyrosine phosphatases [246, 247]. Chemos-
elective methods to access homogenous pCys peptides allows to study the properties
and function of this PTM. Davis and co-workers managed to install pCys on a protein
level [181]; however their protocol relying on the reaction of sodium thiophosphate with
dehydroalanine (Dha) delivers an epimeric mixture of pCys proteins (compare chapter
1.3.3). In contrast, the method by Betran-Vicente et al. relying on the chemoselective
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Scheme 32 Generation of site-specifically phosphorylated cysteine-peptides as reported by
Bertran-Vicente et al. [244].
As illustrated with all the examples in this chapter, reactions between phosphorus(III)
reagents and electrophilic substrates give rise to a broad variety of P(V) organophospho-
rus compounds with interesting properties. Phosphines can be used to reduce azides and
disulfides or be employed in Staudinger-ligations. Moreover, phosphorus(III) reagents
with one or several P-O bonds have been employed in conjugation reactions with var-
ious electrophiles. For instance, the Staudinger-phosphite and Staudinger-phosphonite
reactions with azides give access to phosphoramidates and phosphonamidates, respec-
tively (scheme 33). Interestingly, our group has found that unsaturated vinyl- and
ethynylphosphonamidates are highly selective towards thiol-additions, which was em-
ployed to generate stable bioconjugates. On the other hand, the reaction between
phosphites and disulfides (and in particular unsymmetrical disulfides) results in the for-
mation of phosphorothiolates. Building up on all these results, it consequently seemed
interesting to explore the reactivity between electrophilic disulfides and unsaturated
vinyl- and ethynylphosphonites. The products expected from this transformation are
unsaturated phosphonothiolates. Formally, these are analogues of unsaturated phospho-
namidates, whereby sulphur instead of nitrogen is bonded to phosphorus. Very little has
been reported so far about the synthesis of unsaturated phosphonothiolates from unsat-
urated phosphonites. Few examples exist on the reaction of phenyl-phosphonites with
disufides [248, 249, 250] and in the late 1980s, Trishin et al. have synthesised vinylphos-
phonothiolate derivatives from sulfenyl chlorides and vinylphosphonites [251]. However,
to the best of our knowledge, disulfides have not been explored as substrates in reactions
with vinyl- or ethynylphosphonites. We hypothesised that unsaturated phosphonothio-
lates might as well react in thiol-additions to the corresponding thiol-conjugates. Again,
to the best of our knowledge, this type of transformation has not been described be-
fore. Hence, a major goal within this thesis was to synthesise and evaluate unsaturated
phosphonothiolates as reagents for cysteine-selective bioconjugations.
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Scheme 33 Overview of products formed from the reaction of phosphites and phosphonites
with azides and electrophilic disulfides. Unsaturated phosphonamidates react se-
lectively with thiols, which prompted the question whether this reactivity could be
extrapolated to unsaturated phosphonothiolates, which is the subject of this the-
sis. The dashed triple bond (before thiol addition) indicates that this can either





To date, a plethora of well-optimised strategies exist for the modification of proteins
with various functional tags, including methods that rely on the incorporation of unnat-
ural reactive handles as well as methods that specifically address canonical amino acids.
The development of these methods gave access to a wide range of bioconjugates, includ-
ing biopharmaceuticals and probes to study cellular processes in health and disease.
While it seems that the bar for innovation in this advanced field is high, the challenge of
applying organic chemistry on proteins with precise control still prevails. When relying
on the modification of canonical amino acids and in particular cysteine, the repertoire
of methods that feature both excellent selectivity as well as easy access to starting ma-
terials is still limited. As outlined in detail in the introduction (see chapter 1.3.1), the
direct installation of electrophilic, cysteine-reactive handles into complex molecules such
as polypeptides is prohibited for many of the currently available methods due to the
lack of chemoselectivity in the synthesis of these handles. As a consequence, multi-step
workarounds with protecting group manipulations are often needed to synthesise and
install cysteine-reactive groups in these cases. On the other hand, methods that allow
the installation of cysteine-reactive handles on complex substrates in a chemoselective
manner are rare. In our group, this has been achieved in the chemoselective synthesis
of cysteine-reactive phosphonamidates via the Staudinger-phosphonite reaction. This
strategy is however limited to azide-containing substrates. When relying on canonical
amino acids, the installation of cysteine-reactive electrophilic groups on proteins has
only been demonstrated in a handful of examples as outlined in chapter 1.3.3. Impor-
tantly, these methods in principle allow for protein-protein conjugation solely based on
canonical amino acids, which is highly attractive given that there is a great need for
homogenous protein-protein conjugates in both pharmaceutical industry as well as in
basic research.
In this thesis, our goal was to develop a chemoselective method that enables the in-
stallation of a cysteine-selective electrophilic group on cysteine residues, independent of
unnatural amino acids. Specifically, we set out to investigate unsaturated vinyl- and
ethynylphosphonothiolates as new classes of cysteine-reactive, electrophilic reagents
(Fig. 13A). We hypothesised that these reagents could be incorporated chemoselectively
into unprotected biomolecules by addressing activated cysteine residues with unsatu-
rated phosphonites (see chapter 1.4.2). Assuming that unsaturated phosphonothiolates,
similar to unsaturated phosphonamidates (see chapter 1.4.1), react selectively with cys-
teine, the proposed strategy in this thesis would allow selective thiol-thiol bioconjuga-
tions. Within the main objective of developing a cysteine-selective protein modification
method based on unsaturated phosphonothiolates, the first step was to establish con-
ditions that enable the efficient synthesis of these reagents from electrophilic disulfides
and unsaturated phosphonites. The second step in the method development was to
investigate the properties of unsaturated phosphonothiolates with respect to their reac-
tivity and selectivity towards thiols as well as evaluating the stability of the resulting
thiol-conjugates under physiologically relevant conditions. We thought that these as-




As mentioned above, the main aim for developing this method was the installation
of electrophilic phosphonothiolates on unprotected peptides and proteins to enable site-
selectively linked protein-protein conjugations (Fig. 13B). In two additional applications,
we furthermore set out to employ unsaturated phosphonothiolates as linkers to gener-








Application II: generation of phosphonothiolate-
linked antibody-drug conjugates




Application III: generation of protein-photocrosslinker 
conjugates to study dynamic protein-protein interactions
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Fig. 13 Goals of this thesis. A) Synthesising phosphonothiolates and probing them for cysteine-
selective protein labelling. B) Envisioned applications of unsaturated phosphonothio-
lates as linkers in bioconjugates. The dashed bond in the phosphonite and the phos-
phonothiolates indicates either a double or a triple bond and consequently a single or
a double bond in the thiol-conjugate.
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The research described in this chapter was conceptualised by Prof. Dr. Christian P.
R. Hackenberger and the author and is based on previous work from the Hackenberger
group and in particular from Dr. Jordi Betran-Vicente, Dr. Marc-André Kasper, Dr.
Maria Glanz and Sergej Schwagerus [228, 208, 209, 244]. The author conducted the
research described in this chapter with the following exceptions: The synthesis route to
access unsaturated phosphonothiolates from phosphorus trichloride was developed to-
gether with Stephen Byrne. The finding that TFA inhibits the formation of the thiolate
re-attack side-product was made together with Kevin Broi. Jahaziel Jahzerah assisted
with the synthesis of small molecule phosphonothiolates. Molecular electrostatic po-
tential maps were calculated by Songhwan Hwang from the group of Dr. Han Sun
(FMP Berlin). LC-MS/MS measurements were performed by Dr. Michal Nadler-Holly
and Heike Stephanowitz from the group of Dr. Fan Liu (FMP Berlin). MS/MS data
was processed and analysed by Christian Stieger. The MMAE compound 49 used in
this chapter was synthesised by Dr. Philipp Ochtrop and Dr. Marc-André Kasper. In
addition, Dr. Marc-André Kasper synthesised the EDANS-phosphonamidate deriva-
tive 67 and performed the kinetic measurements with this substrate and also provided
the Dabcyl-cysteine peptide used for the generation of FRET-pairs. Peter Schmieder
and Nils Trieloff set up time-course 31P-NMR experiments and assisted with the analy-
sis. Ines Kretzschmar synthesised cysteine peptides. Dagmar Krause and Beate Kindt
supported the author with some of the small molecule and peptide purifications by
reverse-phase HPLC.
Parts of this chapter were published in and are adapted from A.L. Baumann*, S. Schwa-
gerus*, K. Broi, K. Kemnitz-Hassanin, C. E. Stieger, N. Trieloff, P. Schmieder, C. P.
R. Hackenberger. Chemically Induced Vinylphosphonothiolate Electrophiles for Thiol–
Thiol Bioconjugations. J. Am. Chem. Soc. 2020, 142, 9544-9552 (* shared first au-
thorship). In addition, parts of the technology described in this chapter are substance of
a pending patent application by Alice Leonie Baumann, Marc-André Kasper, Stephen
Byrne, Jonas Helma, Heinrich Leonhardt, Tina Stoschek, Marcus Gerlach, Jonas Helma,
Dominik Schumacher, Christian P. R. Hackenberger. Chemoselective Thiol-Conjugation
with Alkene or Alkyne-Phosphonothiolates and -Phosphonates (PCT/EP2019/055509).
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3 Method development: Chemically induced phosphonothiolate electrophiles for
thiol-conjugations
3.1 Outline
Within this part of the thesis, the first goal was to investigate the reaction between
electrophilic disulfides and unsaturated phosphonites to generate unsaturated phospho-
nothiolates (scheme 34 left). The second goal was to evaluate unsaturated phosphonoth-











1) transformation of electrophilic disulfides
into unsaturated phosphonothiolates












Scheme 34 Proposed synthetic route for the generation of electrophilic phosphonothiolates
(left) and application of electrophilic phosphonothiolates as handles for protein
modification at cysteine (right). The dashed bond in the phosphonite and the
phosphonothiolate indicates either a double or a triple bond and consequently a
single or a double bond in the thiol-conjugate.
3.2 Synthesis of small molecule phosphonothiolates from
electrophilic disulfides
Small molecule electrophilic disulfides were synthesised as substrates to test the envi-
sioned synthetic transformation with unsaturated phosphonites. Therefore, the thiol
ethanethiol was reacted with the bis-disulfide reagents 5,5′-dithiobis-(2-nitrobenzoic
acid) (Ellman’s reagent) and 2,2′-dithiobis(5-nitropyridine) (DTNP) to give the respec-
tive electrophilic disulfides 1 and 2 in good yields (scheme 35). In principle, thiols can
be activated to electrophilic disulfides with a number of reagents [252]. Ellman’s reagent
was chosen here based on our groups previous finding that Ellman’s-activated cysteine
residues reacted efficiently with phosphites in the synthesis of phospho-cysteine peptides
(compare scheme 32) [244]. It was thus hypothesised that this type of electrophilic
disulfide would be reactive also towards phosphonites. The DTNP reagent on the other
hand has been used in the synthesis of a phosphorothiolate-linked diribonucleotide
(compare scheme 31) [243]. Furthermore, DTNP has been described in the literature as
a potent reagent to activate thiols for subsequent thiol-exchange as demonstrated for
the generation of disulfide-linked antibody-drug conjugates [252].
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Scheme 35 Synthesis of small molecule electrophilic disulfides 1 and 2 from the reaction of
ethanethiole with bis-disulfides.
As for the unsaturated phosphonite reaction partners, we commenced our investigations
using the diethyl-ethynyl- and diethyl-vinylphosphonites 3 and 4, respectively. These
phosphonites can be readily synthesised from commercially available diethylchlorophos-
phine and ethynyl- or vinylmagnesiumbromide as previously reported by Montchamp
and co-workers and our group (scheme 36) [224, 208, 209, 223, 226]. As observed before,
unsaturated diethyl-phosphonites are prone to oxidize upon exposure to air and hence
they must either be isolated in protected form or used freshly as crude mixtures. Here,
the unsaturated diethyl-phosphonites 3 and 4 were employed as crude mixtures as it

















Scheme 36 Synthesis of diethyl-ethynyl- and diethyl-vinylphosphonites 3 and 4.
Subsequently, the unsaturated crude diethyl-phosphonites 3 and 4 were employed
in reactions with the above synthesised electrophilic disulfides to test whether this
conversion would lead to the targeted unsaturated vinyl- and ethynylphosphonothio-
lates, respectively. In a first test reaction, electrophilic disulfide 1 was mixed with
one equivalent of crude diethyl-ethynylphosphonite 3 in THF at room temperature
(Fig. 14A). 31P-NMR analysis of the reaction mixture indicated the formation of two
phosphorus-containing species (at 37.2 ppm and at 36.6 ppm, Fig. 14B), which could be
isolated and be assigned to the undesired addition products 5 and 6 (Fig. 14A). The
desired ethynylphosphonothiolate product 7 was not observed. Notably, the product
6 was found to be esterified by an ethyl group at the carboxylic acid. This can be
explained when the the carboxylate residue of the Ellman’s group attacked an ethyl
group in the phosphonium cation intermediate, pointing towards an Arbuzov-like
mechanism (compare introduction, chapter 1.4.2).
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Fig. 14 A) Reaction between ethynylphosphonite 3 and electrophilic disulfide 1 did not give
the desired product 7 but the re-attack products 5 and 6 instead. B) 31P-NMR spectra
of the reaction mixture in THF.
The formation of 5 and 6 indicated that the targeted ethynylphosphonothiolate 7 had
been formed intermediately but reacted in situ with the thiolate group originating from
the reaction of 3 with electrophilic disulfide 1 as depicted in scheme 37. This side
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Scheme 37 Re-attack of the thiolate leaving group to ethynylphosphonothiolate 7 in situ.
It was furthermore noticed that the reaction between phosphonite 3 and disulfide 1 pro-
ceeded very quickly, as the phosphonite was fully converted to the products 5 and 6 when
checked by 31P-NMR after a few minutes (Fig. 14B). Any attempts to inhibit the unde-
sired re-attack reaction by the addition of thiol-scavengers to the reaction mixture (such
as maleimides or iodoacetamide) were not successful. From these first observations, it
could be deduced that unsaturated phosphonites indeed react with electrophilic disul-
fides to form phosphonothiolates as hypothesised. Moreover, the re-attack phenomenon
pointed towards high reactivity of unsaturated phosphonothiolates with thiolates. Since
thiolate re-attack in the reaction with electrophilic disulfide 1 and ethynylphosphonite 3
could not be suppressed by adding thiol scavengers, the disulfide-phosphonite reaction
was next investigated with vinylphosphonite 4 instead. Our group has recently re-
ported that thiol additions to vinylphosphonamidates are significantly slower compared
to ethynylphosphonamidate derivatives (see introduction, chapter 1.4.1) [209]. Hence, it
was hypothesised that this reactivity trend might also translate to the respective phos-
phonothiolate derivatives and that less re-attack for the reaction between electrophilic
disulfide 1 and vinylphosphonite 4 would be obtained consequently (Fig. 15A). Indeed,
for this reaction, the desired vinylphosphonothiolate product 8 was found next to the re-
attack product 9 in a ratio of approximately 1:1.4 based on 31P-NMR signal intensities
(Fig. 15B).
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Fig. 15 A) Reacting vinylphosphonite 4 with electrophilic disulfide 1 gave a mixture of the
desired product 8 and re-attack product 9. B) 31P-NMR spectrum of the reaction
mixture in THF. The signal at 32.2 ppm corresponds to triphenylphosphinoxide, which
was used as internal standard in this experiment. The signal at 26.8 ppm might be
vinylphosphonic acid (compare Fig. 17) but this was not confirmed here.
Continuing with the vinylphosphonite 4, even lesser re-attack occurred when the DTNP-
activated electrophilic disulfide 2 was used (Fig. 16A). With this substrate, the ratio
between vinylphosphonothiolate 8 to re-attack product 10 was approximately 3:1 based
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Fig. 16 Compared to substrate 1, less re-attack side-product is formed in situ for the substrate
2 as judged from 31P-NMR analysis of the crude reaction mixture. The signal at
26.8 ppm might be vinylphosphonic acid (compare Fig. 17) but this was not confirmed
here.
The circumstance that less re-attack product formed in the reaction with DTNP-
activated disulfide 2 compared to Ellman’s activated disulfide 1 might be explained by
the different nucleophilicities of the respective leaving groups 5-nitropyridine-2-thiolate
versus 3-carboxy-4-nitrobenzenethiolate. The more electron-withdrawing the aryl
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3 Method development: Chemically induced phosphonothiolate electrophiles for
thiol-conjugations
substituents are, the better stabilised is the thione form (S=C-R), which is less nucle-
ophilic. Along these lines, it will be interesting to test even less nucleophilic leaving
groups in future optimisations. One could for instance use N -methylated pyridine
derivatives or alternatively, incorporate a second electron-withdrawing nitro-group into
the disulfide activator.
Keeping in mind that THF would not be a suitable solvent when applying the disulfide-
phosphonite reaction on peptide substrates, more polar solvents were considered for the
further optimisation of the reaction conditions. The ideal solvent for the installation of
phosphonothiolates on biomolecules would be water or an appropriate aqueous buffer.
However, when reacting electrophilic disulfide 2 and vinylphosphonite 4 under aque-
ous conditions (DMSO/H2O= 3:1
3), no desired vinylphosphonothiolate 8 was observed
(Fig. 17A). Instead, species at 27.3 and 18.2 ppm were detected in the 31P-NMR of the
reaction mixture (Fig. 17C). Although these phosphorus-containing species were not iso-
lated here, it was hypothesised that they are vinylphosphonate 11 and vinylphosphinate
12, respectively (Fig. 17A). As for the vinylphosphonate 11 this assumption is based
on comparison to a commercial sample of this exact compound, which showed the same
chemical shift under these conditions (see Appendix Fig. 143). Vinylphosphinate 12 on
the other hand has been characterised by Montchamp and co-workers [253]. Although
measured in a different solvent (CDCl3), the
31P-NMR shift they report (25.1 ppm) is
close to the one observed here (27.3 ppm). Furthermore, when crude vinylphosphonite 4
alone was subjected to the same conditions (DMSO/H2O= 3:1), the species at 27.3 ppm




















































































































Fig. 17 A) Under aqueous conditions, the reaction between electrophilic disulfide 2 and
diethyl-vinylphosphonite 4 did not yield vinylphosphonothiolate 8 but vinylphospho-
nate 11 and vinylphosphinate 12 instead. B) 31P-NMR of the reaction mixture in
DMSO/H2O= 3:1.
375% of DMSO was necessary for solubilising both reagents.
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Fig. 18 When subjecting crude vinylphosphonite 4 to a mixture of DMSO/H2O= 3:1, the main
observed species is presumably vinylphosphinate 12.
In order to shed light on the side-reactions occurring under aqueous conditions,
the reaction between disulfide 4 and vinylphosphonite 2 was repeated in DMSO
supplemented with one equivalent of 18O-labelled water (scheme 38). Analysis of
the reaction product by 31P-NMR and MS clearly indicated the formation of phos-
phonate 11 along with its re-attack product (see Experimental Fig. 68 and Fig. 70).
Thereby, a mixture of 16O- and 18O-labelled phosphonate (in similar intensities)
was observed. Vinylphosphonothiolate and its re-attack product were also observed
in about the same amount, however, containing exclusively the normal 16O-isotope
in their P=O bond. These findings can be rationalised by having a closer look at
the Arbuzov-type mechanism (introduced in chapter 1.4.2) the phosphonite-disulfide
likely follows (scheme 38A). First, vinylphosphonite 4 attacks the disulfide 2 at its
more electrophilic sulphur, liberating thereby 5-nitropyridine-2-thiolate. The formed
phosphonium intermediate can then undergo different transformations. In the desired
case, the vinylphosphonothiolate is formed, mediated by a nucleophile attacking the
methylene group of one of the O-ethyl groups (scheme 38A). Possible nucleophiles that
drive the formation of the vinylphosphonothiolate 8 are the thiolate leaving group4
or halide ions originating from the phosphonite synthesis (Fig. 38A). In a different
scenario, the cationic phosphorus in the phosphonium intermediate gets attacked
by nucleophiles such as water. When this happens, the thiolate residue is liberated
preferentially over the alkoxide as it is less basic (Fig. 38B) [254]. This explains why
diethyl-vinylphosphonate was formed in the presence of water (scheme 38, Fig. 17). As
mentioned above, in the reaction between disulfide 2 and phosphonite 4, both 16O-
and 18O-labelled phosphonates were observed. A simple explanation can be that the
reaction mixture was contaminated with H2O
16.
4The ethyl sulfide of the leaving group could be isolated from the reaction mixture (see Experimental,
chapter 8.2.3 for its characterisation).
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Scheme 38 A) Mechanistic proposal for the disulfide-phosphonite reaction. B) Hydrolysis
of the phosphonium intermediate results in release of the thiol residue and the
formation of a phosphonate.
The finding that the reaction between electrophilic disulfides and unsaturated phos-
phonite 4 is not compatible with aqueous conditions, narrowed down the possibilities
for appropriate, polar solvents. Further optimisation studies were continued in dry
dimethylsulfoxide (see below). Nevertheless, in the future one could try to optimise
the reaction for aqueous conditions by using more electron-withdrawing O-substituents
in the phosphonite. Perhaps, this way at least a partial competition between thiolate
versus alkoxide leaving group would be achieved. However, by employing a phosphonite
with electron-withdrawing O-substituents, also the initial attack to the disulfide would
be expected to be slower, owing to the less nucleophilic phosphorus in this case. Another
consequence of using an electron-withdrawing O-substituent (e.g. trifluoroethyl) could
be decreased stability of the phosphonothiolate product. As a P-O(trifluoroethyl) bond
would be more polarised than the P-O(ethyl) bond, hydrolysis through nucleophilic at-
tack of water to the phosphorus in the phosphonothiolate could be enhanced in such
a system (compare chapter 3.7). A different way to decrease undesired hydrolysis of
the phosphonium intermediate could be to incorporate a nucleophile into the phospho-
nite side chain, thereby promoting intramolecular rearrangement of the phosphonium
intermediate to the phosphonothiolate.
As mentioned above, further optimisations using the diethyl-vinylphosphonite 4 were
carried out in dry DMSO (Fig. 19). In this case, the desired vinylphosphonothiolate 8
and the re-attack product 10 were observed in a ratio of approximately 1:1 based on
31P-NMR signal intensities (Fig. 19B). For comparison, the same reaction in THF gave
a better ratio of phosphonothiolate to re-attack product (ca. 3:1, see Fig. 16). A likely
explanation of this difference is the better solubility of the thiolate leaving group in the
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more polar solvent DMSO. In fact, for the reaction in THF, an orange precipitate was
observed, indicating partial insolubility of the leaving group, which can explain why it
re-attacked the vinylphosphonothiolate to a lesser extent. As can be seen in the 31P-
NMR spectrum in Fig. 19B, next to the phosphonothiolate and its re-attack product,
also a shift likely corresponding to vinylphosphonate 11 was observed. The formation
of this by-product can be explained by the mechanism discussed above as a consequence
of contamination with water. Notably, when subjecting the vinylphosphonite 4 alone to











































































































Fig. 19 A) The reaction between electrophilic disulfide 2 and phosphonite 4 in DMSO re-
sults in a mixture of the desired vinylphopshonothiolate 8 and re-attack by-product
10 in a ratio of ca. 1:1. B) 31P-NMR spectrum of the reaction mixture in THF.
The phosphorus-containing species, which are not labelled with numbers could not be
identified.
Eventually, it was found that re-attack of the thiolate leaving group to the unsaturated
phosphonothiolate 8 could be suppressed when the reaction mixture was supplemented
with trifluoroacetic acid (TFA) (Fig. 20). Presumably, under acidic conditions, the thio-
late leaving group gets protonated and is hence no longer a good nucleophile. Complete
inhibition of re-attack could be achieved in the presence of ten equivalents of TFA. Un-
der these conditions, the desired vinylphosphonothiolate 8 was observed as the main
product by 31P-NMR (Fig. 20B). Next to traces of vinylphosphonate 11, another minor
side-product, characterised by two douplet peaks at around 44 and 55 ppm was observed.
It was hypothesised that these signals can be assigned to the structure 13 (Fig. 20A)5.
5Although this product was not isolated here, the assumption that it is in fact compound 13 is
reasonable given than an analogous side-product was observed on peptide level (see scheme 43),
where it has been isolated and characterised (see Experimental scheme 58 and Appendix Fig. 167 &
Fig. 168).
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Fig. 20 A) In the presence of TFA, the re-attack reaction is fully suppressed. B) 31P-NMR
spectrum of the reaction mixture.
As depicted in scheme 39, the side-product 13 presumably forms when vinylphospho-
nite attacks the formed vinylphosphonothiolate 8 at its electrophilic vinyl-bond. The
resulting phosphonium intermediate can then get attacked by a nucleophile (such as the


























































































































































Scheme 39 Mechanistic proposal for the formation of side-product 13.
It was further found that a slight excess (1.5-2 equivalents) of vinylphosphonite was
needed to obtain full conversion of the electrophilic disulfide 2 in DMSO containing
10 eq. TFA. The reason for this is that diethyl-vinylphosphonite 4 oxidises to diethyl-
vinylphosphonate 11 under these conditions. In fact, when subjecting crude vinylphos-
phonite 4 alone to DMSO/TFA, quick oxidation to vinylphosphonate was observed by
31P-NMR analysis. Consequently, the order of mixing the reagents was important.
Vinylphosphonite 4 had to be added to the disulfide dissolved in DMSO/TFA and not
vice versa to minimise oxidation of the phosphonite.
Using the optimised conditions (two equivalents of phosphonite in DMSO supplemented
with ten equivalents TFA), full conversion of 2 was obtained (judged by TLC) and the
desired vinylphosphonothiolate 8 could be isolated in 80% yield (scheme 40).
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Scheme 40 Synthesis of small molecule vinylphosphonothiolates under optimized reaction con-
ditions.
Next, the phosphonite-disulfide reaction was tested on a few other derivatives. There-
fore, benzylmercaptan, a biotinthiol derivative and mercaptopropionic acid were first
activated with DTNP to the corresponding electrophilic disulfides 14-16. These were
then subjected to the reaction with crude vinylphosphonite 4 under the optimised condi-
tions with DMSO/TFA. For all substrates, the targeted vinylphosphonothiolates 17-19
could be isolated in good yields. While the yields for the derivatives 18 and 19 were
comparable to the ethylderivative 8 (80% and 70%, respectively), the benzyl-derivative
17 was obtained only in 55% yield. For the latter substrate, the phosphonothioate side-
product 20 was observed in the reaction mixture. Based on the mechanism discussed
above, the formation of this side product can be explained looking at the corresponding
phosphonium intermediate (scheme 41). In this case, the electrophilic, benzylic position
of the thiol residue competes for nucleophilic attack with the methylene group of the
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Scheme 41 Mechanistic explanation for the formation of phosphonothioate side-product 20.
The optimised protocol for the disulfide-phosphonite reaction was also successfully ap-
plied for the synthesis of ethynylphosphonothiolate 7 from ethynylphosphonite 3 and
electrophilic disulfide 2 (scheme 42). Here, no re-attack product was observed and the
desired ethynylphosphonothiolate could be isolated in 58% yield. This result is in sharp
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contrast to the reaction between ethynylphosphonite 3 and disulfide 1, where exclusive
formation of re-attack products was observed (compare Fig. 14). The finding that TFA
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Scheme 42 Synthesis of ethynylphosphonothiolate 7 from electrophilic disulfide 2 and
ethynylphosphonite 3 using the optimised protocol. Running the reaction under
acidic conditions was key to suppress re-attack.
Taken together, the results described in this chapter demonstrate that unsaturated
phosphonothiolates can be synthesised from electrophilic disulfides in an efficient manner
by suppressing the formation of re-attack by-products under acidic conditions.
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3.3 Synthesis of peptide phosphonothiolates
Based on the promising results with small molecule vinylphosphonothiolates, we next
set out to install vinylphosphonothiolates on unprotected peptides to test whether the
disulfide-phosphonite reaction was chemoselective in the presence of other functional
groups (scheme 43). Therefore a set of DTNP- activated disulfide model peptides 23-
27 with the general sequence KYRCXK were used, whereby X stands for one of the
amino acids alanine (A), serine (S), histidine (H), aspartic acid (D) or methionine (M).
Together with lysine (K), arginine (R) and tyrosine (Y), the potentially interfering func-
tional groups of natural amino acids were thereby covered. As for the small molecule
substrates, the peptides 23-27 reacted quickly with vinylphosphonite 4 in DMSO/TFA
to yield the desired vinylphosphonothiolates 28-32 in 29-41% after reverse-phase HPLC
purification. No reaction with any of the other amino acids was observed, which demon-
strated the excellent chemoselectivity of this transformation on unprotected peptides.
The purified peptides were analysed by 31P-NMR, whereby a 1:1 mixture of two di-
astereoisomers was observed as a consequence of the racemic phosphonothiolate (Ap-
pendix, e.g. Fig. 161). The two main side products in this transformation were reduced
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Scheme 43 Installation of vinylphosphonothiolate on cysteine-activated peptides. The indi-
cated yields are isolated yields after reverse-phase HPLC purification.
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3.4 Synthesis of small molecule phosphonothiolates from
phosphorus trichloride
Next to the chemoselective disulfide-route described above, an alternative route for the
synthesis of vinyl- and ethynylphosphonothiolates was developed starting from phos-
phorus trichloride (PCl3) as depicted in scheme 44. Thereby, PCl3 was first converted
in a three-step one-pot reaction to the vinyl- or ethynyl-intermediates 33 or 34 (pro-
tocol adapted from Ref. [255]). Subsequent tetrazole-mediated substitution of the
diisopropyl-amine residue with thiols and oxidation with t-BuOOH delivered unsatu-
rated phosphonothiolates (protocol adapted from Ref. [256]). This route was followed
for the synthesis of benzylderivatives 35 and 17 as well as for the synthesis of Boc-
protected amine derivatives 36 and 37.
This route is longer compared to the above discussed disulfide route. Here, starting from
PCl3, five steps are needed to obtain phosphonothiolates, whereas the disulfide route
contains only 2 steps (disulfide activation and treatment with phosphonite). Also the
overall yields are lower. Here, the overall yield of vinylphosphonothiolate 17 (starting
from PCl3) is 13%, whereas it was 44% for the same compound via the disulfide route
(starting from benzylmercaptan). Moreover, the PCl3 route can not be used to install
unsaturated phosphonothiolate chemoselectively on biomolecules. Nevertheless, synthe-
sising unsaturated phosphonothiolates via this route provides an alternative solution to
avoid re-attack (compare previous chapter).
i) 1 eq. EtOH, HN(i-Pr)2, Et2O, −40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, −40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, −40 °C to r.t.
1 eq.i)








Scheme 44 Synthesis of unsaturated phosphonothiolates from PCl3.
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3.5 Functionalisation of general building blocks
Carboxylic acid and amine phosphonothiolate derivatives could be further derivatised
by means of amide couplings (scheme 45). Carboxylic acid derivative 19 was for instance
activated to electrophilic NHS-ester 38 and subsequently coupled to EDANS, yielding
the fluorescent vinylphosphonothiolate derivative 39 (scheme 45A). The Boc-protected
amine-derivatives 36 and 37 were deprotected with TFA and then coupled to EDANS-
derivative 42, biotin or succinic acid to give derivatives 43-48 (scheme 45B). The phos-
phonothiolate derivatives 50 and 51 carrying cytotoxins were synthesised from 47 and
48 (scheme 45C). These derivatives were later used for the generation of antibody-drug
conjugates (see chapter 5). Photoreactive derivatives 54 and 55 (used in chapter 6.4)


































































































































































Scheme 45 Derivatisation of amine and carboxylic acid phosphonothiolates through amide
couplings. HATU was used as coupling agent in amide couplings. aIsolated yields
after reverse-phase HPLC-purification. bUsed as crude product without further
purification.
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3.6 Thiol additions to unsaturated phosphonothiolates
Having successfully synthesised vinyl- and ethynylphosphonothiolates, the next aim
was to investigate the reactivity of these compounds in thiol additions. In a first
proof-of-concept experiment, the S -benzyl vinylphosphonothiolate derivative 17 was
mixed with reduced glutathione in aqueous buffer at pH 8.5 and the reaction was
followed by UV-LC-MS (Fig. 21). To our delight, clean conversion was observed and
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Fig. 21 Glutathione (GSH) addition to 17 (10mM) gave thiol-conjugate 56. The reaction was
monitored by LC-UV (220 nm).
Similarily, glutathione addition to ethynylphosphonothiolate 7 gave the conjugate 57
(scheme 46). The thiol addition thereby gave the Z -double bond isomer preferentially
(E/Z=1:10), which is in line with previous observations made by our group and others
for the thiol addition to electron-deficient alkynes [208, 227].
S P OEt
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Scheme 46 Glutathione addition to ethynylphosphonothiolate derivative 7.
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Next, bimolecular rate constants for the thiol addition to vinyl- and ethynylphospho-
nothiolates were determined from equimolecular reactions between reduced glutathione
and water-soluble, fluorescent EDANS-derivatives 39 and 43, respectively (Fig. 22A).
Thereby it was found that glutathione addition to vinylphosphonothiolate derivative 39
proceeds with a bimolecular rate constant of 0.0020M-1s-1 in PBS at pH 7.4 (Fig. 22B).
At pH 8.5, the thiol addition to 39 is roughly an order of magnitude faster with a
bimolecular rate constant of 0.074M-1s-1. This finding can be explained by the fact
that with increasing pH, there is more glutathione present in the reactive, deprotonated
thiolate form. The thiol addition to ethynyl-derivative 43 on the other hand proceeded
approximately 600 times faster compared to the vinyl derivative 39 with a bimolecu-
lar rate constant of 1.32M-1s-1 at pH 7.4. This result coincides with the observation
that more re-attack product was created in the synthesis of ethynylphosphonothiolates
as compared to vinylphosphonothiolates under neutral conditions. The higher reac-
tivity of ethynyl- over vinylphosphonothiolates is further in line with previous work
from our group on unsaturated phosphonamidates, where the same reactivity trend was
observed for vinyl- versus ethynylphosphonamidates [208, 209]. The higher reactivity/-
electrophilicity of ethynylphosphonothiolates could also be visualised by electrostatic
potential maps (Fig. 22C). Therein, the ethynylphosphonothiolate 7 shows lower elec-
tron density at the terminal carbon (more on the blue end of the scale) compared to the
















PBS pH 7.4 or
50 mM NH4HCO3 pH 8.5


















Fig. 22 A/B) Bimolecular rate constants for the thiol addition to unsaturated phosphonothio-
lates 39 and 43. C) Electrostatic potential maps. The atoms in the structures 7 and
8 are colour-coded with respect to the transparent maps on the left. The black wedges
point at the most positive values of the terminal carbons of the triple and the double
bond, respectively.
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Next, the cysteine-selectivity of the thiol addition to vinyl- and ethynylphosphonothio-
lates was investigated on protein level using the monoclonal IgG antibodies Cetuximab
and Trastuzumab. IgG antibodies are large globular proteins with a molecular weight
of about 150 kDa consisting of two identical light and heavy chains (LC, HC), which
are covalently connected via interchain disulfide bridges. These interchain disulfides
can be reduced under mild conditions with DTT or TCEP [228, 257, 258], thereby set-
ting free eight sulfhydril groups for labelling with unsaturated phosphonothiolates. In
non-DTT-treated controls, no modification was expected as IgG antibodies typically
do not contain additional unpaired cysteines. First, to compare the cysteine-selectivity
of vinyl- versus ethynylphosphonothiolates, an excess (50 eq.) of the respective biotin
derivatives 45 and 46 were allowed to react with DTT-reduced antibody Cetuximab
in buffer at pH 8.5 for 16 hours (Fig. 23A). Subsequent Western-blot analysis revealed
labelling of the heavy and the light chains for both biotin-phosphonothiolate derivatives
(Fig. 23B). A higher degree of modification was observed for the more reactive ethynyl-
derivative 45 compared to the vinyl-derivative 46. Importantly, in the negative controls
(-DTT), no labelling was observed for vinylphosphonothiolate 46, indicating excellent
cysteine-selectivity of this derivative. In contrast, with ethynylphosphonothiolate 45,
some labelling was also observed in the negative control, pointing towards unselec-
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Fig. 23 A) Modification of the antibody Cetuximab with biotin derivatives 45 (ethynylphos-
phonothiolate) and 46 (vinylphosphonothiolate) via a mild reduction/alkylation pro-
tocol. B) Western-blot analysis (anti-biotin) of Cetuximab after modification with 45
and 46 at pH 8.5. C) Same analysis for derivative 45 after modification at pH 7.4 and
pH 8.0.
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In comparison to a maleimide-biotin derivative (58), antibody labelling with vinylphos-
phonothiolate 18 is less efficient (based on Western-blot analysis) but features supe-
rior cysteine-selectivity (Fig. 24). Cross-reactivity of maleimides with other nucleophilic
amino acids (mainly lysine and histidine) is a known phenomenon, especially under
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Fig. 24 Modification of Cetuximab with vinylphosphonothiolate 18 or maleimide-biotin 58.
The cysteine-selectivity and labelling efficiency of vinyl- and ethynylphosphonothio-
lates was further investigated by means of intact protein MS. Therefore, the IgG anti-
body Trastuzumab was reacted with either S -ethyl ethynyl- or vinylphosphonothiolate
derivatives 7 or 8, respectively (scheme 47). Here, a larger excess of phosphonothio-
lates (100 eq.) were used at higher antibody concentration (5mg/mL) to challenge the
chemoselectivity. After the modification, the antibodies were deglycosylated and re-
duced before analysis by middle-up MS analysis (Fig. 25). The labelling degrees were


















100 mM NaCl,50 mM NH4HCO3 pH 8.5 or PBS pH 7.4, 







analysis by intact protein MS
and LC-MS/MS after tryptic digest
Scheme 47 Labelling of Trastuzumab with phosphonothiolates 7 and 8.
The MS analysis revealed average modification ratios per antibody of 1.0 with vinylphos-
phonothiolate 8 and 2.5 with ethynylphosphonothiolates 7 at pH7.4 (Fig. 25A/E). At
pH 8.5, almost maximal labelling of ca. 7.6-7.7 modifications per antibody was observed
for both derivatives (Fig. 25C/G). In the negative controls (-DTT) for vinylphospho-
nothiolate 8, no labelling was observed at either pH 7.4 or at pH 8.5 (Fig. 25B/D). In
the negative control for the modification with ethynylphosphonothiolate 7 at pH 8.5
however, some labelling (ca. 0.3 modifications per antibody) was observed (Fig. 25H),
which is in line with the Western-blot analysis above (see Fig. 23). MS/MS analysis
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of this sample after tryptic digest revealed that these modifications were at distinct
histidine, tyrosine and threonine residues, as well as at certain cysteine residues (see
Experimental chapter 8.2.9). An explanation for unexpected cysteine labelling in this
negative control might be that the interchain disulfide bridges spontaneously opened
to some extent and thereby free sulfhydril groups became accessible for the reaction
with ethynylphosphonothiolates. A detailed MS/MS analysis of all the different reac-
tion conditions further revealed –next to labelling of the targeted inter-chain cysteines
– modification at certain histidine residues also for the vinylphosphonothiolate probe
8 at both pH 7.4 and pH 8.5 as well as labelling of the N-termini and a distinct thre-
onine residue with this probe at pH 8.5. Given however that both intact protein MS
as well as Western-blotting are sensitive analytical methods and that in the respective
spectra (Fig. 25) and blots (Fig. 23), no or only traces of labelling could be observed in
the negative controls, still demonstrates that cysteine-selectivity for both unsaturated
phosphonothiolate derivatives is high. Moreover, large excess of both reagents was used
in these experiments and the selectivity might thus further be improved by decreasing
the number of equivalents. Nevertheless, depending on the local environment within
a protein, cross-reactivity with other nucleophilic side chains cannot be excluded and
should be analysed carefully from case to case.
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Fig. 25 Deconvoluted MS spectra (ESI-TOF) of Trastuzumab after labelling with vinylphos-
phonothiolate 8 (panels A-D) or ethynylphosphonothiolate 7 (panels E-H) at either
pH7.4 or pH 8.5. Left column: Trastuzumab was treated with DTT before the ad-
dition of the phosphonothiolates, right column: control reactions without prior DTT
reduction. Trastuzumab samples were deglycosylated with the enzyme PNGaseF and
reduced with DTT before MS analysis. LC: light chain, HC: heavy chain, subscripts:
number of modifications. Modification degrees were estimated based on signal intensi-
ties.
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3.7 Stability of phosphonothiolates
Next to the selectivity in the labelling of proteins, the stability of vinyl- and ethynylphos-
phonothiolates was investigated under conjugation conditions. Therefore, the water-
soluble phosphonothiolates 39 and 43 were subjected to aqueous solutions at pH 7.4
(PBS) or pH 8.5 (50mM NH4HCO3) and their degradation at 25
◦C and at 37 ◦C was
monitored over time via 31P-NMR (Fig. 26). For both derivatives, hydrolysis of the
phosphorus-sulphur bond was observed, giving rise to the respective phosphonic acids
and free thiol-EDANS (Fig. 26A). The degradation was monitored over 90 hours, re-
vealing that vinylphosphonothiolate 39 is significantly more stable than ethynylphos-
phonothiolate 43: At pH 7.4 and 25 ◦C, more than 90% of vinylphosphonothiolate 39
remained intact after 90 hours, while under the same conditions 50% of ethynylphos-
phonothiolate 43 was hydrolysed (Fig. 26B). At pH 8.5, the hydrolysis proceeded faster,
particularly for ethynyl derivative 43. The same trends, but more pronounced, were
observed at 37 ◦C (Fig. 26C). The circumstance that ethynylphosphonothiolates are less
stable in buffer than vinylphosphonothiolates may be explained by the higher elec-
trophilicity of the phosphorus atom as a consequence of the more electron-withdrawing
effect of the ethynyl-residue compared to the vinyl-residue. Notably, for both substrates,
hydrolysis at pH 7.4 and 8.5 occurs on a slower time scale than the reaction with thiols
under these conditions and hence instability of these reagents is not a critical issue under
conjugation conditions.
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Fig. 26 Aqueous stability of unsaturated phosphonothiolates (39=vinyl-derivative,
43=ethynyl-derivative) at 25 ◦C (B) and at 37 ◦C (C). Initial concentration
(100% starting material)= 5mM.
The stability of vinylphosphonothiolates was further investigated on peptide level using
the purified peptides 28-32 described above. Therefore, the vinylphosphonothiolate
peptides 28-32 were subjected to conjugation buffer at pH 7.4 or pH 8.5 and were
monitored by UV-LC-MS over time (Fig. 27). Exemplary LC-UV traces are shown for
peptide 28 (X=A) at pH 7.4 and pH 8.5 in Fig. 27 B and D, respectively. Thereby,
several new species were observed and assigned according to their m/z to the structures
depicted in Fig. 27A. Not surprising, P-S bond hydrolysis was observed, giving rise to
reduced cysteine peptides (II). The cysteine peptides (II) further reacted with remaining
vinylphosphonothiolate peptides (I) to the respective thiol-conjugates (III). In addition,
a new species with the same m/z as the starting materials was observed for all tested
peptides (see Experimental Fig. 83 and 84 for extracted ion chromatograms).
64










































































































X= A, S, H, D, M
KYRCXK
aqueous buffer, 



























































































0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00









(I), (III), (IV), (V)
















































































































peptide 28 (X= A)





Fig. 27 A) Structures of observed products upon incubation of vinylphosphonothiolate peptides
28-32 in aqueous buffers. The Y in structure (IV) stands for any of the nucleophilic
amino acids in the sequence. B) Exemplary LC-UV chromatograms for peptide 28
(X=A) in PBS pH 7.4 over time. C) Quantification of remaining vinylphosphonothio-
late peptides 28-32 over time at pH 7.4. Shown are percentages of remaining intact
peptides (I) based on extracted ion intensities (see Experimental for details). For
legend see panel (E). D, E) Analogous analysis at pH 8.5 (50mM NH4HCO3).
This observation indicated the migration of the vinyl-O-ethylphosphate group to other
nucleophilic residues, giving rise to peptides with the general structure (IV). As this
phenomenon was observed for all the tested peptides 28-32 to similar extents, it is
likely that the P(V) moiety got transferred to the amine groups of either the N-terminus
or lysine, which are present in all the peptides. The migration products (IV) further
reacted with remaining vinylphosphonothiolate peptides (I) to give conjugates of the
general structure (V). As a consequence of all these processes, approximately 50% of
peptides 28-32 (I) were decomposed or consumed after 24 h at neutral pH (Fig. 27C).
The quantification is based on extracted ion intensities (see Experimental for details).
At pH 8.5, all the described processes were faster, leaving approximately 50% of
peptides 28-32 (I) intact after about 8 hours (Fig. 27D).
While these results clearly show that vinylphosphonothiolate peptides undergo hy-
drolysis and other side-reaction in aqueous buffer, employing the freshly synthesised
peptides 28-32 directly with reduced glutathione under the same conditions (PBS pH
7.4 or 50mM NH4HCO3 pH 8.5) resulted in clean conversion into the thiol addition
products (Fig. 28). Migration of the P(V) moiety to other residues was not observed
for any of the peptides 28-32 (exemplified for peptide 28 in Fig 28). It could thus be
concluded that both the migration of the P(V) moiety to other nucleophilic residues, as
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well as the hydrolysis of the P-S bond are slower than the thiol addition and that these
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Fig. 28 Glutathione addition to vinylphosphonothiolate peptide 28 at pH 7.4 (B) or pH 8.5
(C). Shown are LC-UV chromatograms of the reaction mixtures.
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3.7 Stability of phosphonothiolates
Next, the stability of the thiol-phosphonothiolate conjugates was investigated un-
der physiologically relevant conditions such as cell lysate (HeLa), human serum,
PBS (pH7.4) or in the presence of excess glutathione. Therefore, a previously
established FRET quencher pair assay was employed [208] using the ethynyl- and
vinylphosphonothiolate-linked conjugates 59 and 60, respectively (Fig. 29A). Upon
cleavage of the conjugates, fluorescent EDANS-thiol is liberated and generates a fluo-
rescence signal (the more cleavage, the higher the fluorescence value). In a 1M NaOH
solution for instance, both conjugates hydrolyse to full extent within approximately
2 hours (Fig. 29 B/C, red curve). Compared to this maximum fluorescence, both
conjugates showed good stability in neutral buffer, HeLa lysate or in the presence of
excess free thiols. In human serum however, significant cleavage was observed for the

















































































































































































































































































































































































Fig. 29 A) Principle of the fluorescence-quenching assay (adapted from [208]). B) and C)
Stabilities of ethynyl- and vinylphosphonothiolate-linked conjugates 59 and 60, re-
spectively. Shown are mean values and error bars of triplicates. Negative values for
serum samples might be due to serum autofluorescence.
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3.8 Comparison of unsaturated phosphonothiolates to
unsaturated phosphonates and phosphonamidates
After having discovered that unsaturated vinyl- and ethynylphosphonothiolates are re-
active towards thiol additions and that the resulting thiol-conjugates possess good sta-
bility, we were interested in comparing these aspects for thiol additions to other unsat-
urated phosphorus(V) electrophiles, in particular to phosphonates and phosphonami-
dates. These compound classes differ in the kind of heteroatom bound to the phospho-
rus. Phosphonothiolates contain a P-S bond; phosphonates and phosphonamidates a
P-O and a P-N bond, respectively (Fig. 30). As outlined in the introduction (see chapter
1.4.1), our group has intensively investigated unsaturated vinyl- and ethynylphospho-
namidates for cysteine-selective bioconjugations [228, 208, 209]. On the other hand,





































R = e.g. Et, PEG, etc.



























































































































































Fig. 30 General structures and nomenclature of unsaturated P(V)-electrophiles.
In order to access unsaturated phosphonates derivatives for comparative studies, the
route describ in c apter 3.4 using the precursors 33 and 34 was adapted to alcohols
(scheme 48). Using this route, Boc-protected amine-derivatives 61 and 62 were gen-
erated. These were then further modified into the water-soluble, fluorescent EDANS-
derivatives 65 and 66, respectively by means of Boc-deprotection with TFA and subse-









tetrazole, THF, −40 °C to r.t.
1 eq.I)

































Scheme 48 Synthesis of vinyl- and ethynylphosphonate derivatives. aUsed as crude product,
bisolated via reverse-phase HPLC.
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3.8 Comparison of unsaturated phosphonothiolates to unsaturated phosphonates and
phosphonamidates
Using the generated fluorescent derivatives 65 and 66, the bimolecular rate constants
for thiol additions with glutathione at pH 7.4 were determined analogously to the phos-
phonothiolate study (compare Fig. 22). For the ethynylphosphonate derivative 65 the
bimolecular rate constant was found to be 0.146 ± 0.009 M-1s-1 at pH 7.4 (Fig. 31C).
Under the same conditions, the vinylphosphonate derivative 66 reacted too slowly
with glutathione to deduce an accurate rate constant. In comparison to unsaturated
phosphonothiolate derivatives, unsaturated phosphonates react thus roughly an order
of magnitude slower in thiol additions under neutral conditions. As for unsaturated
phosphonamidates, the ethynyl-derivative 67 was used for comparison (see structure
in Fig. 31A). Notably, this derivative bears an aryl residue at the nitrogen. The bi-
molecular rate constant for the glutathione addition to this compound was determined
to 0.0493 ± 0.0023 M-1s-1 at pH 7.4. Since aryl-substituted phosphonamidates are
more reactive than alkyl-substituted derivatives [209], the rate constant for the respec-
tive alkyl-derivative would be estimated to be slightly lower. Overall, it can thus be
concluded that unsaturated phosphonothiolates are clearly the most reactive derivates,
followed by unsaturated phosphonates and phosphonamidates.








ethynylphosphonothiolate 43 1.32 ± 0.04
0.0020 ± 0.0002
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Fig. 31 Comparison of reactivities for the thiol addition to unsaturated P(V)-electrophiles.
A) Structures of the investigated compounds, B) general reaction conditions for the
addition of glutathione, C) experimentally obtained bimolecular rate constants.
While one would generally assume that electron-withdrawing substituents around the
phosphorus atom would render the terminal carbon of the vinyl- and alkynyl groups
more electropositive and thus more reactive for nucleophilic thiolate addition, the ob-
served rate constants do not correlate with the electronegativities of the heteroatoms
(N, O, S). If this was the case, unsaturated phosphonates would expected to be the
most electrophilic/reactive in thiol additions, followed by phosphonamidates and phos-
phonothiolates. The unprecedented finding that unsaturated phosphonothiolates are
69
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considerably more reactive than the other P(V)-derivatives must thus have additional
reasons, likely to be found in the nature of the phosphorus-sulphur bond. In order to
understand these reactivities better, a collaborator is currently working on DFT calcu-
lations to predict reaction energy profiles for the thiol addition to P(V)-electrophiles,
from which information about the reaction rates might be derived. In addition to the
general trend of phosphonothiolates being the most reactive derivatives, followed by
phosphonates and phosphonamidates, the ethynyl-derivatives react much faster with
thiols than the respective vinyl-derivatives within all three compound classes. These
differences in reactivity are also reflected in the electrostatic potential maps as shown
in Fig. 32. The ethynyl-residues show less electron density at the terminal carbon than


















Fig. 32 Electrostatic potential maps of unsaturated P(V)-electrophiles. The black wedges point
at the most positive values of the terminal carbons of the triple and double bonds,
respectively.
Next to the reactivities of different P(V) electrophiles in thiol additions, also the
stability of the respective thiol-conjugates was compared. From the study described
in chapter 3.7, it could be concluded that thiol-phosphonothiolate conjugates are
stable in aqueous, neutral buffer as well as in HeLa lysate and in the presence of
excess free thiols. In serum however, some P-S bond hydrolysis was observed over
time, particularly for the ethynylphosphonothiolate derivative (Fig. 29B). In contrast,
ethynylphosphonamidates employ excellent stability also in serum as well as under
the other conditions, as described in references [208] and [228]. The stability of
thiol-phosphonate conjugates was investigated here using the same assay as described
before and good stability was observed for both ethynyl- and vinyl-conjugates 68/69
under all tested conditions (Fig. 33).
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Fig. 33 A) Fluorescence-quenching assay using phosphonate-linked conjugates 68 and 69.
B/C) Stabilities of ethynyl- and vinylphosphonate-linked conjugates 68 and 69, re-
spectively. Shown are mean values and error bars of triplicates.
In conclusion, all three P(V) compound classes can be used to generate thiol-conjugates.
Ethynylphosphonothiolates are the most reactive derivatives, followed by ethynylphos-
phonates and ethynylphosphonamidates. The respective vinyl-P(V) derivatives are sig-
nificantly less reactive. The stability of the thiol-P(V) conjugates is generally very good
under physiological relevant conditions. An exception are the most reactive ethynylphos-
phonothiolate derivatives, where significant hydrolysis was observed both for the uncon-
jugated reagents (compare Fig. 26) as well as for the thiol-conjugates in serum (compare
Fig. 29). One might thus draw the general conclusion that high reactivity of unsatu-







The research described in this chapter was conceptualised by Prof. Dr. Christian P.
R. Hackenberger, Sergej Schwagerus and the author. Most of the herein presented
experiments were conducted by Sergej Schwagerus, as specified at the beginning of each
section. Briefly, Sergej Schwagerus established the synthesis of vinylphosphonothiolate-
ubiquitin 72 and did most of the protein-protein conjugations with this substrate.
He furthermore performed CD measurements of the synthetic diubiquitin 78, as well
as the stability assay against DUBs and the enzymatic ubiquitination of conjugate
80. Moreover, Sergej Schwagerus worked together with Kristin Kemnitz-Hassanin
on the expression and purification of the proteins used in this chapter. LC-MS/MS
measurements were performed by Dr. Michal Nadler-Holly and the MS/MS data
was analysed by Christian Stieger. Parts of this chapter were published in and are
adapted from A. L. Baumann*, S. Schwagerus*, K. Broi, K. Kemnitz-Hassanin, C.
E. Stieger, N. Trieloff, P. Schmieder, C. P. R. Hackenberger. Chemically Induced
Vinylphosphonothiolate Electrophiles for Thiol–Thiol Bioconjugations. J. Am. Chem.
Soc. 2020, 142, 9544-9552 (* shared first authorship).
4.1 Background and Outline
Building up on the results described in chapter 3, where we could show that vinylphos-
phonothiolates can be chemoselectively installed on unprotected peptides, we wanted
to expand our method to install electrophilic vinylphosphonothiolates on proteins. As
described in chapter 1.3.3, introducing an electrophilic moiety into proteins in principle
enables the subsequent conjugation to other proteins via canonical nucleophilic amino
acid residues. The generation of heterobifunctional proteins is not only gaining interest
for next-generation biopharmaceuticals such as IgG Fc domain fusions [260] but is
also needed in various applications in basic research for example to study protein
ubiquitinations. While heterobifunctional proteins can be generated as genetic fusions,
this approach is limited to connecting the proteins at their N- and C-termini. On
the other hand, chemical approaches give access to more diverse topologies through
conjugation of proteins via side-chain residues. This is not only important for cases
where unmodified termini are required for optimal bioactivity but is also crucial
to study the function of ubiquitinated proteins. As the largest post-translational
modifications of proteins, ubiquitinations regulate various cellular processes from
protein degradation and trafficking to DNA repair and transcription [261]. As outlined
in chapter 6.4, the site at which a substrate protein is modified with ubiquitin, as well
as the connectivity in-between poly-ubiquitins, determines the fate of the substrate
protein [261]. For instance, ubiquitination at distinct lysine residues of α–Synuclein
have been identified in filamentous α–Synuclein depositions, which are a hallmark
of various neurodegenerative diseases [262]. In order to study the effect of distinct
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ubiquitinations, there is thus a great need for methods that allow the generation of
homogeneous, site-specifically ubiquitinated substrate proteins for functional investiga-
tions. Important contributions in this field have been made by the groups of B. Crosas
[263], H. Dohlman and S. Campbell [264], A. Brik [265, 266, 267, 268], A. Marx [269],
M. R. Pratt [270], E. Strieter [271, 272] and very recently by the Liu group [273]. Out of
these methods, only a few allow the generation of uncleavable ubiquitinated proteins by
replacing the natural isopeptide bonds with unnatural, stable linkages, that both resist
cleavage by deubiquitinating enzymes as well as reduction by external thiols under
physiological conditions. Such uncleavable ubiquitin-protein conjugates are powerful
tools to dissect ubiquitin signalling [274]. One of the first contributions toward this
goal has been made by the Marx group, who has generated protease-resistant ubiquitin
chains via stable triazoles linkages from click reactions between genetically incorporated
unnatural alkyne- and azide- containing amino acids [269]. Following a similar goal,
the Brik group has generated uncleavable ubiquitinated proteins via oxime ligations
[267]. In their very recent publication, the Liu group has reported yet a new kind of
DUB-resistant ubiquitin probes based on isopeptide-N -ethylated dimeric or polymeric
Ub chains, which they prepared using a chemoenzymatic protocol. On an impressive
scale, they used their method to generate various homotypic and branched ubiquitin
probes in excellent yields [273].
Complementing these approaches, we set out to generate non-cleavable and site-
selectively linked ubiquitin-protein conjugates using our herein developed phos-
phonothiolate linkers (scheme 49). Thereby, we wanted to install the electrophilic
vinylphosphonothiolate moiety on a ubiquitin mutant containing an activated cysteine
and subsequently conjugate our probe to proteins of interest via cysteine conjugation.
As opposed to the methods above, our method would allow the generation of (pre-
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Scheme 49 Outline for the synthesis of phosphonothiolate-linked ubiquitin-protein conjugates.
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4.2 Synthesis of vinylphosphonothiolate-ubiquitin
4.2 Synthesis of vinylphosphonothiolate-ubiquitin
Note: The synthesis of vinylphosphonothiolate-ubiquitin 72 was first established by
Sergej Schwagerus. The author repeated this synthesis, based on the established protocol.
The herein presented data for the aqeuous stability of 72 was also obtained from Sergej
Schwagerus.
In order to install the vinylphosphonothiolate-electrophile on ubiquitin, the UbG76C
mutant 70, carrying a single cysteine at the C-terminus was first activated to the respec-
tive electrophilic disulfide 71. Here, Ellman’s reagent was used instead of DTNP because
it employs better water-solubility. Following the protocol established for the installation
of vinylphosphonothiolates on unprotected peptides (compare chapter 3.3), activated
ubiquitin 71 was then subjected to DMSO containing 1% TFA, before diethylvinylphos-
phonite 4 (50 eq.) was added as a crude mixture. The reaction mixture was analysed by
intact protein MS, indicating the formation of the desired vinylphosphonothiolate-Ub
72 as well as reduced Ub-Cys as a side-product. This result proved that the developed
protocol can also be applied to more complex substrates. While after 8 hours, there
was still starting material 71 detected by intact protein MS, adding another portion of
diethyl-vinylphosphonite (50 eq.) resulted in full conversion of the starting material 71
and the desired UbG76C-vinylphosphonothiolate 72 was obtained in 24% isolated yield
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r.t., 16 h
4
2) removal of excess Ellman’s 
reagent by spin filtration
Fig. 34 Installation of the vinylphosphonothiolate moiety on protein level. A) Conversion
of cysteine-ubiquitin mutant 70 into vinylphosphonothiolate-ubiquitin 72 via elec-
trophilic disulfide 71. B) Raw and deconvoluted MS spectra of purified 72.
The fact that more equivalents of vinylphosphonite were needed here to obtain full
conversion of the electrophilic disulfide as opposed to the analogous reaction on peptide
level, might be due to the lower concentration of ubiquitin used here (ca. 1.5mM of
Ub 71 as opposed to 30mM of peptides 28-32, (compare chapter 3.3)) as well as due
to the more complex structure of the substrate. Furthermore, diethyl-vinylphosphonite
4 can oxidize over time to the unreactive diethyl-vinylphosphonate 11. Consequently,
to compensate for this side-reaction, more equivalents of diethyl-vinylphosphonite 4
are needed, especially at low substrate concentrations. Given that the formation of
vinylphosphonothiolates was very rapid on small molecule as well as on peptide level,
the long reaction time reported here for the analogous reaction on ubiquitin seems
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surprising. However, since the reaction on ubiquitin could only be followed by intact
protein MS, close and accurate monitoring of the conversion was challenging for this
substrate and further complicated by the small scale these reactions were performed at.
Therefore, when optimising this protocol in the future, it might be worth to re-evaluate
the necessary reaction time to complete disulfide conversion.
Next, the stability of the generated vinylphosphonothiolate-ubiquitin 72 was investi-
gated under protein conjugation conditions (Fig. 35). Therefore, vinylphosphonothiolate-
Ub 72 was subjected to aqueous buffers at pH 7.4 or pH 8.5 and followed over time by
SDS-PAGE (Fig. 35B). Similar to the observed behaviour of peptide vinylphosphonoth-
iolates 28-32, P-S bond hydrolysis was observed over time at pH 8.5 at r.t., as well
as to a smaller extent at pH 7.4 and more pronounced at 37 ◦C than at r.t. Because
of the P-S bond hydrolysis, the free thiol ubiquitin 73 reacts with intact 72 to form
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Fig. 35 Stability of vinylphosphonothiolate-ubiquitin 72 in aqueous buffer. A) Assay condi-
tions and decomposition products, B) SDS-PAGE gel (Coomassie) indicates the for-
mation of covalent homodimer 74.
4.3 Ubiquitin-protein conjugations
Ubiquitin-eGFP conjugation
Note: The herein presented Ub-eGFP conjugation was conducted by Sergej Schwagerus.
With the ubiquitin-vinylphosphonothiolate probe 72 in hand, ubiquitin-protein con-
jugation was first probed in a model system using the eGFP cysteine mutant (C70M
S147C) 75, carrying a single accessible cysteine residue. The conjugation between 72
and 75 was monitored by intact protein MS (see Experimental, Fig. 93) and SDS-PAGE
(Fig. 36). Thereby, the targeted conjugation product 76 could be detected, proving that
thiol addition to ubiquitin probe 72 gives access to covalent protein-protein conjugates.
At pH8.5 and 37 ◦C, more than 80% of eGFP C70M S147C 75 had reacted after 24
hours with Ub-phosphonothiolate 72 to Ub-eGFP conjugate 76. On the other hand, at
pH7.4 the reaction was significantly slower. In addition, the expected side-products 73
and 74 were observed; at pH8.5 more than at pH7.4. As a consequence, we decided to
76
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Fig. 36 Conjugation of vinylphosphonothiolate-Ub 72 to eGFP cysteine mutant 75. A) Re-
action conditions and side-products. B) Monitoring of the reaction by SDS-PAGE
(Coomassie).
Ubiquitin-ubiquitin conjugation
Note: The conjugation between vinylphosphonothiolate ubiquitin 72 and ubiquitin mu-
tant 77 was first established by Sergej Schwagerus. The author repeated and optimised
the protocol slightly. The data shown in Fig. 37 has been produced by the author. All
the data shown in Fig. 38 were obtained by Sergej Schwagerus.
Next, we set out to generate a phosphonothiolate-linked diubiquitin between
vinylphosphonothiolate-Ub 72 and the ubiquitin-cysteine mutant UbK48C 77
(Fig. 37). While in the reaction with eGFP, the vinylphosphonothiolate-Ub 72 had
been used in excess (ten times over eGFP), for this conjugation, UbK48C 77 was used
in excess to economise 72. We reacted vinylphosphonothiolate-Ub 72 with UbK48C
77 at pH 8.0 at 37 ◦C and the reaction was monitored by SDS-PAGE (Fig. 37B) and
intact protein MS (see Experimental Fig. 94), which indicated maximal conversion after
24 hours and the formation of the covalent protein-protein conjugate 78. The product
78 could be isolated in 27% yield after size-exclusion chromatography and showed the
correct mass by intact protein MS (Fig. 37C). In order to confirm site-selective linkage
to phosphonothiolate-ubiquitin, the conjugate 78 was subjected to LC-MS/MS analysis
after tryptic digest. The respective crosslinked peptide was found (see Experimental,
Fig. 98) and no P(V)-transfer conjugation products were observed on protein level.
77
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Fig. 37 Conjugation of vinylphosphonothiolate-Ub 72 to ubiquitin mutant UbK48C 77.
A) Reaction conditions, B) Monitoring the conversion by SDS-PAGE (Coomassie),
C) Deconvoluted MS-spectrum of purified conjugate 78.
We were then able to demonstrate that the isolated phosphonothiolate-linked DiUb(C48)
78 does not get hydrolysed by the deubiquitinating enzyme USP2CD, as opposed to
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Fig. 38 A) Comparison of hydrolytic stability of the conjugate 78 and the wild-type
DiUb(K48), SDS-PAGE gel (Coomassie), (*): impurity arising from the USP2CD sam-
ple. B) Confirmation that conjugate 78 is linked via cysteine C48. Top: SDS-PAGE
(Coomassie), bottom: Western blot (anti-polyUb(K48C)). C) CD-spectra of synthetic
phosphonothiolate-linked DiUb(C48) 78 compared to wild-type DiUb(K48).
78
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Furthermore, the synthetic DiUb 78 shows similar ellipticity in CD-spectra compared
to the wild-type diubiquitin (K48) (Fig. 38B). In addition, the site-selective linkage at
position C48 was verified by Western-blot analysis (Fig. 38C) and by MS/MS analysis
after tryptic digest (see Experimental Fig. 98A). Taken together, these results prove
that synthetic phosphonothiolate linked DiUb 78 is hydrolytically stable and employs
similar properties as the wild-type DiUb(K48), which is linked via an isopeptide bond.
Ubiquitin-α–Synuclein conjugation
Note: The conjugation between vinylphosphonothiolate ubiquitin 72 and α–Synuclein
79 was first established by Sergej Schwagerus. The author repeated and optimised
the protocol slightly. The experiment shown in Fig. 39 has been conducted by the
author. The enzymatic ubiquitination of conjugate 80 (data shown in Fig. 40) has been
conducted by Sergej Schwagerus.
In a final example, vinylphosphonothiolate 72 was conjugated to the α–Synuclein cys-
teine mutant 79 (Fig. 39A). Also here, maximal conversion was observed after approxi-
mately 24 hours, as shown by SDS-PAGE analysis (Fig. 39B). Pure phosphonothiolate-
linked Ub-α-Synuclein conjugate 80 could be obtained in 16% isolated yield after size-
exclusion chromatography and showed the correct mass (Fig. 39C). Furthermore, the
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Fig. 39 Conjugation of vinylphosphonothiolate-ubiquitin 72 to α–Synuclein cysteine mutant
79. A) Reaction conditions, B) SDS-PAGE gel (Coomassie) showing the formation of
covalent conjugate 80, C) intact protein MS (ESI) of purified Ub-α–Synuclein conjugate
80.
Finally, in order to prove that the non-hydrolysable phosphonothiolate-linked ubiquiti-
nated proteins can be recognised by ubiquitin-binding proteins, α-Synuclein-ubiquitin
conjugate 80 was mixed with K48M ubiquitin mutant 81 and the enzymes Ubc1 (E2-
25k) and E1 to enable enzymatic ubiquitination (Fig. 40A). The ubiquitin-conjugating
enzyme Ubc1 catalyses the formation of K48-linked ubiquitin chains from mono ubiqui-
79
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tin [275, 276]. In this assay, the dead-end K48M ubiquitin mutant 81 was used to avoid
poly-ubiquitination. After 24 h incubation at 37 ◦C, the formation of di-ubiquitinated
α-Synuclein 82 was detected by ESI-MS (Fig. 40B), demonstrating that the ubiquiti-
nating enzymes indeed recognise the synthetic phosphonothiolate-linked ubiquitin as a
substrate. By Western-blot using a specific anti-polyUb(K48) antibody (Fig. 40C), it
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Fig. 40 Enzymatic ubiquitination of α-Synuclein-ubiquitin conjugate 80. A) Reaction condi-
tions, B) Intact protein MS spectrum of the reaction mixture, showing the formation
of Ub2-α-Syn conjugate 82. C) lanes 1) and 2): SDS-gel (silver stain) of the reaction
mixture at time 0 and 24 hours, respectively, lane 3) Western-blot (anti-polyUb(K48)).
Taken together, the results in this chapter demonstrate that vinylphosphonoth-
iolate electrophiles could be installed site-selectively on a cysteine residue in a
single cysteine-containing ubiquitin mutant. The resulting electrophilic ubiquitin-
vinylphosphonothiolate 72 could be conjugated to Cys-containing mutants of
α-Synuclein and ubiquitin, generating non-hydrolysable conjugates, which were ac-
cepted as substrates for subsequent enzymatic ubiquitination. The herein described
method thus enables the conjugation of two biomolecules containing single free cysteines
in a site-selective manner.
In addition to using electrophilic phosphonothiolates for cysteine-selective protein-
protein conjugations, a further goal in this thesis was to apply phosphonothiolates as





The research described in this chapter was conceptualised by Prof. Dr. Christian P.
R. Hackenberger and Dr. Marc-André Kasper and is based on previous work from
our group on phosphonamidate-linked ADCs [228]. The author conducted the research
described in this chapter with the following exceptions: The evaluation of the herein
generated ADCs in cytotoxic assays was performed by Stefanie Boldt and Dr. Marcus
Gerlach from the company Tubulis. The stability study of ADCs in rat serum was per-
formed together with Dr. Marc-André Kasper.
Parts of the technology described in this chapter are substance of a pending patent ap-
plication by Alice Leonie Baumann, Marc-André Kasper, Stephen Byrne, Jonas Helma,
Heinrich Leonhardt, Tina Stoschek, Marcus Gerlach, Jonas Helma, Dominik Schu-
macher, Christian P. R. Hackenberger. Chemoselective Thiol-Conjugation with Alkene
or Alkyne-Phosphonothiolates and -Phosphonates. PCT/EP2019/055509.
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5 Phosphonothiolate-linked antibody-drug conjugates
5.1 Background and Outline
ADCs have emerged as one of the most promising concepts for targeted cancer thera-
peutics [8]. In this concept, highly potent cytotoxic molecules are selectively delivered
to cancer cells by means of cancer-targeting antibodies (Fig. 41A). As opposed to non-
targeted cancer therapies, the ADC-approach delivers a higher concentration of the
cytotoxic agent at the cancer site, while (in an ideal case) not affecting healthy tissue.
To guarantee a safe and efficient delivery it is crucial that the cytotoxic agents are linked
via stable, covalent bonds to the antibody in order to prevent premature release during
blood circulation associated with off-target toxicity. Several of the recently approved
ADCs are conjugated via cysteine residues [8]. The ADC Adcetris R© (83) for instance is
a maleimide-linked conjugate between the antibody brentuximab (targeting the CD30
receptor) and the construct Val-Cit-PAB-MMAE with an average drug-to-antibody ra-






























































































































Fig. 41 A) Concept of targeted cancer-therapy using ADCs, B) Adcetris R©, C)
phosphonamidate-linked ADC, D) structure of Val-Cit-PAB-MMAE and cleavage
mechanism.
The cleavable valin-citrulin-para-amino-benzyl (Val-Cit-PAB) linker enables the release
of the toxin Monomethyl auristatin E (MMAE) after ADC internalisation into cells
by means of cathepsin B cleavage and subsequent self-immolation of the para-amino-
benzyl (PAB) linker (Fig. 41D). While Adcetris R© shows good efficacy in treatments
of refractory Hodgkin lymphoma [278] and systemic anaplastic large cell lymphoma
[279], its stability during blood circulation is suboptimal. As demonstrated by Kasper
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et al., thiol-exchange of the thiol-maleimide conjugate leads to significant transfer of
toxins to serum proteins [228]. Tackling this issue, our group has recently introduced
a stable analogue to Adcetris R©, wherein the thiol-maleimide linkage is replaced with
a thiol-phosphonamidate linkage (Fig. 41C) [228]. As opposed to Adcetris R©, the
phosphonamidate-linked ADC 84 proved to be stable in rat serum and showed excellent
anti-tumour efficacy in mice models.
In this chapter, unsaturated ethynyl- and vinylphosphonothiolates are evaluated as al-
ternative linkers for the generation of ADCs. Specifically, the antibody brentuximab was
conjugated with ethynyl- and vinylphosphonothiolate Val-Cit-PAB-MMAE derivatives
47 and 48, thereby making use of the earlier introduced reduction-alkylation protocol
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Scheme 50 General scheme for the generation of phosphonothiolate-linked ADCs via a
reduction-alkylation protocol and structures of the employed phosphonothiolate-
toxin derivatives.
5.2 Ethynylphosphonothiolates as linkers for ADC
generation
First, ethynylphosphonothiolate-MMAE derivative 47 was employed in a screen to find
conditions to generate an ADC with an average DAR of around 4 for direct comparison
to Adcetris R©. Therefore, brentuximab was reduced with DTT and reacted with different








































































































Tris buffer pH 8.5 










































Scheme 51 General conditions for the generation of brentuximab-MMAE ADCs 85 with
ethynylphosphonothiolate-toxin 47. Reduction: 1000 eq. DTT, pH 8.0, 37 ◦C,
40min. DTT was removed before the addition of 47 by gel filtration. The pH
during modification and the number of eq. of 47 was varied according to table 2.
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5 Phosphonothiolate-linked antibody-drug conjugates
After modification, antibody samples were deglycosylated and reduced for analysis by
middle-up LC-MS. The drug-to-antibody ratios were then estimated based on MS signal
intensities. First, no modification was observed when employing an antibody concentra-
tion of 1mg/mL and 25 eq. of 47 at pH 7.4 (table 2, entry 1). Increasing the antibody
concentration to 5mg/mL and using 4-50 eq. of 47 increased the modification efficiency
and delivered average DARs between 1.14 and 6.63 (entries 2-6). Increasing the pH to
8.5 even allowed efficient labelling at lower antibody concentration (entry 7).





pH eq. 47 DAR (n)
1 1 7.4 25 0
2 5 7.4 4 1.14
3 5 7.4 8.8 3.15
4 5 7.4 25 4.60
5 5 7.4 16 5.70
6 5 7.4 50 6.63















































Fig. 42 Middle-up protein MS (deconvoluted spectrum) of purified ADC 85 after deglycosy-
lation and reduction. PNGaseF: enzyme used for deglycosylation, LC= light chain,
HC= heavy chain, subscripts indicate number of modifications. LC0 exp: 23724, obs:
23725; LC1 exp: 25122, obs: 25123; HC0 exp: 48877, obs: 48877; HC1 exp: 50275,
obs: 50277; HC2 exp: 51673, obs: 51677; HC3 exp: 53071, obs: 53075 Da.
The purified ADC with a DAR of 3.15 (ADC 85, see Fig. 42 for MS spectrum) was
then evaluated in a cell-viability assay using a CD30-overexpressing cell line. Here,
the phosphonothiolate-linked ADC 85 showed potent toxin- and CD-30-dependent cell
killing (IC50 = 2.23 ± 0.17 pM), comparable to that of Adcetris R© (IC50 = 2.24 ±
0.16 pM) (Fig. 43).
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5.2 Ethynylphosphonothiolates as linkers for ADC generation


























































































Fig. 43 Cell viability assays for ADC 85, Adcetris R© and wild-type brentuximab.
As for the stability of ADCs generated with ethynylphosphonothiolates however, it
was found that the phosphorus-sulphur bond in the conjugates is prone to hydrolysis
(scheme 52). For an ADC with a DAR of 5.70, approximately 25% of the toxins were
lost after incubation for 16 hours in PBS at pH 7.4 and 25 ◦C (see Appendix Fig. 235 for
MS spectra). At 37 ◦C, even 35% of the toxins were lost as a result of P-S bond hydrol-
ysis, resulting in a DAR of 3.68. This finding was surprising since the small molecule
ethynylphosphonothiolate conjugate 59 was found to be stable in neutral buffer (com-
pare FRET-based stability assay in Fig. 29B). The local environment of the phospho-
nothiolate linkage however is different on ADCs than in the previously employed model
and nucleophilic side chains of the antibody might catalyse and promote hydrolysis of
the phosphonothiolate moiety.
PBS pH 7.4














at 25 °C: 25% hydrolysis; n= 4.23
at 37 °C: 35% hydrolysis; n= 3.68
Scheme 52 Hydrolysis of ADC 85 in PBS pH 7.4 results in loss of the toxin.
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5 Phosphonothiolate-linked antibody-drug conjugates
5.3 Vinylphosphonothiolates as linkers for ADC generation
Assuming that ADCs generated with vinylphosphonothiolates would be more stable
than the above described ADC 85, we set out to generate the respective brentuximab-








































































































Tris buffer pH 8.5 










































Scheme 53 General conditions for the generation of brentuximab-MMAE ADCs 86 with
vinylphosphonothiolate-toxin 48. The reduction protocol, the temperature and
the number of eq. of 48 was varied according to table 3.
Using the modification conditions producing high DARs for the ethynyl-derivative 47
(5mg/mL antibody, 50 eq. of toxin) only gave a DAR of 0.14 with 50 eq. of vinyl-
derivative 48 at pH 8.5 (table 3, entry 1). The observation that antibody modification
with 48 is less efficient compared to the ethynyl-derivative 47 was expected as our previ-
ous analysis showed that thiol additions to vinylphosphonothiolates are orders of magni-
tudes slower than to ethynylphosphonothiolates (compare Fig. 22). As a consequence of
this slow modification rate, thiol addition to 48 competes with re-oxidation of the inter-
chain cysteines. While additional DTT could in principle be added to restore accessible
cysteines for modification with 48, DTT itself would react with vinylphosphonothiolate
in a thiol addition and thereby consume 48. We therefore considered an alternative
reduction protocol based on TCEP for further optimisation. As shown by Kasper et
al. for the generation of phosphonamidate-linked ADCs, a one-pot reduction-alkylation
protocol with TCEP enabled effective antibody modification while circumventing the
removal of the reducing agent [228]. Although TCEP can also add to vinylphosphonoth-
iolates, these by-products can be minimised by using only few eq. of TCEP. As shown by
Bahou et al. [280] as well as our group [228], efficient reduction of the interchain disul-
fide bridges of IgG antibodies can be achieved with stoichiometric amounts of TCEP.
Indeed, using 6 eq. of TCEP in one pot with only 10 eq. of vinylphosphonothiolate
48 gave a DAR of 0.12 (table 3, entry 2), which is comparable to the initially applied
two-step DTT-reduction alkylation protocol with 50 eq. of 48 (entry 1). The average
DAR could further be doubled to 0.24 by using 10 eq. TCEP and 10 eq. 48 (entry 3)
and yet increased to 0.89 using 50 eq. 48 (entry 4). To reach yet higher average DARs
though, the antibody concentration had to be increased to 12mg/mL (entry 5 and 6).
Under these concentrated conditions, 48 was not fully soluble when used with 50 eq.
Increasing the temperature to 25 ◦C let to a slight improvement of the average DAR to
2.09 (entry 7). To reach the targeted DAR of 4, the temperature was further increased
to 37 ◦C and additional portions of TCEP and 48 had to be added over the course of
several days (entry 8). Not surprisingly, these harsh conditions led to the formation
of antibody aggregates and the final DAR of the soluble fraction after purification by
size-exclusion chromatography (SEC) was 3.10 (ADC 86, see Fig. 44 for MS spectrum).
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5.3 Vinylphosphonothiolates as linkers for ADC generation
Table 3 Screening conditions for the generation of vinylphosphonothiolate-linked brentuximab-
MMAE ADCs. aDAR=4.36 before purification; DAR=3.10 after purification by SEC.








eq. 48 DAR (n)
1 5 14 DTT 50 0.14
2 5 14 6 10 0.12
3 5 14 10 10 0.24
4 5 14 10 50 0.89
5 12 14 10 25 1.15
6 12 14 10 50 1.71
7 12 25 10 50 2.09















































Fig. 44 Middle-up protein MS (deconvoluted spectrum) of purified ADC 86 after deglycosy-
lation and reduction. PNGaseF: enzyme used for deglycosylation, LC= light chain,
HC= heavy chain, subscripts indicate number of modifications, LC0 exp: 23724, obs:
23724; LC1 exp: 25124, obs: 25124; HC0 exp: 48876, obs: 48876; HC1 exp: 50276,
obs: 50277; HC2 exp: 51676, obs: 51677; HC3 exp: 53076, obs: 53078 Da.
87
5 Phosphonothiolate-linked antibody-drug conjugates
To our delight, the ADC 86 not only showed potent in vitro cell killing (ADC 86: IC50 =
3.62 ± 0.26 pM, Adcetris R©: IC50 = 4.15 ± 0.25 pM, Fig. 45) but also improved stability
under neutral conditions compared to ADC 85. In PBS at pH 7.4, no hydrolysis of
ADC 86 was observed in neutral buffer.
































































































Fig. 45 Cell viability assays for ADC 86, Adcetris R© and wild-type brentuximab.
Moving on to more physiological relevant conditions, the stability of ADC 86 was next
investigated in rat serum at 37 ◦C. Thereby, hydrolysis of the phosphorus-sulphur bond
in the conjugate was observed, leading to approximately 30% loss of the toxin after seven
days incubation at 37 ◦C (see Experimental Fig. 100 for MS spectra). In comparison,
under the same conditions, Adcetris R© approximately lost 70% of toxin already after
three days as shown by Kasper et al. in Ref. [228]. As for the phosphonamidate-linked
ADC 83, only 10% of toxin was lost after seven days.
Overall, these results indicate that unsaturated phosphonothiolate and in particular
vinylphosphonothiolates do have potential as linkers in ADCs, however, both the sta-
bility of the conjugates as well as the modification efficiency remain to be optimised.
In comparison to ethynylphosphonamidates (see ADC 84 Fig. 41), unsaturated phospho-
nothiolates seem less suitable as linkers for the efficient generation of stable antibody-
drug conjugates. The phosphonamidate-linked ADC 84 with a DAR of 3.8 could be
obtained with as little 4 equivalents of O-diethylene glycol ethynylphosphonamidate as
linker at pH 8.5 and an antibody concentration of 5mg/mL [228]. Furthermore, this
ADC proved to be highly stable under serum conditions [228].
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6 Studying dynamic protein-protein
interactions by photocrosslinking
Responsibility assignment
The research described in the first part of this chapter (subchapter 6.1) was concep-
tualised by Prof. Dr. Christian P. R. Hackenberger, Prof. Dr. Janine Kirstein,
Manuel Iburg and the author. The author performed the herein described antibody-
photocrosslinker conjugations, photocrosslinking experiments and SDS-PAGE/Western-
blot analysis together with Manuel Iburg. In addition, Manuel Iburg expressed and pu-
rified the herein used proteins. The polyclonal antibodies were provided by the Kirstein
group and were purified by Manuel Iburg.
The research described in the second part of this chapter (subchapter 6.4) was concep-
tualised by Prof. Dr. Christian P. R. Hackenberger and Prof. Dr. Yogesh Kulathu.
Dr. Michal Nadler-Holly performed LC-MS/MS measurements and Christian Stieger
analysed the MS/MS data.
6.1 Studying dynamic interactions of chaperone proteins:
Background and Outline
An efficient protein homeostasis system is of fundamental importance for the survival
of any cell and organism. Protein misfolding and aggregation are associated with
many age onset diseases, including neurodegenerative diseases like Huntington’s dis-
ease, Alzheimer’s disease and Parkinson’s disease [281]. In the view of that it is crucial
that cells have the capacity to maintain protein homeostasis by either correctly refolding
or eliminating aggregated proteins. As for the quality control of proteins in cells, molec-
ular chaperones play a central role. Chaperones assist the de novo folding of proteins,
prevent protein misfolding and aggregation and also facilitate the disaggregation and
refolding of denatured proteins (Fig. 46) [282]. On the other hand, well-known processes
for the elimination of damaged proteins are autophagy and the ubiquitin-proteasome
system [283]. Rampelt et al. have recently identified a novel mechanism for aggregate-
clearance in metazoans: a protein disaggregase that is formed by a triage chaperone
complex HSP-110-HSP-70-HSP-40 [284] 6. This chaperone complex has the ability to
disaggregate and subsequently refold protein aggregates and thereby can restore the
function of endogenous proteins that have been sequestered into aggregates.
6Molecular chaperones (also called heat-shock proteins (HSP)) are classified for C. elegans into the
following families according to their molecular weight: small HSPs, HSP-40 (also called J- or DNJ-
proteins), HSP-60, HSP-70 and HSP-90. HSP-110 is a member of the HSP-70 family.
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6 Studying dynamic protein-protein interactions by photocrosslinking
Fig. 46 A chaperone network maintains protein homeostasis. A protein complex composed of
chaperones HSP-110, HSP-70 and HSP-40 (J-proteins) facilitates the disaggregation
of aggregated proteins into their native form. This figure has been kindly provided by
Prof. Dr. Janine Kirstein.
To date, only little is known about the composition of the three chaperone families
within the disaggregase complex and the initial substrate recognition. Metazoans like
C. elegans encode for only one HSP-110 protein but for ten different HSP-70 and about
30 HSP-40 chaperones. Any combination of these three chaperone families has in prin-
cipal the potential to form a specific disaggregase complex. Nillegoda et al. have for
instance identified specific complexes consisting of HSP-110, HSP-17 and DNJ-12 or
DNJ-13 that have the ability to disaggregate preformed amorphous protein aggregates
[285]. And a different complex composed of HSP-110, HSP-1 and DNJ-13 can inhibit
the formation of HttExon1Q48 amyloid fibrils [286]. The identification of yet further
specific chaperone complexes in an efficient manner has turned out to be an experimen-
tal challenge. Given the large number of possible chaperone combinations, individual
testing with purified chaperone proteins was regarded as prohibitively laborious. On
the other hand, conventional co-immunoprecipitations analyses will miss out on a large
number of potential interaction partners as the interaction with protein substrates and
chaperone interaction partners is too dynamic. To address this challenge in collabora-
tion with the Kirstein group, we proposed that the interactions between chaperones in
active disaggregase complexes as well as the interaction with specific aggregated sub-
strate proteins could be identified by means of photocrosslinking. As demonstrated for
other dynamic protein interactions, photocrosslinking is a powerful method to covalently
link transiently interacting proteins, thereby enabling pull-downs under denaturing con-
ditions and subsequent identification of the isolated proteins by means of LC-MS/MS
analysis [287].
7a member of the HSP-70 family
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6.1 Studying dynamic interactions of chaperone proteins: Background and Outline
Here, we wanted to conjugate photocrosslinkers (by means of P(V)-electrophiles)
to polyclonal antibodies, which the Kirstein group had generated against a number
of individual chaperone proteins from immunising rabbits [286]. These antibody-
photocrosslinker conjugates would then be subjected to lysates of C. elegans, where
they would bind specifically to their target chaperone proteins. Upon irradiation with
UV light, any adjacent, interacting proteins would be covalently crosslinked, thus
enabling the isolation of stable protein complexes and subsequent identification of
chaperone-interacting proteins (Fig. 47). We expected that these antibody-crosslinker
tools would eventually enable us to study specific chaperone-protein interactions in







































































































Fig. 47 Envisioned approach to capture interacting proteins of specific chaperones by means
of light-induced covalent crosslinking.
Given that the position of the target chaperones with respect to their protein interac-
tion partners is dynamic, the crosslinkers were designed to be long and flexible in order
to reach possible interacting proteins within a large space. Therefore, PEG-spacers
were incorporated between the antibody attachment site and the photoreactive moi-
eties. In addition, biotin was introduced in the crosslinker for detection and pull-down
purpose (see Fig. 48 for structure). Trifluoromethyl-aryldiazirine [288] and 2-phenyl-5-
carboxytetrazole [289] were employed as photo-reactive groups (scheme 54). The choice
fell for these two types of photocrosslinkers as they have proven to be efficient in many
reported applications to crosslink dynamic protein interactions [287]. The activation of
diazirines with UV-light (typically at 350-365 nm) generates reactive carbenes, which can
insert into S-H, N-H, O-H, as well as C-H bonds [290] (scheme 54A). We considered the
unspecific reactivity profile of diazirines to be an advantage for the proposed application
of crosslinking chaperone interacting proteins, as these types of bonds are ubiquitous in
proteins. Crosslinking would thus be independent of specific amino acid residues in the
protein to be captured, thereby increasing the chance of successful crosslinking events.
Nevertheless, carbenes are very short-lived reactive species and are prone to be quenched
by water, hampering crosslinking yields [291]. In this regard, 2-aryl-5-carboxytetrazole
photocrosslinkers proved to be attractive alternatives to diazirines. As recently demon-
strated by Herner et al., photocrosslinking with 2-aryl-5-carboxytetrazoles can be more
efficient compared to diazirine [289].
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6 Studying dynamic protein-protein interactions by photocrosslinking
Upon irradiation of 2-aryl-5-carboxytetrazoles (typically at 302 nm), a carboxy-nitrile
imine is formed, which is more stable and thus more long-lived than carbenes, which
can result in higher photocrosslinking yields [292] (scheme 54B). A distinct difference
to carbenes is that nitrile imines react selectively with nucleophiles. On proteins, sta-
ble adducts are formed with carboxylate residues of aspartic and glutamic acids [289].
Attack of carboxylates to carboxy nitrile imines, followed by a 1,4-acyl shift, gives rise
to stable photo-adducts. Although nitrile imines can also react with thiols [293], the
resulting adduct is less stable as it can not undergo an acyl shift. Thus, other than








































































































































Scheme 54 Proposed photocrosslinking mechanisms for A) trifluoromethyl-aryldiazirine and
B) 2-aryl-5-carboxytetrazole.
6.2 Modification of anti-chaperone antibodies with
photocrosslinkers
We started our investigations by generating photocrosslinker conjugates of chaperone-
specific polyclonal antibodies, and in particular with anti-HSP-1 and anti-DNJ-12 an-
tibodies (Fig. 48 and Fig. 49, respectively). The crosslinker molecules were synthesised
by means of solid-phase peptide synthesis (SPPS) (see Experimental chapter 8.5.1). To
start with, four diethylene-glycol units were incorporated between the P(V)-electrophile
and the photo-reactive head-groups. These constructs were then conjugated to the anti-
chaperone antibodies using the previously described reduction-alkylation protocol with
DTT. As can be seen in the Western-blots in Fig. 48B and Fig. 49B, both anti-HSP-1 and
anti-DNJ-12 antibodies were successfully modified with the photocrosslinker molecules.
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1) reduction with DTT
2) 50 eq. photocrosslinker 88,
    50 mM NH4HCO3, pH 8.5, 
    1mM EDTA, 2 % DMSO, 

















































1: HSP-1 blotted, incubated with native anti-HSP-1, 
detected with anti-rabbit-HRP or streptavidin-HRP
2: HSP-1 blotted, incubated with anti-HSP-1-
photocrosslinker conjugate, 







Fig. 48 Modification of polyclonal anti-HSP-1 antibody with photocrosslinker 88. A) Modifi-
cation conditions, B) Western blot (anti-biotin) of the modified antibody. HC: heavy












1) reduction with DTT
2) 50 eq. photocrosslinker 90 or 91,
   50 mM NH4HCO3, pH 8.5, 
   1mM EDTA, 2 % DMSO, 


















































Fig. 49 Modification of polyclonal anti-DNJ-12 antibody with diazirine- and tetrazole-
photocrosslinkers 90 and 91, respectively. A) Modification conditions, B) Western
blot (anti-biotin) of the modified antibodies (90=diazirine derivative, 91=tetrazole
derivative). HC: heavy chain, LC: light chain, M: marker C) Structure of the pho-
tocrosslinkers 90 and 91.
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6.3 Photocrosslinking
With the generated antibody-photocrosslinker conjugates 89, 92 and 93 we first wanted
to see whether those conjugates would have the ability to crosslink their primary target
proteins HSP-1 or DNJ-12, respectively. Therefore, the anti-DNJ-12-photocrosslinker
conjugates 92/93 (diazirine and tetrazole derivatives, respectively) were mixed sepa-
rately with purified DNJ-12 protein and the mixtures were irradiated with UV-light
(Fig. 50A).
SDS-PAGE (silver stain) WB (anti-biotin)
WB (1° anti-DNJ-12, 2° anti-rabbit-HRP)
M M1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8
1:  DNJ-12 protein - UV 
2:  DNJ-12 protein + UV
3:  93 - UV 
































1 2 3 4 1 2 3 4
-UV +UV
legend for B): 
1: 92 (diazirine)
2: 93 (tetrazole)
3: 92 (diazirine) + DNJ-12
4: 93 (tetrazole) + DNJ-12
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2.) UV crosslinking 
      for 92: 365 nm,
      for 93: 302 nm, 
      15 min, on ice
DNJ-12
legend for C: 
1: anti-DNJ-12-photocl. xx 
2: anti-DNJ-12-photocl. xx
3: anti-DNJ-12-photocl. xx 
    + DNJ-12
4: anti-DNJ-12-photocl. xx 
    + DNJ-12
xx= B, also tetrazole
5:  native anti-DNJ-12 - UV
6:  native anti-DNJ-12 + UV
7:  93 + DNJ-12 protein - UV




2.5 µM in PBS pH 7.4, 1 h
Fig. 50 Attempt to crosslink DNJ-12 protein. A) Reaction conditions, B) Comparison between
photocrosslinker 92 and 93 C-D) Additional control reactions for conjugate 93.
If crosslinking to DNJ-12 occurs, the respective covalent conjugates between either the
heavy or the light chain of the antibody and DNJ-12 were expected to be seen by a band
shift in SDS-PAGE/Western-blot analysis. While some higher molecular species were
detected for both conjugates compared to non-irradiated controls (Fig. 50B), they did
not seem to originate from crosslinking to DNJ-12 but rather be a consequence of UV-
94
6.3 Photocrosslinking
induced aggregation of the antibodies, themselves. The same species (indicated with *)
were also observed in the absence of DNJ-12 (Fig. 50C, lane 4), as well as in the control
of the native DNJ-12 antibody carrying no photocrosslinker (Fig. 50C, lane 6). Similar
observations were also made in the analogous photocrosslinking experiment with the
anti-HSP-1-photocrosslinker conjugate 89 (Fig. 51). These experiments were repeated
under various conditions, screening different antibody and chaperone concentrations,
temperatures, UV-irradiation times and intensities. Moreover, shorter as well as longer
crosslinkers were tested, by varying the number of diethyleneglycol units between two
and six. In none of these trials though was specific crosslinking observed.
anti HSP-1-photo-
crosslinker conjugate 89 (0.5 µM)
HSP-11.)
2.) UV crosslinking





















0.5 µM in PBS pH 7.4, 1 h
Fig. 51 Attempt to crosslink HSP-1 protein. A) Reaction conditions, B) Western-blot against
HSP-1, C) Western-blot against anti-HSP-1.
Although crosslinking to the primary targets was not successful, it still remained pos-
sible that crosslinking to secondary, interacting proteins would work. To test this, the
experiment with anti-HSP-1-photocrosslinker conjugate 89 was repeated in the pres-
ence of the chaperone DNJ-13, which is a known interaction partner of HSP-1 (Fig. 52).
Denatured luciferase was added to simulate physiological conditions. After irradiation
with UV light, the protein mixture was subjected to a pull-down (strepatavidin) to
enrich for crosslinked species. Crosslinks between DNJ-13 and either the light or the
heavy chain of 89 would be expected between 55-90 kDa (DNJ-13 plus light or heavy
chain of the antibody). However, no distinct bands of similar molecular weight could
be detected by SDS-PAGE/Western-blot analysis (Fig. 52B).
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2.) UV crosslinking


























WB (1° α-HSP-1, 2° α-rabbit-HRP)











































Fig. 52 A) Attempt to crosslink DNJ-13 with antibody-crosslinker conjugate 89 mediated by
HSP-1 and denatured luciferase. B) Western blot against DNJ-13, detected by anti-
rabbit-HRP (chemiluminescence). F: flow-through after pull-down, E: elution from
streptavidin-coated beads.
The fact that no crosslinking of chaperone proteins was observed in any of these pre-
liminary test experiments pointed towards a general problem of this strategy. Next to
the observed UV-induced aggregation of antibodies, the other main problem seemed to
be lacking pre-organisation of the photocrosslinker with respect to the proteins to be
captured. The initial idea was to compensate for the unknown binding architectures be-
tween the chaperone proteins and their substrates by using long and flexible crosslinkers
of different length by varying the number of PEG groups inside the linker. However,
these molecules will not adopt a linear conformation in water but rather fold up in an
unpredictable way. This makes it virtually impossible to predict which space the photo-
reactive moiety covers in solution and if it could in principle reach the desired protein,
especially given that the position of the proteins to be captured is a further unknown
parameter, also because polyclonal antibodies were used here. Lacking pre-organisation
and hence proximity of the photocrosslinker and the target proteins decreases the prob-
ability of specific crosslinking events. More likely outcomes are inactivation of the
short-lived reactive intermediates by other surrounding molecules such as water or by













Fig. 53 The main problem identified with the antibody-photocrosslinker approach is lacking
pre-organisation between the photocrosslinkers and the proteins to be captured. As
a consequence, inactivation of photocrosslinkers by water or self-crosslinking are more
likely events.
Another complication was the characterisation of the antibody-photocrosslinker con-
jugates. At the time of these experiments, intact-protein analysis was not available
for us and the antibody-photocrosslinker conjugates were only characterised by means
of anti-biotin Western blots. Thereby, the presence of the photocrosslinker could only
be indirectly detected via the biotin included in the linker. The integrity of the pho-
tocrosslinker moieties as well as the number of photocrosslinkers attached to the anti-
body remained unknown. Even if MS analysis was available, the interpretation of the
spectra might have been complicated by the fact that polyclonal antibodies were used
here.
An alternative, more promising approach for the system we tried to study here, could
be to apply a global crosslinking method by using for instance lysine-reactive DSSO
crosslinkers [294].
Still, we were convinced that photocrosslinking is in principle a powerful tool to study
dynamic protein-protein interactions, in particular for better defined systems that allow
more rational and controlled placing of the photocrosslinker with respect to the targets
to be captured. Motivated by these thoughts, we therefore turned our attention to
study different kinds of dynamic protein-protein interactions and in particular specific
interactions between deubiquitinating enzymes and their substrates (see next chapter,
6.4).
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6.4 Studying substrate specificity of DUBs: Background
and Outline
The post-translational modification of proteins with ubiquitin controls almost every pro-
cess in cells, in particular through regulation of protein levels by providing proteasomal
and lysosomal targeting signals and by controlling signalling networks [295, 296, 297].
Ubiquitins are commonly attached to substrate proteins at lysine residues catalysed by
a complex enzyme machinery involving ubiquitin ligases E1, E2 and E3. These en-
zymes install ubiquitin either as a single moiety or in the form of polymeric chains, in
which ubiquitin molecules are connected through specific isopeptide bonds via internal
lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) and their carboxyl
terminus [298].
On the other hand, to dynamically regulate this process, there are around 100 deu-
biquitinating enzymes (DUBs) that revert ubiquitination by means of hydrolysis of the
isopeptide bonds within ubiquitins as well as between ubiquitins and their substrate
proteins (Fig. 54) [299, 297]. The combination of these two dynamic processes gives rise
to distinct “ubiquitin codes”, which are tightly coupled to the regulation of protein levels
[261]. Malfunction of this complex system have been implicated with various diseases






UV light, 10 min
for 94: 365 nm































Fig. 54 Functions of DUBs in the ubiquitin pathway. A: Editing or rescue of ubiquitin con-
jugates, B: recycling of ubiquitin or ubiquitin oligomers from ubiquitin-protein conju-
gates, C: disassembly of unanchored ubiquitin oligomers. The graph was adapted from
Ref. [299].
98
6.4 Studying substrate specificity of DUBs: Background and Outline
One of the predominant research question towards understanding the ubiquitin code is
to decipher substrate specificity of DUBs. DUB-specificity can be mediated by unique
protein-protein interaction domains [302] or through recognition of specific topologies of
ubiquitin chains [303, 304]. To date, around 100 different DUBs, the majority of which
are cysteine proteases, have been identified and are grouped into seven distinct families
[297]. Although a few substrates have been identified for some DUBs in these families,
the specificity of most DUBs is still poorly defined. Given that most DUBs are cys-
teine proteases, they are well suited for activity-based studies [274, 305]. To that end,
non-hydrolysable, synthetic ubiquitin probes are typically equipped with electrophilic
handles that allow covalent trapping of the active site cysteine of DUBs. This approach
facilitates pull-down and subsequent identification of the covalently-linked conjugates.
In this chapter, we thought to investigate the substrate specificity from the other side
by employing DUBs themselves as reactive probes. Specifically, we set out to equip
DUBs with photoreactive crosslinkers through conjugation with vinylphosphonothio-
lates (Fig. 55). In a next step, these DUB-photocrosslinker conjugates would then be
subjected to substrate proteins and irradiation with UV-light would trigger covalent





























Fig. 55 Envisioned approach to study substrate specificities of DUBs in this thesis. A) Mod-
ification of DUBs with photoreactive crosslinkers by means of cysteine-selective con-
jugation with vinylphosphonothiolates, B) photocrosslinking specifically interacting
ubiquitinated substrate proteins within complex environments.
In first proof-of-concept experiments, the cysteine protease DUBs USP2CD and UCHL3
were employed. Next to the active site cysteine, both of these DUBs contain several ad-
ditional cysteines. It remained to evaluate experimentally, which of those cysteines were
addressable for the conjugation with the photocrosslinkers and importantly, how the po-
sitioning of the photocrosslinker would influence the outcome of the photocrosslinking
experiment.
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6.5 Modification of DUBs with photocrosslinkers
To begin, the two DUBs USP2CD and UCHL3 were each conjugated to two different
photocrosslinkers via vinylphosphonothiolates. Crosslinker 54 carries a diazirine pho-
toreactive group and crosslinker 55 a N -methylpyrroletetrazole (mPyT) as depicted
in Fig. 56. The latter type of photocrosslinker, developed by Tian et al., is an im-
proved version of the phenyltetrazole derivative used in chapter 6.1. After conjugation,
the DUBs were digested and subjected to MS/MS in order to analyse which cysteine
residues carried the photocrosslinkers. Crystal structures of both DUBs in complex with
ubiquitin are depicted in Fig. 56 and Fig. 57, respectively and the cysteines that were
found to be modified with the photocrosslinkers (based on the MS/MS analysis) are
marked therein. In the USP2CD-photocrosslinker conjugate 94, the vinylphosphonoth-
iolate photocrosslinker 54 modified cysteines C476 and C477 (Fig. 56B). Interestingly,
for the same DUB, modification with photocrosslinker 55 was found additionally on the
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Fig. 56 A) Conjugation of the DUB USP2CD (25 µM) with photocrosslinkers 54 and 55
(625µM). B) Crystal structure of USP2A (USP2CD) (blue) in complex with ubiquitin
(green), PDB entry: 3NHE. Cysteine residues are highlighted in orange and magenta
(active site cysteine). The cysteines modified with the photocrosslinkers are labelled
with the respective numbers 54 and 55.
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As for UCHL3, modifications with photocrosslinkers 54 and 55 were found both at
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Fig. 57 A) Conjugation of the DUB UCHL3 (25 µM) with photocrosslinkers 54 and 55
(625µM). B) Crystal structure of UCHL3 (blue) in complex with a ubiquitin-VME
probe (green), PDB entry: 1XD3. Cysteine residues are highlighted in orange and
magenta (active site cysteine). The cysteines modified with the photocrosslinkers are
labelled with the respective numbers 54 and 55.
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6.6 Photocrosslinking
Next, it was evaluated whether the modified DUB-photocrosslinker conjugates 94-97
retained their ability to interact with ubiquitin. First, USP2CD-photocrosslinker conju-
gates 94 (diazirine head group) and 95 (mPyT head group) were mixed with wild-type
ubiquitin and irradiated with UV-light (Fig. 58A). In control reactions, GFP was added
to check for specificity. As can be seen in the gel in Fig. 58B, covalent crosslinks between
USP2CD and wild-type ubiquitin formed for both conjugates and the crosslinking to
ubiquitin was specific in the presence of GFP. This experiment proved that it was pos-
sible to covalently and specifically crosslink ubiquitin with the DUB-photocrosslinker
conjugate. It was further observed that the crosslinking with the tetrazole crosslinker
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Fig. 58 A) Photocrosslinking between USP2CD-photocrosslinker conjugates 94 & 95
(each 6µM) with wild-type ubiquitin (wt Ub, 25 µM) alone or in the presence of GFP
(25µM). B) SDS-PAGE (Coomassie). All samples were irradiated with UV-light.
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The analogous experiment with UCHL3-photocrosslinker conjugates 96 & 97 (Fig. 59A)
also resulted in covalent DUB-ubiquitin crosslinks and again, the photocrosslinking was
more efficient with the tetrazole derivative (conjugate 97, Fig. 59B).
UCHL3
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Fig. 59 A) Photocrosslinking between UCHL3-photocrosslinker conjugates 96 & 97
(each 6µM) with wild-type ubiquitin (25 µM) alone or in the presence of GFP (25 µM).
B) SDS-PAGE (Coomassie). All samples were irradiated with UV-light.
Based on these promising results, photocrosslinking was next attempted with diubiquitin
(DiUb) substrates and in particular with K48- and K63-linked DiUb (Fig. 60A). As for
USP-DUBs it has been shown that they can recognise both types of linkages [306].
UCHL3 on the other hand interacts preferentially with K27-linked ubiquitins and to a
much lesser extent with other DiUbs as demonstrated by Zhang et al. [307]. As shown
in Fig. 60B, covalent crosslinks between DUBs and DiUbs were obtained also in this
experiment. Interestingly, differences in-between the different DUBs also with regard to
the photo-reactive moieties were observed. Covalent crosslinking to DiUb(K48) was for
instance observed for USP2CD-tetrazole conjugate 95 (see 1* in Fig. 60B) but not for
the respective USP2CD-diazirine conjugate 94. This might be either due to differences
in the efficiencies of the photo-reactive groups or reflect the different positions of the
photocrosslinkers in conjugate 94 and 95. As shown in Fig. 56, the MS/MS analysis
of these two conjugates revealed that modification with photocrosslinker 54 (diazirine)
was found only at cysteines C476 and C477, while modification with photocrosslinker
55 was additionally found at the cysteines C458 and C276, the latter being the active
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site cysteine. It may thus be that crosslinking to DiUbK48 happened with conjugate 95
through the crosslinkers attached at one of these additional sites. In future experiments
it will be important to determine the crosslinked sites by means of MS/MS. This analysis
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1: USP2CD + DiUb
2: UCHL3 + DiUb
3: USP2CD + monoUb
4: UCHL3 + DiUb
Fig. 60 A) Photocrosslinking between DUB-photocrosslinker conjugates (3 µM) and diubiq-
uitins (DiUb, 6µM). B) SDS-PAGE (Coomassie). All samples were irradiated with
UV-light.
For the UCHL3-photocrosslinker conjugates 96 and 97 the opposite outcome was
observed in the crosslinking experiment with DiUb(K48). Here, the diazirine-modified
UCHL3 96 showed more efficient crosslinking (2*) than the tetrazole-UCHL3 97. This
finding is particularly interesting because for UCHL3, both photocrosslinkers were
found at the same two cysteine residues (C209 and C95 (active site), see Fig. 57B). A
possible reason for the observed difference between the crosslinkers can be that the
carbene species, resulting from irradiation of the diazirine, react unselectively with
various functional groups, while the carboxynitrilimine species of the activated tetra-
zole derivative reacts more selectively with carboxylates and maybe other nucleophilic
side chain residues [289, 308]. Consequently, the absence of nucleophilic residues in
proximity to the tetrazole photocrosslinker might be the reason why crosslinking was
not efficient with this substrate. Again, the SDS-PAGE analysis does not reveal at
which site crosslinking between UCHL3 and the diubiquitin happened and further
MS/MS analysis will be necessary to gain more insight. Another observation was
that in the samples containing USP2CD, diubiquitins hydrolysed to a large extent to
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monoubiquitins (monoUb, see bottom of the gel in Fig. 60). This remaining protease
activity of USP2CD conjugates can be explained by incomplete modification of the
active site cysteine.
As for the experiment with K63-linked DiUb, the outcomes were yet different. Here,
only little crosslinking was observed with USP2CD (3*) but the band shift of this
species indicates crosslink to mono-ubiquitin (monoUb). There are two scenarios that
can lead to this outcome. Either USP2CD-tetrazole conjugate 95 first crosslinked
DiUb(K63) followed by hydrolysis or USP2CD crosslinking happened with monoUb
present in the mixture originating from previous DiUb(K63) hydrolysis. Thus, for
future experiments in lysates it will be important to test whether crosslinked substrates
are still amenable to cleavage by DUBs. This would mean, that the pulled-down species
do not necessarily correlate with the initially recognised substrates.
Using DiUb(K63) together with UCHL3 resulted in crosslinking for the UCHL3-
tetrazole conjugate 97 and also for UCHL3-diazirine conjugate 96 (see 4* for both).
In general, UCHL3 did not significantly hydrolyse the DiUbs over the course of the
experiment, which was expected based on the low activity of UCHL3 towards K48-
and K63-linked diubiquitins [307]. This finding also indicates, that substrates with a
certain affinity to DUBs might be crosslinked although the activity of the DUB towards
the hydroylsis of this substrate is low.
In the next steps of this project, we will carefully evaluate the positioning of the pho-
tocrosslinkers within the tested DUBs to investigate its impact on the selectivity and
the efficiency for substrate crosslinking. Site-selective placing of the crosslinker might
then be achieved via site-directed mutagenesis of cysteine residues. Alternatively, un-
natural amino acids could be incorporated into DUBs and be addressed selectively using
bioorthogonal labelling strategies. Apart from the chosen model DUBs used in these
first proof-of-concept experiments, the approach will be extended to recently identified
DUBs with yet unexplored substrate specificity. Finally, for photocrosslinking experi-
ments in cell lysates, an appropriate handle for pull-down purpose has to be incorporated
into the DUB. As mentioned above, a critical aspect in the evaluation of pulled-down
substrate proteins will be to confirm if these hits are true-positives and indeed reflect
substrate specificity. Overall, the preliminary data described in this chapter point to-
wards promising possibilities of using DUB-photocrosslinker conjugates as tools to study
DUB-substrate interactions and we are hopeful that this approach will enable the iden-
tification of specific substrate proteins in complex environments.
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7 Summary & Outlook
In this work, vinyl- and ethynylphosphonothiolates were synthesised and explored as a
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Fig. 61 The method developed in this thesis enables the chemoselective synthesis of unsatu-
rated phosphonothiolates, thereby inducing reactivity for subsequent cysteine-selective
thiol additions.
Vinyl- and ethynylphosphonothiolates have not been investigated for bioconjugation
purpose and also their synthesis has not seen a lot of attention so far. In this work,
we thus aimed at developing first an efficient synthetic protocol to access unsaturated
phosphonothiolates in order to then evaluate their properties as handles in protein mod-
ifications. Based on previous work from our group and others, where it has been shown
that phosphorus(III) species react efficiently with disulfides [237, 239, 243, 309, 244],
we hypothesised that vinyl- and ethynylphosphonothiolates could be synthesised from
electrophilic disulfides and unsaturated phosphonites. This thesis documents that we
succeeded in accessing vinyl- and ethynylphosphonothiolates from electrophilic disul-
fides and vinyl- and ethynylphosphonites (scheme 55A). We optimised this disulfide-
phosphonite reaction using unsymmetrical 5-nitropyridine disulfide derivatives and dis-
covered that this reaction proceeds very quickly in organic solvents, following presum-
ably an Arbuzov-type mechanism. In the presence of water, the targeted phosphonothio-
lates could not be obtained, which might be due to substitution of the thiol residue in the
phosphonium intermediate by water. We further found that the disulfide-phosphonite
reaction must be performed under acidic conditions in order to inhibit the formation
of a side-product originating from the addition of the thiolate leaving group to the un-
saturated phosphonothiolates. Under the optimised conditions, various small molecule
derivatives could be obtained in good yields.
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In addition, an alternative synthetic route was developed to access unsaturated phospho-
nothiolates in five steps from phosphorus trichloride (scheme 55B). Both routes allowed
us to synthesise general building blocks, which could further be derivatised by means of
amide couplings.
Importantly, it was found that the disulfide-phosphonite reaction proceeds with excel-
lent chemoselectivity, as demonstrated for the installation of vinylphosphonothiolate
electrophiles at activated cysteine residues on unprotected peptides and the protein
ubiquitin. This method thus enables the site-selective installation of an electrophilic
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Examples:
Scheme 55 A) Chemoselective synthetic route to access unsaturated phosphonothiolates from
electrophilic disulfides. B) Alternative synthetic route starting from PCl3.
Using the generated vinyl- and ethynylphosphonothiolates, we then explored their reac-
tivity towards thiol additions. It was found, that the ethynyl-derivatives are significantly
more reactive in thiol additions with bimolecular rate constants in the low M-1s-1 range,
as opposed to mM-1s-1 rates for the thiol addition to the respective vinyl-derivatives at
neutral pH (scheme 56).
The enhanced reactivity of ethynylphosphonothiolates is however compromised by the
stability of these reagents in aqueous buffer. We found that the phosphorus-sulphur
bond in ethynylphosphonothiolates is prone to hydrolysis, especially under basic condi-
tions. P-S bond hydrolysis was also observed for vinylphosphonothiolate reagents but
on a much slower time scale compared to the ethynyl-derivatives. This trend was also
found for the respective thiol-conjugates, although the thiol-conjugates are generally
more stable than the unconjugated phosphonothiolates.
Notably, thiol addition to both vinyl- and ethynylphosphonothiolates is irreversible,
also in the presence of excess free thiols, as opposed to thiol conjugates formed from
maleimides for example.
As for the chemoselectivity of the thiol additions to vinyl- and ethynylphosphonoth-
iolates, we found that both compound classes employ high, although not exclusive,
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Scheme 56 Thiol additions to ethynyl- and vinylphosphonothiolates.
Based on the promising results documented in this thesis, further optimisations will
likely help to improve the synthesis of unsaturated phosphonothiolates and their use in
thiol-conjugation reactions. One limitation of the developed system in its current stage
is the low reactivity of vinylphosphonothiolates, necessitating relatively high concentra-
tions of the reaction partners to obtain sufficient labelling. Ethynylphosphonothiolates
on the other hand react almost three orders of magnitude faster with thiols but the
P-S bond in these reagents and the corresponding thiol conjugates is prone to hydrol-
ysis. As previously shown by our group [208, 209], the more electron-withdrawing the
substituents around the phosphorus are, the more reactive unsaturated P(V)-reagents
become towards thiol addition. Following this logic, vinylphosphonothiolates could be
rendered more reactive by introducing more electron-withdrawing residues at the O-
substituent. However, such derivatives would expected to be less stable, as a conse-
quence of the more electropositive phosphorus being more prone towards nucleophilic
attack by water. The compromise of decreased stability for increased reactivity must
thus be kept in mind when developing new electrophilic phosphonothiolate derivatives.
Another limitation of the current system concerns the synthesis of unsaturated phospho-
nothiolates. As demonstrated in this thesis, the disulfide-phosphonite reaction requires
dry conditions as the reactive intermediates otherwise can get quenched by water. This
is particularly a problem for peptide and protein substrates, as it limits the applicability
of this method to polypeptides that are soluble in organic solvents and can subsequently
be refolded. Also here, one could try to derivatise the vinylphosphonite such, that the
Arbuzov-mechanism is favoured over hydrolysis. This might be achieved by means of
introducing more electron-withdrawing substituents at the O-residue or maybe also by
incorporating a nucleophile into the phosphonite side chain to promote intramolecular
rearrangement. A further parameter that can be changed is the type of activated disul-
fide employed. Using less nucleophilic leaving groups might obviate the need for acidic
conditions to inhibit re-attack of the respective thiolate leaving group to the desired
unsaturated phosphonothiolates. Although there is room for optimising the developed
method in the future, the potential of unsaturated phosphonothiolates as linkers to gen-
erate functional bioconjugates could be demonstrated in this thesis in three different
applications (Fig. 62).
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Fig. 62 Overview of generated phosphonothiolate-linked bioconjugates.
First, we succeeded in generating site-selectively ubiquitinated protein conjugates
using a vinylphosphonothiolate-ubiquitin probe. In particular, we generated a
non-hydrolysable diubiqutin as well as a ubiquitin-α-Synuclein conjugate. The chemos-
elective installation of electrophilic vinylphosphonothiolates on ubiquitin thus enabled
the generation of protein-protein conjugates relying solely on canonical amino acids.
In a second application, we evaluated unsaturated phosphonothiolates as linkers in
antibody-drug conjugates (ADCs). Specifically, brentuximab-MMAE conjugates were
generated. While ethynylphosphonothiolates allowed for the efficient generation of
brentuximab-MMAE ADCs with high average drug to antibody ratios (DARs), these
ADC hydrolysed under physiological conditions. On the other hand, the generation of
ADCs with decent DARs was more challenging using the less reactive vinylphospho-
nothiolate derivatives but the resulting ADCs proved to be more stable. Compared to
the clinically approved ADC Adcetris R©, the ADC generated with vinylphosphonothio-
late was more stable in rat serum and showed similar in vitro efficacy.
In a final application, vinylphosphonothiolates were employed as linkers to modify
proteins with photoreactive crosslinkers to study dynamic protein-protein interactions.
On the one hand, we equipped chaperone-specific antibodies with photocrosslinkers
and tried to crosslink chaperone interacting proteins. This approach was not successful,
most likely because the photocrosslinkers were too flexible and thus did not reach the
target proteins, thereby prohibiting successful crosslinking. On the other hand, we
modified deubiquitinating enzymes with photocrosslinkers. With these tools, we were
able to efficiently crosslink model ubiquitin substrates, which indicates potential of
DUB-photocrosslinker conjugates for the identification of specific substrate proteins.
Taken together, the herein developed method enables the chemoselective transformation
of activated disulfides into electrophilic vinyl- and ethynylphosphonothiolates, thereby
inducing reactivity for subsequent cysteine-selective thiol dditions. We believe that
this formal conjugation of two complex thiol-containing molecules will be used for the
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8.1 General information
8.1.1 Chemicals and solvents
If not mentioned specifically, chemicals and solvents were purchased from Merck (Merck
group, Germany), TCI (Tokyo chemical industry CO., LTD., Japan) and Acros Organics
(Thermo Fisher scientific, USA) and used without further purification. Dry solvents
were purchased from Acros Organics (Thermo Fisher scientific, USA).
8.1.2 Flash- and thin layer chromatography
Flash column chromatography was performed using NORMASIL 60 R© silica gel (40-
63µm, VWR international, USA) or high purity grade (60 µm, Davisil Grade 633,
Sigma-Aldrich Co., USA). Aluminium TLC plates (silica gel 60 coated with fluores-
cent indicator UV254) were purchased from Macherey-Nagel (Macherey-Nagel GmbH
& Co. Kg, Germany). Spots were visualised by fluorescence depletion with a 254 nm
lamp or manganese staining (10 g K2CO3, 1.5 g KMnO4, 0.1 g NaOH in 200mL H2O),
followed by heating.
8.1.3 Preparative HPLC
Preparative HPLC was performed on a Gilson PLC 2020 system (Gilson Inc, WI, Mid-
dleton, USA) using a VP 250/32 Macherey-Nagel Nucleodur C18 HTec Spum column
(Macherey-Nagel GmbH & Co. Kg, Germany).
8.1.4 Semipreparative HPLC
Semipreparative HPLC was performed on a Shimadzu prominence HPLC system (Shi-
madzu Corp., Japan) with a CBM20A communication bus module, a FRC-10A fraction
collector, 2 pumps LC-20AP, and a SPD-20A UV/VIS detector, using a VP250/21
Macherey-Nagel Nucleodur C18 HTec Spum column (Macherey-Nagel GmbH & Co.
Kg, Germany). For protein purification a Vydac R© protein C4 column (10µm, 300 ,
10mm ID x 250mm L, Cat#214TP1010) was used. Eluents: A = H2O + 0.1% TFA,




Analytical HPLC for thiol addition kinetic measurements was conducted on a Shimadzu
prominence HPLC system (Shimadzu Corp., Japan) with a CBM-20A communication
bus module, a SIL-20A auto sampler, 2 pumps LC-20AT, and a SPD-M20A UV/VIS
detector, a CTO-20A column oven and a RF-10AXL fluorescence detector, using an
Agilent Eclipse C18 5µm, 250 x 4.6 mm RR-HPLC column (Agilent Technologies, USA)
with a flow rate of 1.0mL/min. The following gradients were used: (A = H2O + 0.1%
TFA, B = MeCN + 0.1% TFA), 2% B 0-5 min, 2-45% B 5-35 min, 45-95% B 35-36 min,
95% B 36-40min, 95 to 2% B 40-41min, 2% B 41-45min. Fluorescence spectra with
Ex/Em 336/490 nm were recorded.
8.1.6 UPLC-UV/MS
UPLC-UV/MS traces were recorded on a Waters H-class instrument equipped with
a quaternary solvent manager, a Waters autosampler, a Waters TUV detector and a
Waters Acquity QDa detector with an Acquity UPLC BEH C18 1.7 µm, 2.1 x 50mm
RP column with a flow rate of 0.6mL/min (Waters Corp., USA). The following gradients
were used: A = H2O + 0.1% TFA in; B = MeCN + 0.1% TFA. Long gradient: 5% B 0-
1.5min, 5- 95% B 1.5-13.0min, 95% B 13.0-13.9min, 5% B 13.9-15min. Short gradient:
3% B 0-0.5min, 3-60% B 0.5-3.0min, 95% B 3.0-3.9min, 3% B 3.9-5min.
8.1.7 Size-exclusion chromatography
Protein purification by size-exclusion chromatography was conducted with an ÄKTA
FPLC system (GE Healthcare, United States) equipped with a P-920 pump system, a
UPC-900 detector and a FRAC-950 fraction collector. For antibody purification a 5mL
HiTrap R© desalting column was used with a flow-rate of 1.5mL/min. For ubiquitin
and α-Synuclein proteins or protein conjugates, a Superdex 75 10/300 GL column (GE
Healthcare, USA) was used with a flow-rate of 0.8mL/min.
8.1.8 High resolution MS
High-resolution ESI-MS spectra were recorded on two different instruments: 1) Agilent
6220 TOF Accurate Mass coupled to an Agilent 1200 LC (Agilent Technologies, USA).
On this system, samples were measured at 35 ◦C between 100-2000 m/z. The used
column was an Accucore RP-MS (30 x 2.1mm; 2.6µm particle size) eluted with a flow
of 0.8mL/min and the following gradient (A = H2O + 0.1% TFA, B = MeCN + 0.1%
TFA), gradient: 5% B 0-0.2min, 5-99% B 0.2-1.1min, 99% B 1.1-2.5min. 2) Agilent
Technologies 6230 Accurate Mass TOF LC/MS linked to Agilent Technologies HPLC
1260 Series; Column: Thermo Accuore RP-MS; Particle Size: 2.6 µM; Dimension: 30 x
2.1mm. The following gradient was used: A = H2O + 0.1% formic acid, B = MeCN
+ 0.1% formic acid, 5% B 0.0-0.2min, 5-99% B 0.2-1.1min, 99% B 1.1-3.6min, 5% B
3.6-4.9min. Flow rate: 0.8mL/min; UV-detection: 220 nm, 254 nm, 300 nm.
8.1.9 Intact protein MS
Intact proteins were analysed using a Waters H-class instrument equipped with a qua-
ternary solvent manager, a Waters sample manager-FTN, a Waters PDA detector and a
Waters column manager with an Acquity UPLC protein BEH C4 column (300 , 1.7 µm,
2.1 mm x 50 mm). Proteins were eluted at a column temperature of 80 ◦C with a flow
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rate of 0.3 ml/min. For proteins the following gradient was used: A = H2O + 0.01%
formic acid, B = MeCN + 0.01% formic acid. 5-95% B 0-6min at 40 ◦C. Mass analysis
was conducted with a Waters XEVO G2-XS QTof analyzer. Proteins were ionized in
positive ion mode applying a cone voltage of 40 kV. Raw data was deconvoluted with
MaxEnt 1.
8.1.10 NMR
NMR spectra were recorded with a Bruker AV-III 300MHz spectrometer and a Bruker
AV III 600MHz spectrometer, both equipped with a broadband probe (BBFO). For sta-
bility measurements at 25 ◦C or 37 ◦C, a Bruker AV-III 600MHz spectrometer equipped
with a QCI cryoprobe with one-axis self-shielding gradients and a cooled 31P-coil and
preamplifier was used. Chemical shifts δ are reported in ppm relative to residual solvent
peaks (CDCl3: 7.26 [ppm]; DMSO−d6: 2.50 [ppm]; CD3CN 1.94 [ppm]; 4.79 D2O [ppm]
for 1H-spectra and CDCl3: 77.16 [ppm]; DMSO−d6: 39.52 [ppm]; CD3CN 1.32 [ppm];
for 13C-spectra.
8.1.11 UV-irradiation for photocrosslinking experiments
Protein samples in photocrosslinking experiments were irradiated using an Analytik Jena
bench-top 8-Watt UV-lamp (UVLMS-38) equipped with a switch to choose between
254/302/365 nm. The samples were typically placed with a distance of 2-3 cm to the
UV-lamp and directly irradiated from the top.
8.1.12 Tryptic digest of proteins and LC-MS/MS analysis
Note: LC-MS/MS measurements were done by Dr. Michal Nadler-Holly and Heike
Stephanowitz from the group of Dr. Fan Liu (FMP Berlin). Christian Stieger analysed
MS/MS data and wrote the corresponding Experimental.
For MS/MS analysis, proteins were run on a SDS-gel, stained with Coomassie brilliant
blue and further processed by in-gel protein digest using trypsin. For this, the desired
protein band was cut into pieces and transferred in a 1mL test tube. 200 µL of washing
buffer (50mM triethylammonium bicarbonate (TEAB from Sigma) pH 8.5/ acetonitrile
1:1) was added and the mixture was shaken for 10min at 30 ◦C. The washing buffer
was removed and 200µL of 50mM TEAB pH 8.5 was added and the sample was again
shaken for 10min at 30 ◦C. The buffer was removed and the gel pieces were shrunk by
the addition of 200µL acetonitrile. The last step was repeated one additional time and
then the solvent was removed. Next, 100µL of a DTT solution (5mM in 50mM TEAB)
was added and the mixture was shaken for 45min at 56 ◦C. The supernatant was re-
moved and immediately afterwards, 100µL of chloroacetamide (CAA) solution (40mM
in 50mM TEAB) was added and shaken for 30min in the dark at r.t. The buffer was
removed and the residue was washed with 200µL washing buffer. After buffer removal,
the gel pieces were shrunk by the addition of 200µL acetonitrile (two times). Subse-
quently, 0.1µg trypsin in 40µL of digest buffer (50mM TEAB pH 8.5) was added and
the mixture was shaken over night at 37 ◦C. The sample was then shortly centrifuged
and 30µL of 0.5% trifluoroacetic acid in acetonitrile was added to stop the digest. The
supernatant was transferred from the test tube into a glass MS vial. The remaining gel
pieces were shrunk by the addition of 20µL acetonitrile and this supernatant was com-
bined with the solution in the MS vial. The solvent was then removed under vacuum
and the residue was redissolved in 6µL H2O/acetonitrile 95/5 containing 0.1% TFA and
subjected to LC-MS/MS analysis:
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Peptide mixtures after tryptic digest were analysed by a reversed-phase capillary liquid
chromatography system (Dionex Ultimate 3000 NCS-3500RS Nano, Thermo Scientific)
connected to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, Ger-
many). For sample loading, a PepMap C-18 trap-column (Thermo Fischer Scientific) of
0.075mm ID x 50mm length, 3µm particle size, 100Å pore size was used. The loading
mobile phase A contained 1% acetonitrile and 0.1% TFA in water, and mobile phase B
0.1% TFA acid in acetonitrile. LC separation was performed with a 200 cm µPACTM
column (PharmaFluidics, Ghent, Belgium) at an eluent flow rate of 750 nL/min using a
gradient of 4-50% B in 59min. The separation mobile phase A contained 0.1% formic
acid in water, and mobile phase B 0.1% formic acid in acetonitrile. FT survey scans
were acquired in a range of 350 to 1500 m/z with a resolution of 120000 (FWHM) and
an AGC target value of 4e5. Precursor ions with charge states 2-5 were isolated with a
mass selecting quadrupole (isolation window m/z 1.2) with 10 s dynamic exclusion. Pre-
cursor ions were fragmented using stepped higher-energy collisional dissociation (HCD).
Stepped HCD MS/MS spectra were acquired with 27-30-33% normalised collision en-
ergy (NCE). The maximum injection time was set to 54ms to collect 2e4 precursor
ions. Fragment ion spectra were acquired in the Orbitrap with a resolution of 15000
(FWHM).
8.1.13 SDS-PAGE and Western-blot analysis
SDS-PAGE
SDS-gels were prepared using standard protocols. All probes were boiled in SDS sam-
ple buffer containing β-mercaptoethanol prior to loading. Gels were run in a Mini-
PROTEAN system from Bio-Rad at 250V for 30min. Bands were detected with stan-
dard Coomassie stain.
Silver staining
For silver staining, gels were fixed and rinsed in fixing solution (40% methanol (v/v),
10% acetic acid (v/v), 50% H2O (v/v)) over 18 h. Gels were then rinsed in 20% EtOH
in water over 10min, followed by incubation in 10 % sodium thiosulfate for 1min.
After washing the gel two times in H2O for 1min each, the gel was incubated in 0.2
% silver nitrate for 20min. The gel was briefly washed in H2O for 1min, followed
by developing solution (3% K2CO3 (w/v); 25µL formaldehyde (37%), 12.5µL sodium
thiosulfate (10%) in 100mL H2O). After sufficient visualisation had been acquired,
developing solution was replaced with stopping solution (4% Tris (w/v), 2% acetic acid
(v/v)) for at least 30min of incubation. The gel was then washed twice in H2O for at
least 30min each.
Western blotting
Western blotting was carried out after SDS-PAGE in a wet chamber (Bio-Rad). In
brief, the gel and a PVDF membrane were equilibrated in transfer buffer (25mM Tris,
190mM glycine, 10% EtOH (v/v)) for 5min before the transfer sandwich was assem-
bled. Western blots were performed at constant current of 250mA for 60min. After
blotting, membranes were stained with Ponceau (0.1% Ponceau S (w/v), 5% acetic acid
(v/v) in H2O) and then blocked for 1 h with ROTI
R©Block (Roth) (ROTI R©Block: 0.01%
Tween in PBS (v/v) = 1:9) or in 5% milk powder (w/v). After blocking, the membrane
was washed two times with 0.01% Tween in PBS (v/v) for 2min. Primary antibody
incubation (with anti-HSP-1 or anti-DNJ-13, 1:5000 dilution from serum) was carried
out overnight at 4 ◦C in 1x Roti Block in H2O). Secondary antibody (Thermo Fisher
Scientific, goat-anti-rabbit IgG (H+L), peroxidase conjugated, 1:15000) was incubated
for 90min in 1x Roti Block in H2O. Alternatively, for anti-biotin Western-blotting, the
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membrane was incubated with 0.03% Streptavidin-POD conjugate (Roche Diagnostics
GmbH) (v/v) in PBS containing 0.01% Tween (v/v) and 1% ROTI R©Block (v/v) for 1
hour at r.t. Detection was carried out using the ECL-reagent (Thermo Fisher Scien-
tific), following the manufacturer’s instructions and utilising a ChemiDoc XRS Imaging
System (Universal Hood III, BioRad Laboratories GmbH).
8.2 Experimental part for method development chapter

























































A round-bottom flask equipped with a magnetic stir bar was charged with Ellman’s
reagent (255mg, 0.64mmol, 2.0 eq.) and DMF (3mL). To this stirred, clear solution
was added triethylamine (466µL, 3.2mmol, 10 eq.) and ethanethiol (24µL, 0.32mmol,
1.0 eq.), and the resulting clear red solution was stirred at 10min at r.t. The solvents
were evaporated under reduced pressure and the residue was dissolved in 0.5mL DCM
and purified by flash column chromatography on silica (EtOAc/hexane (containing
0.1% formic acid) = 2:1 to 1:1). Pure product-containing fraction were pooled and
solvents were evaporated under reduced pressure to yield the title compound as a
yellow solid (62mg, 0.24mmol, 75%). 1H-NMR: (600MHz, CDCl3): δ = 7.95 (d, J
= 2.1Hz, 1H), 7.91 (d, J = 8.6Hz, 1H), 7.78 (dd, J = 8.6, 2.1Hz, 1H), 2.81 (q, J =
7.3Hz, 2H), 1.34 (t, J = 7.3Hz, 3H). 13C-NMR: (151MHz, CDCl3): δ = 170.60, 146.43,
145.90, 128.63, 127.40, 126.48, 124.82, 33.12, 14.36. HR-MS (ESI+) for C9H10NO4S2
+
[M+H+] calcd.: 260.0046, found: 260.0051.
























































A round-bottom flask equipped with a magnetic stir bar was charged with thiol (1.0 eq.)
dissolved in THF or DMF at a concentration of 0.1M. Triethylamine or DIPEA (3.0 eq.)
and disulfide 2,2′-dithiobis(5-nitropyridine) (DTNP) (1.2 eq.) were subsequently added,
resulting in a colour-change from colourless to yellow-red and the reaction mixture was
stirred at r.t. When full conversion was achieved (approximately after 10min), the
volatiles were evaporated under reduced pressure and the crude product was purified by
flash column chromatography on silica gel or by reverse-phase HPLC.
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Compound 2 was prepared according to general procedure 1 from ethanethiol (103 µL,
1.34mmol) in THF with Et3N. The crude product was purified by flash column
chromatography on silica gel (n-hexane/EtOAc = 10:1) to yield the title compound as
a yellow oil (228mg, 1.05mmol, 78%). 1H-NMR: (300MHz, CDCl3): δ = 9.24 (d, J =
2.6Hz, 1H), 8.39 (dd, J = 8.9Hz, 2.6Hz, 1H), 7.92 (d, J = 8.9Hz, 1H), 2.85 (q, J =
7.3Hz, 2H), 1.34 (t, J = 7.3Hz, 3H). 13C-NMR: (75MHz, CDCl3): δ = 169.40, 145.13,

































Compound 14 was prepared according to general procedure 1 from benzyl mercaptan
(48µL, 0.41mmol) in THF with Et3N. The crude product was purified by flash column
chromatography on silica gel (n-hexane/EtOAc = 10:1) to yield the title compound as
a colourless solid (91mg, 0.33mmol, 80%). 1H-NMR: (300MHz, CDCl3): δ = 9.18 (d,
J = 2.6Hz, 1H), 8.15 (dd, J = 8.9Hz, 2.6, 1H), 7.49 (d, J = 8.9Hz, 1H), 7.30-7.24 (m,
2H), 7.24-7.17 (m, 3H), 4.04 (s, 2H). 13C-NMR: (75MHz, CDCl3): δ = 168.90, 144.86,
141.81, 136.10, 131.17, 129.50 (2C), 128.83 (2C), 128.04, 119.03, 43.86. HR-MS (ESI+)
for C12H11N2O2S2































Following a literature procedure [310], D-biotin was first converted into the correspond-
ing biotin-succinimidyl-ester and then reacted with 2-aminoethane-1-thiol to give the
respective biotin-thiol derivative. This biotin-thiol derivative (44mg, 0.179mmol) was
then activated with DTNP according to general procedure 1 in DMF with DIPEA. The
crude product was purified by flash column chromatography on silica gel (DCM/MeOH
= 20:1 to 10:1) to yield the title compound as a yellow solid (53mg, 0.134mmol, 75%).
1H-NMR: (300MHz, DMSO−d6): δ = 9.25 (d, J = 2.2Hz, 1H), 8.57 (dd, J = 8.9,
2.7Hz, 1H), 8.11-7.97 (m, 2H), 6.39 (d, J = 18.1Hz, 2H), 4.30 (dd, J = 7.7, 5.0Hz,
1H), 4.12 (ddd, J = 7.4, 4.4, 1.8Hz, 1H), 3.32 (m, 2H), 3.15 - 3.02 (m, 1H), 2.95 (t,
J = 6.6Hz, 2H), 2.81 (dd, J = 12.4, 5.0Hz, 1H), 2.59 (m, 1H), 2.06 (t, J = 7.3Hz,
2H), 1.65-1.19 (m, 6H). 13C-NMR: (75MHz, DMSO−d6): δ = 172.42, 167.35, 162.81,
145.03, 142.34, 132.76, 119.59, 61.11, 59.27, 55.50, 40.43, 37.74, 37.62, 35.21, 28.27,
28.10, 25.25. HR-MS (ESI+) for C17H24N5O4S3


































Compound 16 was prepared according to general procedure 1 from mercaptopropionic
acid (250µL, 2.85mmol) in THF with Et3N. The crude product was purified by flash
column chromatography on silica gel (n-hexane/EtOAc = 1:1 + 0.1% formic acid) to
yield the title compound as a yellow oil (80mg, 1.54mmol, 54%). 1H-NMR: (300MHz,
CDCl3): δ = 9.94 (s, broad), 9.27 (d, J = 2.6Hz, 1H), 8.41 (dd, J = 8.9, 2.6Hz, 1H),
7.87 (d, J = 8.8Hz, 1H), 3.10 (t, J = 6.9Hz, 2H), 2.82 (t, J = 6.8Hz, 2H). 13C-NMR:
(75MHz, CDCl3): δ = 177.23, 168.03, 145.32, 142.33, 131.89, 119.66, 33.67, 33.31.
HR-MS (ESI+) for C8H9N2O4S2
+ [M+H+], calcd.: 260.9998, found: 261.0005.





















Peptides with the general sequence KYRCXK (X= A, S, H, D, M) were obtained from
Fmoc-based solid-phase-peptide synthesis on a Rink-amide resin8. The crude peptides
(0.1mmol, 1.0 eq.) and 2,2’-dithiobis(5-nitropyridine) (47mg, 0.15mmol, 1.5 eq.) were
dissolved in 1.0mL DMF containing DIPEA (87µL, 0.5mmol, 5.0 eq.) and the mixtures
were shaken at r.t. for 10min. Solvents were then removed under reduced pressure
and the residues were redissolved in 5mL H2O/MeCN 9:1 + 0.1% TFA, filtered and
subsequently purified by semipreparative HPLC (gradient: A = H2O + 0.1% TFA, B
= MeCN + 0.1% TFA, 3-60% B in A over 50min, flow-rate: 30mL/min). Products
23-27 were obtained as yellow powder after lyophilization and analysed by UPLC-UV
(long gradient) and HR-MS.








KYRCAK 23 33.5 0.0364 36
KYRCSK 24 21.7 0.0232 23
KYRCHK 25 13.5 0.0137 14
KYRCDK 26 31.0 0.0321 32
KYRCMK 27 17.9 0.0182 18
8The author thanks Ines Kretzschmar for peptide synthesis.
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HR-MS (ESI) analysis of peptides 23-27:
peptide 23: for C38H61N14O9S2
+ [M+H+] calcd.: 921.4182, found: 921.4268.
peptide 24: for C38H61N14O10S2
+ [M+H+] calcd.: 937.4131, found: 937.4155.
peptide 25: for C41H63N16O9S2
+ [M+H+] calcd.: 987.4400, found: 987.3994.
peptide 26: for C39H61N14O11S2
+ [M+H+] calcd.: 965.4080, found: 965.4174.
peptide 27: for C40H65N14O9S3
+ [M+H+] calcd.: 981.4216, found: 981.4238.
Fig. 63 UPLC-UV analysis (220 nm) of purified peptide 23.
Fig. 64 UPLC-UV analysis (220 nm) of purified peptide 24.
Fig. 65 UPLC-UV analysis (220 nm) of purified peptide 25.
Fig. 66 UPLC-UV analysis (220 nm) of purified peptide 26.
119
8 Experimental
Fig. 67 UPLC-UV analysis (220 nm) of purified peptide 27.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, −40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, −40 °C to r.t.
iii) 1.1. eq.
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50 mM NH4HCO3
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The procedure described here for the synthesis of diethyl-ethynylphosphonite is based
on Ref. [208]: A Schlenk-flask was charged with diethyl chlorophosphite (Sigma,
278µL, 2.00mmol, 1.0 eq.) under an argon atmosphere, cooled to –78 ◦C (in an aceton
dry-ice bath) and ethynylmagnesium bromide solution (Sigma, 0.5M in THF, 4.40mL,
2.20mmol, 1.1 eq.) was added drop-wise and stirred for 10min at –78 ◦C. The solution
was allowed to warm to r.t. and used without further dilution for subsequent reactions.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, −40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, −40 °C to r.t.
iii) 1.1. eq.
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1 eq.i)
















































































































































PBS pH 7.4 or
50 mM NH4HCO3
















DMSO + 10 eq. TFA, 
























The procedure described here for the synthesis of diethyl-vinylphosphonite is based on
Ref. [209]: A Schlenk-flask was charged with diethyl chlorophosphite (Sigma, 278 µL,
2.00mmol, 1.0 eq.) under an argon atmosphere, cooled to –78 ◦C and vinylmagnesium
bromide solution (Sigma, 1.0M in THF, 2.20mL, 2.20mmol, 1.1 eq.) was added
drop-wise and stirred for 10min at –78 ◦C. The solution was allowed to warm to r.t.
and used without further dilution for subsequent reactions. 31P-NMR: (122MHz, crude
in THF): δ = 158.60.
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8.2.3 Synthesis of phosphonothiolates from electrophilic disulfides
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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1 eq.i)






























































































































































































































































































































































































































































































Ellman’s-activated disulfide 1 (63mg, 0.243mmol, 1.0 eq.) was dissolved in dry
THF (0.6mL). To this stirred solution was added drop-wise freshly synthesized
diethyl-ethynylphosphonite 3 (crude in THF, ca. 0.45M, 0.54mL, 0.243mmol, 1.0 eq.)
at r.t. and the mixture was stirred at r.t. for 1.5 hours and analysed by 31P-NMR
(see Fig. 14B). The crude products were then purified by silica gel chromatography
(n-hexane/EtOAc = 1:1 + 0.1% formic acid to MeOH/DCM = 5:95 + 0.1% formic acid)
to give products 5 (13mg, 0.0344mmol, 14%, ca. 75% pure according to 1H-NMR) and
6 (3mg, 0.0074mmol, 3%, ca. 95% pure according to 1H-NMR). The low yields can
be explained by incomplete conversion of electrophilic disulfide 1 (33mg, 0.127mmol
of 1 were recovered.) The product were characterized by 1H-NMR, 31P-NMR and
low-resolution M :
Re-attack product 5:
1H-NMR: (300MHz, CDCl3): δ = 8.08-7.87 (m, 2H), 7.83 (d, J = 8.5Hz, 1H), 7.56
(dd, J = 8.5, 2.0Hz, 1H), 6.09 (dd, J = 21.0, 16.6Hz, 1H), 4.31-4.18 (m, 2H), 2.89
(dt, J = 13.4, 7.4Hz, 2H), 1.39 (t, J = 7.2Hz, 6H). 31P-NMR: (122MHz, CDCl3): δ
= 42.65. LR-MS (ESI+) for C13H17NO6PS2
+ [M+H+], calcd.: 378.02, found: 378.16.
Re-attack product 6:
1H-NMR: (300MHz, CDCl3): δ = 7.96 (d, J = 8.5Hz, 1H), 7.72 (d, J = 2.0Hz, 1H),
7.64 (dd, J = 8.5, 2.1Hz, 1H), 7.53 (dd, J = 20.6, 16.5Hz, 1H), 6.03 (dd, J = 19.5,
16.4Hz, 1H), 4.42 (q, J = 7.2Hz, 2H), 4.27-4.12 (m, 2H), 2.84 (dq, J = 14.5, 7.3Hz,
2H), 1.37 (three overlapping triplets, 9H). 31P-NMR: (122MHz, CDCl3): δ = 39.29.
LR-MS (ESI+) for C15H21NO6PS2
+ [M+H+], calcd.: 406.05, found: 406.17.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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Ellman’s-activated disulfide 1 (105mg, 0.405mmol, 1.0 eq.) was dissolved in dry
THF (3.5mL). To this stirred solution was added drop-wise freshly synthesized
diethyl-vinylphosphonite 4 (crude in THF, ca. 0.80M, 506µL, 0.405mmol, 1.0 eq.)
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containing internal standard triphenylphosphineoxide (PPh3O) at r.t. and the mixture
was stirred at r.t. for 30min and analysed by 31P-NMR (see Fig. 15B. The crude
products were then purified by silica gel chromatography (n-hexane/EtOAc = 1:1
+ 0.1% formic acid to MeOH/DCM = 5:95 + 0.1% formic acid) to give products 8 and 9.
Vinylphosphonothiolate 8:
1H-NMR: (300MHz, CDCl3): δ = 6.40-5.98 (m, 3H), 4.30-4.06 (m, 2H), 2.89-2.72 (m,
2H), 1.41-1.30 (m, 6H). 13C-NMR: (75MHz, CDCl3): δ = 133.92 (d, J = 1.5Hz),
130.86 (d, J= 145.4Hz), 61.83 (d, J = 6.7Hz), 24.98 (d, J = 3.0Hz), 16.57 (d, J =
5.3Hz), 16.45 (d, J=6.9Hz). 31P-NMR (122 MHz, CDCl3): δ = 42.12. HR-MS (ESI+)
for C6H14O2PS
+ [M+H+] calcd.: 181.0447, found: 181.0460.
Re-attack product 9:
1H-NMR: (600MHz, CDCl3): δ = 8.68 (s, 1H), 7.86 (d, J = 8.6Hz, 1H), 7.60 (d, J
= 2.1Hz, 1H), 7.46-7.41 (m, 1H), 4.32-4.14 (m, 2H), 3.42-3.32 (m, 2H), 2.97-2.88 (m,
2H), 2.45-2.36 (m, 2H), 1.39 (t, J = 7.6Hz, 3H), 1.38 (t, J = 7.2Hz, 3H). 13C-NMR:
(151MHz, CDCl3): δ = 167.64, 144.98, 144.43, 129.38, 129.17, 127.22, 124.73, 62.82
(d, J = 7.5Hz), 33.05 (d, J = 102.4Hz), 25.62 (d, J = 3.5Hz), 25.05, 16.88 (d, J
= 5.0Hz), 16.27 (d, J = 7.1Hz). 31P-NMR: (243MHz, CDCl3): δ = 52.77. HR-MS
(ESI+) for C13H19NO6PS2
+ [M+H+] calcd.: 380.0386, found: 380.0380.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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Scheme 57 Test reaction between electrophilic disulfide 2 and vinylphosphonite 4 in THF
DTNP-activated disulfide 2 (98mg, 0.453mmol, 1.0 eq.) was dissolved in dry THF
(4mL) under an argon atmosphere. To this stirred solution was added drop-wise freshly
synthesized diethyl-vinylphosphonite 4 (crude in THF, ca. 0.80M, 566µL, 0.453mmol,
1.0 eq.) at r.t.. The mixture was stirred at r.t. for 30min and analysed by 31P-
NMR (see Fig. 16B). The crude mixture was purified by silica gel chromatography (n-
hexane/EtOAc= 4:1 to 2:1 to 1:1), giving vinylphosphonothiolate 8 (43mg, 0.140mmol,
53%) and re-attack product 10 (20mg, 0.060mmol, 13%). The characterization of
vinylphosphonothiolate 8 is described above.
Re-attack product 10: 1H-NMR: (300MHz, CDCl3): δ = 9.25 (dd, J = 2.7, 0.7Hz,
1H), 8.24 (dd, J = 8.9, 2.7Hz, 1H), 7.30 (dd, J = 8.9, 0.7Hz, 1H), 4.35-4.05 (m, 2H),
3.58-3.47 (m, 2H), 3.00-2.86 (m, 2H), 2.56-2.39 (m, 2H), 1.42 (t, J = 7.5Hz, 3H), 1.37
(t, J = 7.2Hz, 3H). 13C-NMR: (75MHz, CDCl3): δ = 166.79, 145.25, 141.42, 130.66,
121.78, 61.76 (d, J = 7.6Hz), 34.37, 33.02, 25.30 (d, J = 3.3Hz), 23.94, 17.06 (d, J
= 4.5Hz), 16.42 (d, J = 6.7Hz). 31P-NMR (122MHz, CDCl3): δ = 53.30. HR-MS
(ESI+) for C11H18N2O4PS2
+ [M+H+] calcd.: 337.0440, found: 337.0446.
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DTNP-activated electrophilic disulfide 2 (26mg, 0.12mmol, 1.0 eq.) was dissolved in
dry DMSO (1mL) containing H2O
18 (Sigma, 2.4µL, 0.12mmol, 1.0 eq.). To this stirred
mixture was added vinylphosphonite 4 (crude in THF, ca. 0.78M, 154µL, 1.0 eq.)














Fig. 68 31P-NMR of the reaction mixture of the reaction between electrophilic dislufide 2 and
vinylphosphonite 4 in DMSO + H2O18. The identified products are indicated; for the
re-attack-phosphonate species, the corresponding signal is in the range of 27-28 ppm
but could not be unambiguously assigned in this crude 31P-NMR spectrum.
The crude mixture was subjected to purification via semipreparative HPLC (5-70%
MeCN + 0.1% TFA in H2O + 0.1% TFA over 50min, flow: 10mL/min) and the two
re-attack products were thereby isolated, see characterization below.
The vinylphosphonothiolate 8 and the vinylphosphonate 11 were not isolated here.
The vinylphosphonothiolate 8 has been characterized above and has a characteristic
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31P-NMR chemical shift of ca. 42 ppm, which fits to the signal observed in Fig. 68.
The assignment of vinylphosphonate 8 in the crude 31P-NMR shown in Fig. 68 is based
on comparison to the commercially available diethylvinylphosphonate (Sigma), which


































































The NMR and HR-MS analysis is in line with the above described characterization for
this compound. UPLC-MS analysis of the HPLC-purified 10 is shown below (Fig. 69).
The observed mass corresponds to the 16O-isotope.
Fig. 69 UPLC-MS analysis of isolated product 10. LR-MS for C11H18N2O4PS2+ [M+H+]
calcd.: 337.04, found: 337.04.

































































1H-NMR: (300MHz, CDCl3): δ = 9.27 (dd, J = 2.7, 0.7Hz, 1H), 8.26 (dd, J = 8.9,
2.7Hz, 1H), 7.34-7.29 (m, 1H), 4.27-4.10 (m, 4H), 3.55-3.40 (m, 2H), 2.37-2.19 (m, 2H),
1.45-1.34 (m, 6H). 31P-NMR (122MHz, CDCl3): δ = 27.82, 27.78. HR-MS (ESI+)
for C11H18N2O5PS
+ [M+H+] calcd.: 321.0669, found: 321.0667. HR-MS (ESI+) for
C11H18N2O4O
18PS+ [M+H+] calcd.: 323.0711, found: 323.0711.
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UPLC-MS analysis is shown below in Fig. 70.
Fig. 70 UPLC-MS analysis of isolated re-attack to phosphonate. LR-MS for C11H18N2O5PS+
[M+H+] calcd.: 321.07, found: 321.07 and for C11H18N2O4O18PS+ [M+H+] calcd.:
323.07, found: 323.07.




1H-NMR: (300MHz, DMSO−d6): δ = 6.30-6.00 (m, 3H), 3.97 (dq, J = 8.3, 7.1Hz, 4H),
1.23 (t, J = 7.1Hz, 6H). 13C-NMR (75MHz, DMSO−d6): δ = 135.50 (d, J = 1.8Hz),
126.47 (d, J = 179.7Hz), 61.35 (d, J = 5.7Hz), 16.22 (d, J = 6.0Hz). 31P-NMR
(122MHz, DMSO−d6): δ = 16.97.
Test reaction between electrophilic disulfide (2) and vinylphosphonite (4) in
DMSO without TFA
DTNP-activated electrophilic disulfide 2 (80mg, 0.370mmol, 1.0 eq.) was dissolved in
dry DMSO (3.7mL) to reach a disulfide concentration of 0.1M. To this stirred mixture
was added drop-wise a solution of diethyl-vinylphosphonite (crude, ca. 0.78M in THF,
474µL, 1.0 eq.) at r.t. The reaction mixture was stirred at r.t., analysed by 31P-NMR
(see Fig. 19B) and then purified by silica-gel chromatography (n-hexane/EtOAc = 4:1
to 2:1 to 1:1) to give vinylphosphonothiolate 8 (26mg, 0.144mmol, 39%), re-attack
product 10 and the alkylated leaving group (30mg, 0.163mmol, 44%).
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Vinylphosphonothiolate 8 and re-attack product 10 have been characterized above.




1H-NMR: (300MHz, CDCl3): δ = 9.22 (dd, J = 2.7, 0.7Hz, 1H), 8.20 (dd, J = 8.9,
2.7Hz, 1H), 7.31-7.21 (m, 1H), 3.25 (q, J = 7.3Hz, 2H), 1.39 (t, J = 7.4Hz, 3H).
13C-NMR (75MHz, CDCl3): δ = 168.25, 145.15, 141.04, 130.34, 121.51, 25.06, 14.40.
HR-MS (ESI+) for C7H9N2O2S
+ [M+H+] calcd.: 185.0379, found: 185.0382.



































































crude, 2 eq. P
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DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.











tetrazole, THF, -40 °C to r.t.
1 eq.i)


















































































DTNP-activated electrophilic disulfides (1.0 eq.) were dissolved in dry DMSO contain-
ing trifluoroacetic acid (10 eq.) to reach a disulfide concentration of 0.1M. To this
stirred mixture was added drop-wise a solution of diethyl-vinyl- or ethynylphosphonite
(crude in THF, 2.0 eq.) at r.t. Typically, the reactions were complete within one
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Compound 8 was prepared according to general procedure 2 from mixed electrophilic
disulfide 2 (100mg, 0.462mmol). The crude product was purified by flash column
chromatography (n-hexane/EtOAc = 4:1 to 2:1 gradient) to yield the title compound
as a colourless oil (67mg, 0.370mmol, 80%). This product has been characterized above.
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Compound 17 was prepared according to general procedure 2 from mixed electrophilic
disulfide 14 (100mg, 0.359mmol). The crude product was purified by flash column
chromatography (n-hexane/EtOAc = 4:1 to 1:1 gradient) to yield the title compound as
a colourless oil (48mg, 0.198mmol, 55%). 1H-NMR: (300MHz, CDCl3): δ = 7.39-7.21
(m, 5H), 6.34-5.91 (m, 3H), 4.27-3.95 (m, 4H), 1.32 (t, J = 7.0Hz, 3H). 13C-NMR:
(75MHz, CDCl3): δ = 163.06, 137.15 (d, J = 5Hz), 134.68 (d, J = 1.6Hz), 129.70 (d,
J = 146.5Hz), 129.00, 128.71, 127.70, 62.36 (d, J = 6.9Hz), 34.51 (d, J = 2.8Hz),
16.22 (d, J = 6.9Hz). 31P-NMR (122 MHz, CDCl3): δ = 42.69. HR-MS (ESI+) for
C11H15O2PS
+ [M+H+] calcd.: 242.0525, found: 242.0551.
The phosphonothioate by-product (S=P-R) (compare for example scheme 41) was not
isolated/characterized but its indicative 31P-NMR-shift at 85 ppm in DMSO (observed
in the crude reaction mixture), is in line with literature [311]. Furthermore, when
vinylphosphonite was treated with molecular sulphur in DMSO, a single species with
the same shift of 85 ppm was observed by 31P-NMR.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)


























































































































































































































































Compound 18 was prepared according to general procedure 2 from mixed electrophilic
disulfide 15 (15mg, 0.0328mmol). The crude product was purified by flash column
chromatography (DCM/MeOH = 50:1 to 9:1 gradient) to yield the title compound as
a colourless solid (11mg, 0.0262mmol, 80%).
1H-NMR: (600MHz, DMSO−d6): δ = 8.02 (t, J = 5.7Hz, 1H), 6.47-6.12 (m, 5H),
4.33-4.27 (m, 1H), 4.12 (ddd, J = 8.4, 4.8, 1.8Hz, 1H), 4.11-4.04 (m, 2H), 3.26 (q, J
= 6.7Hz, 2H), 3.09 (ddd, J = 8.5, 6.1, 4.4Hz, 1H), 2.85-2.73 (m, 3H), 2.58 (d, J =
12.4Hz, 1H), 2.06 (t, J = 7.4Hz, 2H), 1.61 (ddt, J = 12.2, 9.7, 6.1Hz, 1H), 1.55-1.42
(m, 3H), 1.36-1.29 (m, 2H), 1.28 (t, J = 7.0Hz, 3H). 13C-NMR: (151MHz, DMSO−d6):
δ = 172.20, 162.67, 134.39, 130.55 (d, J = 144Hz), 61.43 (d, J = 7.3Hz), 61.02,
59.18, 55.39, 40.06, 35.10, 29.05, 28.15, 28.01, 25.17, 16.12 (d, J = 7Hz). 31P-NMR
(243MHz, DMSO−d6): δ = 41.34. HR-MS (ESI+) for C16H29N3O4PS2+ [M+H+]
calcd.: 422.1332, found: 422.1340.
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Compound 19 was prepared according to general procedure 2 from mixed electrophilic
disulfide 16 (146mg, 0.561mmol). The crude product was purified by flash column
chromatography (gradient: n-hexane/EtOAc=4:1 to EtOAc + 0.1% formic acid)
to yield the title compound as a colourless oil (88mg, 0.393mmol, 70%). 1H-NMR:
(600MHz, CDCl3): δ = 9.25 (s, 1H), 6.38-6.07 (m, 3H), 4.26-4.13 (m, 2H), 3.09-2.96 (m,
2H), 2.74 (t, J = 7.2Hz, 2H), 1.35 (t, J = 7.1Hz, 3H). 13C-NMR: (151MHz, CDCl3): δ
= 174.98, 134.92, 130.18 (d, J = 145.9Hz), 62.52 (d, J = 6.9Hz), 35.73 (d, J = 3.5Hz),
25.02 (d, J = 2.8Hz), 16.38 (d, J = 6.9Hz). 31P-NMR (243MHz, Chloroform-d):
δ = 43.17. HR-MS (ESI+) for C7H14O4PS
+ [M+H+] calcd.: 225.0345, found: 225.0358.
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Compound 7 was prepared according to general procedure 2 from mixed electrophilic
disulfide 2 (100mg, 0.462mmol). The crude product was purified by flash column
chromatography (n-hexane/EtOAc = 2:1 to 100% EtOAc gradient) to yield the
title compound as a colourless oil (48mg, 0.270mmol, 58%). 1H-NMR: (300MHz,
CDCl3): δ = 4.24 (dq, J = 9.6, 7.1Hz, 2H), 3.17 (d, J = 12.5Hz, 1H), 3.07-2.87
(m, 2H), 1.41 (td, J = 7.2, 5.9Hz, 6H). 13C-NMR: (75MHz, CDCl3): δ = 89.23
(d, J = 42.8Hz), 77.33 (d, J = 236.9Hz), 63.93 (d, J = 6.8Hz), 25.72 (d, J =
3.7Hz), 16.21 (d, J = 7.4Hz), 16.12 (d, J = 6.4Hz). 31P-NMR (122MHz, CDCl3):
δ = 17.40. HR-MS (ESI+) for C6H12O2PS
+ [M+H+] calcd.: 179.0290, found: 179.0301.
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Scheme 58 Synthesis of vinylphosphonothiolate peptides and observed side-products.
DTNP-activated cysteine peptides 23-27 (0.010mmol, 1.0 eq.) were dissolved in
dry DMSO containing trifluoroacetic acid (10 eq.) to reach a peptide concentration
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of 30mM. To these stirred mixtures was added drop-wise a solution of diethyl-
vinylphosphonite (crude in THF, 2.0 eq.). After the reaction was complete (typically
less than 2 minutes), the reaction mixtures were diluted with 4.5mL H2O and
purified by semipreparative HPLC (gradient: 5-50% MeCN + 0.1% TFA, 95-40%
H2O + 0.1% TFA over 40min, flow: 5mL/min), yielding products 28-32 as white
powders after lyophilization. The purified peptides were analysed by UPLC-UV,
HR-MS and 31P-NMR (see Appendix). The 31P-NMR spectra show two species in
a ratio of 1:1, which correspond to the two diastereoisomers of the product, as the
phosphonite-disulfide reaction results in a racemic mixture of the phosphonothiolate.
In case of peptide 32, the two diastereoisomers could be separated by HPLC and were
analysed separately. Next to the desired phosphonothiolate peptide products, two side
products were identified. The main side product in this reaction is reduced cysteine
peptide (ca. 10-14% isolated yields). In addition, ca. 5-8% of the addition products of
vinylphosphonite to vinylphosphonothiolate peptides were isolated (see Appendix for
31P-NMR spectrum).
















KYRCAK 28 3.6 4.07 41 10 5
KYRCSK 29 3.0 3.33 33 14 7
KYRCHK 30 3.0 3.15 32 13 7
KYRCDK 31 2.7 2.91 29 13 8
KYRCMK 32 1.7+1.6 3.49 35 14 5
HR-MS (ESI) analysis of peptides 28-32:
peptide 28: for C37H66N12O9PS
+ [M+H+] calcd.: 885.4529, found: 885.4482.
peptide 29: for C37H66N12O10PS
+ [M+H+] calcd.: 901.4478, found: 901.3964.
peptide 30: for C40H68N14O9PS
+ [M+H+] calcd.: 951.4747, found: 951.5656.
peptide 31: for C38H66N12O11PS
+ [M+H+] calcd.: 929.4427, found: 929.4526.
peptide 32: for C39H70N12O9PS2
+ [M+H+] calcd.: 945.4562, found: 945.4465.
Fig. 71 UPLC-UV analysis (220 nm) of purified peptide 28.
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Fig. 72 UPLC-UV analysis (220 nm) of purified peptide 29.
Fig. 73 UPLC-UV analysis (220 nm) of purified peptide 30.
Fig. 74 UPLC-UV analysis (220 nm) of purified peptide 31.
Fig. 75 UPLC-UV analysis (220 nm) of purified peptide 32.
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8.2.4 Synthesis of phosphonothiolates via PCl3 route
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)









A flame-dried round bottom Schlenk flask was charged with phosphorus trichloride
(12.5mmol, 1090µL, 1.0 eq.) and dry ether (50mL) under an argon atmosphere and
cooled to –30 ◦C in an aceton dry ice bath. Ethanol (12.5mmol, 728µL, 1.0 eq.)
and triethylamine (12.5mmol, 1.733mL, 1.0 eq.) were added and the solution was
stirred at –30 ◦C for 10min before warming to r.t. and stirred for another hour. The
resulting white suspension was quickly filtered over celite. The filtrate was collected in
a flame-dried round bottom Schlenk flask and cooled again to –30 ◦C under an argon
atmosphere. Diisopropylamine (25mmol, 3.528mL, 2.0 eq.) was added and the reaction
mixture was stirred at –30 ◦C for 10min before warming up to r.t. and stirred for
another hour. The resulting suspension was filtered over celite again. The clear filtrate
was cooled to –78 ◦C under an argon atmosphere and a solution of ethylmagnesium
bromide (Sigma, 0.5M in THF, 13.75mmol, 27.5mL, 1.1 eq.) was added, stirred for
10min at –78 ◦C and then at r.t. for another hour. The reaction mixture was then
concentrated to roughly 20mL under reduced pressure, diluted with saturated aqueous
NaHCO3 (60mL) and extracted with EtOAc (3x 120mL). The combined organic layers
were dried over NaSO4, filtered and the solvents were removed under reduced pressure.
The resulting oily residue was purified by silica gel (Sigma, Davisil Grade 633, pore
size 60Å, 200-425 mesh particle size) chromatography (n-hexane + 1% Et3N) to yield
the titled compound as a yellow oil (1.236 g, 6.14mmol, 49%). 1H-NMR: (300MHz,
CD3CN): δ = 3.77-3.63 (m, 4H), 3.33 (d, J = 1.8Hz, 1H), 1.21-1.13 (m, 15H).
13C-
NMR: (75MHz, ceCD3CN): δ = 92.75 (d, J = 7.4Hz), 86.85 (d, J = 18.5Hz), 62.86 (d,
J = 16.20Hz), 48.36, 24.37, 17.40 (d, J = 7.5Hz). 31P-NMR (122MHz, CD3CN) δ =
92.22. HR-MS (ESI+) for NaC10H20NOP
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)









A flame-dried round bottom Schlenk flask was charged with phosphorus trichloride
(12.5mmol, 1090µL, 1.0 eq.) and dry ether (50mL) under an argon atmosphere
and cooled to –30 ◦C in a dry ice bath. Ethanol (12.5mmol, 728µL, 1.0 eq.) and
triethylamine (12.5mmol, 1.733mL, 1.0 eq.) were added and the solution was stirred
at –30 ◦C for 10min before warming to r.t. and stirred for another hour. The resulting
white suspension was quickly filtered over celite. The filtrate was collected in a
flame-dried round bottom Schlenk flask and cooled again to –30 ◦C under an argon
atmosphere. Diisopropylamine (25mmol, 3.528mL, 2.0 eq.) was added and the reaction
mixture was stirred at –30 ◦C for 10min before warming up to r.t. and stirred for
another hour. The resulting suspension was filtered over celite again. The clear filtrate
was cooled to –78 ◦C under an argon atmosphere and a solution of vinylmagnesium
bromide (Sigma, 1.0M in THF, 13.75mmol, 13.75mL, 1.1 eq.) was added, stirred for
10min at –78 ◦C and then at r.t. for another hour. The reaction mixture was then
concentrated to roughly 20mL under reduced pressure, diluted with saturated aqueous
NaHCO3 (60mL) and extracted with EtOAc (3x 120mL). The combined organic layers
were dried over NaS 4, filtered and the solvents were removed under reduced pressure.
The resulting oily residue was purified by silica gel (Sigma, Davisil Grade 633, pore
size 60Å, 200-425 mesh particle size) chromatography (n-hexane + 1% Et3N) to yield
the titled compound as a colourless oil (852mg, 4.19mmol, 34%). 1H-NMR: (300MHz,
CD3CN): δ = 6.36-6.14 (m, 1H), 5.77-5.53 (m, 2H), 3.81-3.61 (m, 2H), 3.53-3.38 (m,
2H), 1.23-1.04 (m, 15H). 13C-NMR: (75MHz, CD3CN): δ = 142.23 (d, J = 7.0Hz),
125.34 (d, J = 19.7Hz), 63.01 (d, J = 21.0Hz), 46.63 (d, J = 9.5Hz), 24.83 (dd, J =
22.3, 6.9Hz), 17.59 (d, J = 7.6Hz). 31P-NMR (122MHz, CD3CN) δ = 113.79. HR-MS
(ESI+) for C10H23NOP
+ [M+H+] calcd.: 204.1517; found: 204.1596.
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General procedure 3: Synthesis of ethynyl- and vinylphosphonothiolates from
intermediates 33 and 34
R SH
tetrazole, THF, −40 °C to r.t.
1 eq.i)












Scheme 59 Synthesis of ethynyl- and vinylphosphonothiolates from 33 and 34, respectively.
A round bottom flask was charged with 33 or 34 (1.0 eq.), dissolved in dry acetonitrile
(to reach a concentration of 0.1M) and cooled to –40 ◦C. Separately, a solution of the
desired thiol (1.0 eq.) and tetrazole (Sigma, 0.45M in MeCN, 2.0 eq.) was prepared
and added drop-wise to the first stirred solution at –40 ◦C. The reaction mixture was
stirred for 10min at –40 ◦C before allowed to warm to r.t. and stirred for another
30min. Then, a tert-butyl hydroperoxide solution (70 wt. % in H2O, 1.0 eq.) was
added at r.t. and stirred for 10min. The reaction mixture was then diluted with H2O
(e.g. 3mL for 0.1mmol scale) and extracted with DCM (3x 10mL). The combined
organic layers were dried over Na2SO4, filtered and the solvents were removed under
reduced pressure. The crude product was purified by silica gel chromatography.
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DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)











Compound 35 was prepared according to general procedure 3 starting from 33 (25mg,
0.123mmol) and mercaptobenzyl (14.4µL, 0.123mmol). Purification by silica gel
chromatography (100% EtOAc) gave the desired compound as a colourless oil (10mg,
0.042mmol, 34%). 1H-NMR: (300MHz, CDCl3): δ = 7.40-7.27 (m, 5H), 4.27-3.99 (m,
4H), 3.10 (d, J = 12.5Hz, 1H), 1.33 (td, J = 7.1, 0.6Hz, 3H). 13C-NMR: (75MHz,
CDCl3): δ = 136.58 (d, J = 6.3Hz), 129.21, 128.86, 127.95, 88.99 (d, J = 42.7Hz),
77.41 (d, J = 238.2Hz), 63.62 (d, J = 6.5Hz), 35.16 (d, J = 3.4Hz), 16.17 (d, J =
7.5Hz). 31P-NMR (122MHz, CDCl3): δ = 15.36. HR-MS (ESI+) for C11H14O2PS
+
[M+H+] calcd.: 241.0447; found: 241.0447.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)











Compound 36 was prepared according to general procedure 3 starting from 33
(93mg, 0.465mmol) and tert-butyl (2-mercaptoethyl)carbamate (82mg, 0.465mmol).
Purification by silica gel chromatography (100% EtOAc) gave the desired compound
as a colourless oil (44mg, 0.15mmol, 32%). 1H-NMR: (600 MHz, DMSO−d6): δ =
5.02 (d, J = 12.7Hz, 1H), 4.33 (dq, J = 10.1, 7.0Hz, 2H), 3.11 (dt, J = 15.5, 6.9Hz,
2H), 2.69 (p, J = 1.8Hz, 2H), 1.57 (s, 9H), 1.49 (t, J = 7.0Hz, 3H). 13C-NMR:
(151MHz, DMSO−d6): δ = 155.42, 93.47 (d, J = 40.6Hz), 77.93, 77.11 (d, J =
234Hz), 63.18 (d, J = 6.7Hz), 40.19, 30.01, 28.15, 15.86 (d, J = 7.1Hz). 31P-NMR
(243MHz, DMSO−d6): δ = 11.75. HR-MS (ESI+) for C11H20NO4PSNa+ [M+Na+]
calcd.: 316.0743; found: 316.0746.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, t2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 q.i)











Compound 17 was prepared according to general procedure 3 starting from 34 (25mg,
0.123mmol) and mercaptobenzyl (14.4µL, 0.123mmol). Purification by silica gel
chromatography (100% EtOAc) gave the desired compound as a colourless oil (11mg,
0.0454mmol, 37%). This compound has already been characterized above.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)











Compound 37 was prepared according to general procedure 3 starting from 34 (93mg,
0.465mmol) and tert-butyl (2-mercaptoethyl)carbamate (82mg, 0.465mmol). Purifi-
cation by silica gel chromatography (100% EtOAc) gave the desired compound as a
colourless oil (30mg, 0.10mmol, 22%). 1H-NMR: (300MHz, CDCl3): δ = 6.41-5.98 (m,
3H), 4.30-4.09 (m, 2H), 3.39 (t, J = 6.5Hz, 2H), 3.06-2.80 (m, 2H), 1.44 (s, 9H), 1.36
(t, J = 7.1Hz, 3H). 13C-NMR: (75MHz, CDCl3): δ = 155.95, 134.62, 130.27 (d, J =
145Hz), 79.66, 62.55 (d, J = 6Hz), 41.41, 30.19, 28.44, 16.32 (d, J = 6.7Hz). 31P-NMR
(122MHz, Chloroform-d): δ = 42.26.
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8.2.5 Derivatisation of general phosphonothiolate building blocks
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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Carboxylic acid 19 (10mg, 0.0446mmol, 1.0 eq) and N -hydroxysuccinimide (5.1mg,
0.0446mg, 1.0 eq.) were dissolved in 400µL of a 1,4-dioxane/EtOAc = 1:1 mixture
and cooled to 0 ◦C. Dicyclohexylcarbodiimide (9.2mg, 0.0446mmol, 1.0 eq.) was added
to the stirred solution and the mixture was allowed to warm to r.t. After 1 h, the
suspension was filtered and the clear residue was dried under reduced pressure to yield
compound 38 (12mg, 0.0374mmol, 84%). 1H-NMR: (600MHz, CDCl3): δ = 6.39-6.09
(m, 3H), 4.29-4.13 (m, 2H), 3.19-2.99 (m, 4H), 1.37 (t, J = 7.1Hz, 3H). 13C-NMR:
(151MHz, CDCl3): δ =168.92, 166.85, 134.76, 130.50 (d, J = 146.2Hz), 62.41 (d, J
= 6.8Hz), 33.03 (d, J = 3.0Hz), 25.71, 24.57 (d, J = 2.9Hz), 16.40 (d, J = 6.9Hz).
31P-NMR (243MHz, CDCl3): 41.44. HR-MS (ESI+) for C11H17NO6PS
+ [M+H+]
calcd: 322.0509, found: 322.0540.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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NHS ester 38 (30mg, 0.0934mmol, 1.0 eq.) and EDANS (Biomol, 30mg, 0.103mmol,
1.1 eq.) were dissolved in 470µL DMF in an Eppendorf tube. DIPEA (33µL,
0.189mmol, 2.0 eq.) was added and the suspension was stirred at r.t. for 15min. The
volatiles were evaporated under reduced pressure and the crude product was purified by
preparative HPLC (5-60% MeCN in 40min, flow: 16mL/min) to yield compound 39
(24mg, 0.0508mmol, 54%) as a white powder after lyophilisation. 1H-NMR: (600MHz,
DMSO−d6): δ = 8.32 (d, J = 8.6Hz, 1H), 8.22 (t, J = 5.8Hz, 1H), 8.07 (d, J =
8.5Hz, 1H), 7.96 (d, J = 7.0Hz, 1H), 7.40 (dd, J = 8.5, 7.1Hz, 1H), 7.34 (t, J =
8.1Hz, 1H), 6.81 (d, J = 7.3Hz, 1H), 6.38 (ddd, J = 28.0, 18.4, 12.4Hz, 1H), 6.25-6.11
(m, 2H), 4.14 ‚Äì 3.98 (m, 2H), 3.41 (t, J = 6.2Hz, 2H), 3.32 (t, J = 6.5 z, 2H),
2.93 (ddt, J = 18.0, 12.9, 6.6Hz, 2H), 1.26 (t, J = 7.0Hz, 3H). 13C-NMR: (151MHz,
DMSO−d6): δ = 170.42, 144.21, 134.28, 130.60 (d, J = 142Hz), 130.09, 125.92, 124.59,
124.07, 123.23, 122.62, 61.37 (d, J = 6.7Hz), 44.79, 37.23, 36.23 (d, J = 4.0Hz),
25.42 (d, J = 2.8Hz), 16.10 (d, J = 6.5Hz). 31P-NMR (243MHz, DMSO−d6): δ =
41.29. HR-MS (ESI+) for C19H26N2O6PS2
+ [M+H+] calcd.: 473.0964, found: 473.0984.
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Boc-protected ethynylphosphonothiolate derivative 36 was dissolved in TFA/H2O=95:5
at a concentration of 0.1M. The solution was stirred for 10min at r.t. and then di-
luted with water (1:10). The product 40 (an oil) was obtained quantitatively after
lyophilization and was directly used for subsequent reactions.



















































































































































































































































Boc-protected vinylphosphonothiolate derivative 37 was dissolved in TFA/H2O=95:5
at a concentration of 0.1M. The solution was stirred for 10min at r.t. and then
diluted with water (1:10). The product 41 (an oil) was obtained quantitatively after
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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HATU (690mg, 1.814mmol, 1.0 eq.) and succi ic acid (21 mg, 1.814mmol, 1.0 eq.)
were dissolved in 6mL DMF containing DIPEA (1.263mL, 7.254mmol, 4.0 eq.). This
solution was added to EDANS (483mg, 1.814mmol, 1.0 eq.) dissolved in 3mL DMF
and the mixture was stirred at r.t. for 30min. The solvents were then removed under
reduced pressure and the crude product was purified by preparative HPLC, giving
product 42 (508mg, 1.387mmol, 76%) as a slightly greenish powder after lyophilization.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (24.2mg, 0.0635mmol, 1.1 eq.), EDANS-derivative 42
(23.3mg, 0.0635mmol, 1.1 eq.) and DIPEA (30µL, 0.173mmol, 3.0 eq.) in 0.2mL
DMF was added to amine derivative 40 (11.2mg, 0.0578mmol, 1.0 eq.) dissolved
in 0.1mL DMF and the mixture was stirred at r.t. for 30min. The solvents were
then evaporated under reduced pressure and the crude product was purified via
semipreparative HPLC (gradient: 10-50% MeCN+0.1% TFA in H2O+0.1% TFA over
50min, flow: 5mL/min) giving product 43 (10mg, 0.0185mmol, 32%) as a white
powder after lyophilization. 1H-NMR: (600MHz, DMSO−d6): δ = 8.40 (m, broad,
1H), 8.17-8.05 (m, 3H), 8.01-7.95 (m, 1H), 7.45-7.40 (m, 1H), 7.39-7.34 (m, 1H),
6.93 (m, broad, 1H), 4.83 (d, J = 12.8Hz, 1H) 4.13 (dq, J = 10.1, 7.0Hz, 2H),
3.41 (q, J = 6.1Hz, 2H), 3.33 (p, J = 6.6, 5.9Hz, 4H), 3.11-3.04 (m, 1H), 2.92
(dtd, J = 16.2, 6.9, 2.7Hz, 2H), 2.38-2.32 (m, 4H), 1.29 (t, J = 7.1Hz, 3H), 1.16
(t, J = 7.3Hz, 1H). 13C-NMR: (151MHz, DMSO−d6): δ = 172.22, 171.59, 144.19,
130.09, 125.90, 124.71, 124.35, 124.21, 123.80, 123.60, 123.40, 122.66, 93.55 (d, J =
41.8Hz), 77.12 (d, J = 232.1Hz), 63.29 (d, J = 6.6Hz), 45.78, 38.94 (d, J = 5.4Hz),
30.69, 30.61, 29.70, 15.90 (d, J = 7.2Hz), 8.61. 31P-NMR (243MHz, DMSO−d6): δ =
11.77. HR-MS (ESI+) for C22H29N3O7PS2
+ [M+H+] calcd.: 542.1179, found: 542.1156.


































































crude, 2 eq. P
O
DMSO + 10 eq. TFA














































DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (20.6mg, 0.0541mmol, 1.1 eq.), EDANS-derivative 42
(19.8mg, 0.0541mmol, 1.1 eq.) and DIPEA (26µL, 0.147mmol, 3.0 eq.) in 0.2mL
DMF was added to amine derivative 41 (9.6mg, 0.0490mmol, 1.0 eq.) dissolved
in 0.1mL DMF and the mixture was stirred at r.t. for 30min. The solvents were
then evaporated under reduced pressure and the crude product was purified via
semipreparative HPLC (gradient: 10-50% MeCN+0.1% TFA in H2O+0.1% TFA over
50min, flow: 5mL/min) giving product 44 (11mg, 0.0202mmol, 41%) as a white
powder after lyophilization. 1H-NMR: (600MHz, DMSO−d6): δ = 8.39 (d, J = 8.7Hz,
1H), 8.11 (dt, J = 10.8, 5.7Hz, 2H), 8.07 (d, J = 8.7Hz, 1H), 7.98 (d, J = 7.1Hz,
1H), 7.43 (t, J = 7.8Hz, 1H), 7.37 (t, J = 8.1Hz, 1H), 6.46-6.33 (m, 1H), 6.25-6.11
(m, 2H), 4.15-4.01 (m, 2H), 3.40 (q, J = 6.2Hz, 2H), 3.33 (t, J = 6.4Hz, 2H), 3.25
(q, J = 6.7Hz, 2H), 3.08 (qd, J = 7.3, 4.8Hz, 1H), 2.77 (dqt, J = 19.9, 13.1, 6.9Hz,
2H), 2.38-2.30 (m, 4H), 1.26 (t, J = 7.0Hz, 3H), 1.16 (t, J = 7.3Hz, 2H). 13C-NMR:
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(151MHz, DMSO−d6): δ = 172.22, 171.52, 144.17, 134.41, 130.54 (d, J = 142.1Hz),
130.07, 125.92, 124.71, 124.27, 123.56, 122.68, 61.45 (d, J = 7.7Hz), 45.78, 37.07,
30.71, 30.62, 28.98, 16.11 (d, J = 6.5Hz), 8.61. 31P-NMR (243MHz, DMSO−d6): δ =
38.38. HR-MS (ESI+) for C22H31N3O7PS2
+ [M+H+] calcd.: 544.1341, found: 544.1316.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (61mg, 0.160mmol, 1.1 eq.), biotin (39mg, 0.160mmol,
1.1 eq.) and DIPEA (76µL, 0.435mmol, 3.0 eq.) in 0.4mL DMF was added to amine
derivative 40 (28mg, 0.145mmol, 1.0 eq.) dissolved in 0.2mL DMF and the mixture
was stirred at r.t. for 30min. The solvents were then evaporated under reduced pressure
and the crude product was purified via semipreparative HPLC (gradient: 10-50%
MeCN+0.1% TFA in H2O+0.1% TFA over 50min, flow: 10mL/min) giving product 45
(20mg, 0.0477mmol, 33%) as a white powder after lyophilization. 1H-NMR: (600MHz,
DMSO−d6): δ = 8.06 (t, J = 5.7Hz, 1H), 4.83 (d, J = 12.6Hz, 1H), 4.30 (ddd, J = 7.7,
5.2, 1.0Hz, 1H), 4.19-4.10 (m, 3H), 3.33 (td, J = 6.8, 5.6Hz, 2H), 3.10 (ddd, J = 8.5,
6.3, 4.4Hz, 1H), 2.94 (dtd, J = 15.7, 6.8, 3.0Hz, 2H), 2.85-2.80 (m, 1H), 2.58 (d, J =
12.3Hz, 1H), 2.50 (p, J = 1.9Hz, 1H), 2.07 (t, J = 7.4Hz, 2H), 1.61 (m, 1H), 1.56-1.41
(m, 3H), 1.36-1.26 (m, 5H (a multiplet (2H) and a triplet (3H) are overlaying)).
13C-NMR: (151MHz, DMSO−d6): δ = 177.26, 162.67, 93.51 (d, J = 40.8Hz), 77.12 (d,
J = 234.1Hz), 63.26 (d, J = 6.4Hz), 61.01, 59.18, 55.37, 38.80 (d, J = 5.4Hz), 35.09,
29.80, 28.13, 28.00, 25.16, 15.89 (d, J = 7.0Hz). 31P-NMR (243MHz, DMSO−d6): δ =
11.77. HR-MS (ESI+) for C16H27N3O4PS2
+ [M+H+] calcd.: 420.1175, found: 420.1154.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (31.7mg, 0.0834mmol, 1.1 eq.), biotin (20.4mg,
0.0834mmol, 1.1 eq.) and DIPEA (40µL, 0.227mmol, 3.0 eq.) in 0.4mL DMF was
added to amine derivative 41 (14.8mg, 0.0758mmol, 1.0 eq.) dissolved in 0.1mL DMF
and the mixture was stirred at r.t. for 30min. The solvents were then evaporated
under reduced pressure and the crude product was purified via semipreparative HPLC
(gradient: 10-50% MeCN+0.1% TFA in H2O+0.1% TFA over 50min, flow: 10mL/min)
giving product 46 (14mg, 0.0332mmol, 44%) as a white powder after lyophilization.
This compound has been characterized above (compare compound 18).
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (122mg, 0.321mmol, 1.0 eq.), succinic acid (38mg,
0.321mmol, 1.0 eq.) and DIPEA (167µL, 0.962mmol, 3.0 eq.) in 1.0mL DMF was
added to amine derivative 40 (62mg, 0.321mmol, 1.0 eq.) dissolved in 1.0mL DMF
and the mixture was stirred at r.t. for 30min. The solvents were then evaporated
under reduced pressure and the crude product was purified via semipreparative HPLC
(gradient: 20-60% MeCN+0.1% TFA in H2O+0.1% TFA over 60min, flow: 10mL/min)
giving product 47 (34mg, 0.116mmol, 36%) as a white powder after lyophilization.
1H-NMR: (600MHz, DMSO−d6): δ = 12.05 (s, broad, 1H), 8.12 (t, J = 5.8Hz, 1H),
4.84 (d, J = 12.7Hz, 1H), 4.19-4.10 (m, 2H), 3.36-3.30 (m, 2H, overlay with H2O),
2.97-2.88 (m, 2H), 2.42 (t, J = 6.9Hz, 2H), 2.31 (t, J = 6.9Hz, 2H), 1.30 (t, J = 7.0Hz,
3H). 13C-NMR: (151MHz, DMSO−d6): δ = 173.71, 171.18, 93.50 (d, J = 40.1Hz),
77.12 (d, J = 233.6Hz), 63.27 (d, J = 6.9Hz), 38.93 (d, J = 5.4Hz), 29.91, 29.67 (d, J
= 3.7Hz), 29.00, 15.88 (d, J = 6.7Hz). 31P-NMR (243MHz, DMSO−d6): δ = 11.75.
HR-MS (ESI+) for C10H17NO5PS
+ [M+H+] calcd.: 294.0560, found: 294.0558.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (117mg, 0.308mmol, 1.0 eq.), succinic acid (36mg,
0.308mmol, 1.0 eq.) and DIPEA (160µL, 0.923mmol, 3.0 eq.) in 1.0mL DMF was
added to amine derivative 41 (60mg, 0.308mmol, 1.0 eq.) dissolved in 1.0mL DMF
and the mixture was stirred at r.t. for 30min. The solvents were then evaporated
under reduced pressure and the crude product was purified via semipreparative HPLC
(gradient: 20-60% MeCN+0.1% TFA in H2O+0.1% TFA over 60min, flow: 10mL/min)
giving product 48 (42mg, 0.142mmol, 46%) as a white powder after lyophilization.
1H-NMR: (300MHz, CDCl3): δ = 7.79 (s, broad, 1H), 7.46 (t, J = 5.4Hz, 1H),
6.43-6.02 (m, 3H), 4.27-4.09 (m, 2H), 3.61-3.42 (m, 2H), 3.09-2.78 (m, 2H), 2.73-2.61
(m, 2H), 2.60-2.48 (m, 2H), 1.35 (t, J = 7.1Hz, 3H). 13C-NMR: (75MHz, CDCl3): δ =
175.52, 173.12, 135.41 (d, J = 1.6Hz), 129.78 (d, J = 145.9Hz), 62.90 (d, J = 7.0Hz),
40.79 (d, J = 2.8Hz), 30.79, 29.92, 28.97 (d, J = 2.8Hz), 16.39 (d, J = 6.9Hz).
31P-NMR (122MHz, CDCl3): δ = 44.28. HR-MS (ESI+) for C18H19NO5PS
+ [M+H+]
calcd.: 296.0716, found: 296.0724.
139
8 Experimental


































































crude, 2 eq. P
O
DMSO + 10 eq. TFA














































DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (2.44mg, 6.41µmol, 1.2 eq.), carboxylic acid ethynylphos-
phonothiolate derivative 47 (1.88mg, 6.41µmol, 1.2 eq.) and DIPEA (4.7µL, 26.7µmol,
5 eq.) in 100µL DMF was mixed with a solution of Val-Cit-PHB-MMAE 499 (6mg,
5.34µmol, 1.0 eq.) in 100µL DMF. The mixture was shaken at r.t. for 1 hour before
diluted with water (4mL). The crude product was purified by semipreparative HPLC
(gradient: 30-99%MeCN+ 0.1% TFA in H2O+ 0.1% TFA over 50min, flow: 5mL/min)
to give product 50 (3mg, 2.14µmol, 40%) as a white powder after lyophilization.
HR-MS (ESI+) for C68H110N11O16PS
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Fig. 76 UPLC-UV analysis (220 nm) of purified compound 50.
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i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.
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A solution containing HATU (3.0mg, 7.90µmol, 1.2 eq.), carboxylic acid vinylphospho-
nothiolate derivative 48 (2.33mg, 7.90µmol, 1.2 eq.) and DIPEA (5.8µL, 32.9µmol,
5 eq.) in 150µL DMF was mixed with a solution of Val-Cit-PHB-MMAE 49 (7.4mg,
6.59µmol, 1.0 eq.) in 150µL DMF. The mixture was shaken at r.t. for 15min before
diluted with water (5mL). The crude product was purified by semipreparative HPLC
9Compound 49 was synthesized and has been kindly provided by Dr. Philipp Ochtrop and Dr. Marc-
André Kasper.
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(gradient: 30-99%MeCN+ 0.1% TFA in H2O+ 0.1% TFA over 50min, flow: 5mL/min)
to give product 51 (4.74mg, 3.38µmol, 51%) as a white powder after lyophilization.
HR-MS (ESI+)for C68H112N11O16PS
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Fig. 77 UPLC-UV analysis (220 nm) of purified compound 51.
Tetrazole synthesis



























i. LiOH, MeOH/H2O, 0 °C to r.t.






































i. LiOH, MeOH/H2O, 0 °C to r.t.



















To a solution of ethyl cyanoformate (1.50 g, 15mmol, 1.0 eq.) in DMF (10mL) in a
microwave tube was added NaN3 (1.97 g, 30mmol, 2.0 eq.) and Et3N•HCl (4.20 g,
30mmol, 2.0 eq.). The mixture was stirred at 110 ◦C under microwave irradiation for
2 h (Biotage, Initiator+). Then 2N HCl (10mL) was added at 0 ◦C and the mixture was
extracted with EtOAc (3 times with 20mL). The combined organic layer was washed
with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was
redissolved in water and lyophilized. After lyophilization, the title compound was






























i. LiOH, MeOH/H2O, 0 °C to r.t.



















To a solution of 1-methyl-1H-pyrrole (1 g, 12.5mmol, 2.5 eq.) in trifluoroethanol
(10mL) under an argon atmosphere was added PhI(OAc)2 (4.00 g, 12.5mmol, 2.5
eq.) at –40 ◦C. The mixture was stirred at –40 ◦C for 2 h, then concentrated un-
der reduced pressure. The residue was dissolved in dry DCM (20mL), then ethyl
2H-tetrazole-5-carboxylate (710mg, 5mmol, 1.0 eq.), Cu(OTf)2 (722mg, 2mmol,
0.4 eq.) and Et3N (3.43mL, 25mmol, 5.0 eq.) were added at r.t.. The mixture
was stirred at r.t. under an argon for 16 h, then washed with saturated NH4Cl,
brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was
purified by silica gel flash chromatography (n-hexane/EtOAc = 3:1) to afford the title
compound as a brown oil (368mg, 1.66mmol, 33%). 1H-NMR: (300MHz, CDCl3): δ
= 6.62 (dd, J = 3.0, 2.0Hz, 1H), 6.47 (dd, J = 4.0, 2.0Hz, 1H), 6.05 (dd, J = 4.0,
2.9Hz, 1H), 4.39 (q, J = 7.1Hz, 2H), 3.60 (s, 3H), 1.32 (t, J = 7.1Hz, 3H). 13C-NMR:



































































crude, 2 eq. P
O
DMSO + 10 eq. TFA














































DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)






































































































































































































































































































































































































To a solution of ethyl 2-(1-methyl-1H-pyrrol-2-yl)-2H-tetrazole-5-carboxylate (463mg,
2.181mmol) in MeOH/H2O (1:1, 8mL) was added a 1N LiOH solution in H2O
(1.6mL) at 0 ◦C. The mixture was stirred at r.t. for 30min. Then, the solution was
acidified with 1N HCl at 0 ◦C to pH = 2-3, and the mixture was extracted with
DCM (3 times 10mL). The combined organic layer was washed with brine, dried
over anhydrous Na2SO4, filtered and concentrated to afford the title compound as a
brown solid (284mg, 1.47mmol, 67%). 1H-NMR: (300MHz, CDCl3): δ = 6.75 (dd,
J = 2.9, 2.0Hz, 1H), 6.71 (dd, J = 4.0, 1.9Hz, 1H), 6.26 (dd, J = 4.0, 2.9Hz, 1H),
3.79 (s, 3H). HR-MS (ESI+) for C7H8N5O2
+ [M+H]+ calcd.: 194.0673, found: 194.0674.










































































































































































































































































































































































i. LiOH, MeOH/H2O, 0 °C to r.t.






























A solution containing HATU (41mg, 0.108mmol, 1.5 eq.), 4-[3-(trifluoromethyl)-
3H-diazirin-3-yl]benzoic acid (TCI, 25mg, 0.108mmol, 1.5 eq.) and DIPEA (37 µL,
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0.215mmol, 3.0 eq.) in 0.3mL DMF was added to a solution of amine vinylphospho-
nothiolate derivative 41 (14mg, 0.717mmol, 1.0 eq.) in 0.1mL DMF. The mixture
was stirred at r.t. for 1 hour before diluted with water (4mL). The crude product
was purified by semipreparative HPLC (gradient: 5-99% MeCN + 0.1% TFA in
H2O+0.1% TFA over 40min, flow: 5mL/min). After lyophilization, the titled product
was obtained as a white powder (9.7mg, 0.0238mmol, 33%).
1H-NMR: (300MHz, CDCl3): δ = 8.24 (s, 1H), 8.16-7.96 (m, 3H), 7.32-7.19 (m, overlap
with CDCl3 signal), 6.43-6.01 (m, 3H), 4.23-4.06 (m, 2H), 3.90-3.63 (m, 2H), 3.24-2.96
(m, 2H), 1.31 (t, J = 7.1Hz, 3H). 13C-NMR: (75MHz, CDCl3): δ = 168.93, 166.57,
135.30, 135.08, 132.35, 130.52, 128.89 (d, J = 146.6Hz), 127.88, 126.57, 122.02 (q, J =
275Hz), 62.95 (d, J = 7.2Hz), 42.01, 28.75 (d, J = 2.7Hz), 28.55 (d, J = 46.6Hz),
16.36 (d, J = 6.9Hz). 31P-NMR: (122MHz, CDCl3): δ = 45.04. HR-MS (ESI+) for
C15H18F3N3O3PS
+ [M+H]+ calcd.: 408.0753, found: 408.0761.


































































crude, 2 eq. P
O
DMSO + 10 eq. TFA














































DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)
































































































































































































































































































































































































A solution containing HATU (58mg, 0.154mmol, 3.0 eq.), methyl-pyrrole-tetrazole car-
boxylic acid derivative 53 (30mg, 0.154mmol, 3.0 eq.) and DIPEA (27µL, 0.154mmol,
3.0 eq.) in 0.2mL DMF was added to a solution of amine vinylphosphonothiolate
derivative 41 (10mg, 0.0512mmol, 1.0 eq.) in 0.1mL DMF. The mixture was stirred
at r.t. for 1 hour before diluted with water (4mL). The crude product was purified
by semipreparative HPLC (gradient: 5-99% MeCN + 0.1% TFA in H2O+0.1% TFA
over 40min, flow: 5mL/min). After lyophilization, the title product was obtained as a
white powder (4mg, 0.0108mmol, 21%). 1H-NMR: (600MHz, DMSO−d6): δ = 9.33
(s, 1H), 7.05 (dd, J = 2.9, 2.0Hz, 1H), 6.63 (dd, J = 3.9, 2.0Hz, 1H), 6.50-6.12 (m,
4H, the vinyl protons and one proton from the pyrrol ring overlap), 4.15-4.07 (m, 2H),
3.65 (s, 3H), 3.60-3.53 (m, 2H), 2.97 (ddt, J = 14.0, 8.8, 6.9Hz, 2H), 1.28 (t, J =
7.0Hz, 3H). 13C-NMR: (151MHz, DMSO−d6): δ = 159.24, 156.14, 134.52, 130.44 (d, J
= 142.0Hz), 124.31, 124.09, 107.17, 106.05, 61.49 (d, J = 6.7Hz), 40.05, 34.09, 28.45,
16.09 (d, J = 6.5Hz). 31P-NMR: (243MHz, DMSO−d6): δ = 38.20. HR-MS (ESI+)
for C13H20N6O3PS






















































tetrazole, THF, -40 °C to r.t.
1 eq.i)


















































































































































































































To a solution of Dabcyl peptide10 (2.5mg, 2.35µmol, 1.0 eq.) in aqueous 50mM
NH4HCO3 buffer containing 1mM EDTA at pH 8.5 was added EDANS ethynylphos-
phonothiolate derivative 43 (1.5mg, 2.82µmol, 1.2 eq.) dissolved in DMF (280µL).
The reaction mixture was shaken at r.t. for 1 hour and then diluted with water
(4.7mL) for purification via semipreparative HPLC (gradient: 10-50% MeCN+0.1%
TFA in H2O+0.1% TFA over 45 min, flow: 16mL/min). After lyophilization, product
59 was obtained as a red powder (3mg, 1.87µmol, 80%).
HR-MS (ESI+) for C70H94N15O21PS3
+ [M+H]+ calcd.: 803.7819, found: 803.7806.
Fig. 78 UPLC-UV analysis (220 nm) of compound 59.
10The Dabcyl-cysteine peptide was kindly provided by Dr. Marc-André Kasper, who synthesized it
according to Ref. [208].
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tetrazole, THF, -40 °C to r.t.
1 eq.i)


















































































































































































































To a solution of Dabcyl peptide (2.5mg, 2.35µmol, 1.0 eq.) in aqueous 50mM
NH4HCO3 buffer containing 1mM EDTA at pH 8.5 was added EDANS vinylphospho-
nothiolate derivative 44 (1.5mg, 2.82µmol, 1.2 eq.) dissolved in DMF (280µL). The
reaction mixture was shaken at r.t. for 3 hours and then diluted with water (4.7mL)
for purification via semipreparative HPLC (gradient: 10-50% MeCN+0.1% TFA in
H2O+0.1% TFA over 45 min, flow: 16mL/min). After lyophilization, product 60 was
obtained as a red powder (3mg, 1.87µmol, 80%).
HR-MS (ESI+) for C70H96N15O21PS3
+ [M+H]+ calcd.: 804.7897, found: 804.7889.
Fig. 79 UPLC-UV analysis (220 nm) of compound 60.
145
8 Experimental
8.2.6 Glutathione addition to phosphonothiolates
Glutathione addition to vinylphosphonothiolate (17)
S P OEt
O

































50 mM NH4HCO3, 1 mM EDTA,






































Reduced glutathione (20.3mg, 0.066mmol, 2.0 eq.) was dissolved in 1.32mL aqueous
50mM NH4HCO3 buffer at pH 8.5 containing 1mM EDTA and added to a solution
of vinylphosphonothiolate 17 (8mg, 0.033mmol, 1.0 eq.) dissolved in 0.33mL DMF
and the mixture was stirred at r.t. for 180min. The solvents were then removed
under reduced pressure and the residue was redissolved in 5mL H2O and purified via
semipreparative HPLC (gradient: 20-60% MeCN + 0.1% TFA in H2O + 0.1% TFA
over 40min, flow: 16mL/min). After lyophilization product 6 was obtained as a
white powder (14mg, 0.026mmol, 77%). 1H-NMR: (300MHz, D2O): δ = 7.46-7.28 (m,
5H), 4.50 (dd, J = 8.4, 5.3Hz, 1H), 4.19-3.93 (m, 7H), 2.90 (dd, J = 14.1, 5.3Hz, 1H),
2.76 (ddd, J = 14.1, 8.4, 1.9Hz, 1H), 2.69-2.47 (m, 4H), 2.25-2.01 (m, 4H), 1.26 (t, J
= 7.1Hz, 3H). 13C-NMR: (75MHz, D2O): δ = 174.29, 172.82, 172.51, 172.08, 137.34,
128.95, 128.84, 127.95, 63.15 (d, J = 7.7Hz), 52.79, 52.60, 41.06, 33.90, 32.66, 31.37,
30.93, 25.58, 23.95, 15.38 (d, J = 6.5Hz). 31P-NMR: (122MHz, D2O): δ = 60.52.
HR-MS (ESI+) for C21H33N3O8PS
+ [M+H+] calcd.: 550.1441, found: 550.1451.
Glutathione addition to ethynylphosphonothiolate (7)
S P OEt
O

































50 mM NH4HCO3, 1 mM EDTA,






































Reduced glutathione (141mg, 0.460mmol, 2.0 eq.) was dissolved in 10.35mL aqueous
50mM NH4HCO3 buffer at pH 8.5 containing 1mM EDTA and added to a solution
of ethynylphosphonothiolate 7 (41mg, 0.230mmol, 1.0 eq.) in 1.15mL DMF and the
mixture was stirred at r.t. for 90min. The solvents were then removed under reduced
pressure and the residue was redissolved in 5mL H2O and purified via semipreparative
HPLC (gradient: 5-90% MeCN + 0.1% TFA in H2O + 0.1% TFA over 40min,
flow: 10mL/min). The E - and Z -double bond isomers could be separated and were
lyophilized individually to give: E -isomer of 57 (6mg, 0.0124, 5%) and Z -isomer of 57
(61mg, 0.1256, 55%).
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E -double bond isomer of 57:
1H-NMR: (600MHz, D2O): δ = 7.57 (dd, J = 22.6, 16.6Hz, 1H), 6.08 (ddd, J =
21.3, 16.6, 1.4Hz, 1H), 4.78-4.75 (m, 1H, overlaps with D2O signal), 4.23 (dq, J = 9.3,
7.1Hz, 2H), 4.06 (s, 2H), 4.00 (t, J = 6.5Hz, 1H), 3.46 (dd, J = 14.4, 5.5Hz, 1H),
3.29 (ddd, J = 14.4, 7.9, 1.6Hz, 1H), 2.91-2.80 (m, 2H), 2.66-2.54 (m, 2H), 2.24 (q,
J = 8.1, 7.7Hz, 2H), 1.39 (t, J = 7.1Hz, 3H), 1.35 (t, J = 7.4Hz, 3H). 13C-NMR
(151MHz, D2O): δ = 177.19, 175.66, 175.15, 174.57, 165.58, 152.82 (d, J = 9.7Hz),
115.13 (d, J = 151Hz), 66.28 (d, J = 5.9Hz), 55.66, 55.22, 43.96, 35.52, 33.79, 28.38,
27.45, 18.24 (d, J = 6.3Hz). 31P-NMR: (243MHz, D2O): δ = 45.25 (d, J = 9.1Hz).
HR-MS (ESI+) for C16H31N3O8PS2
+ [M+H+] calcd.: 488.1285, found: 488.0925.
Z -double bond isomer of 57:
1H-NMR: (600MHz, D2O): δ = 7.53 (ddd, J = 49.8, 12.3, 2.4Hz, 1H), 5.97 (dt, J =
21.5, 12.0Hz, 1H), 4.70 (ddd, J = 20.1, 8.6, 5.2Hz, 1H), 4.23 (dq, J = 9.3, 7.1Hz, 2H),
4.08 (td, J = 6.6, 1.5Hz, 1H), 4.04 (s, 2H), 3.43 (ddd, J = 14.4, 5.2, 3.8Hz, 1H), 3.23
(dt, J = 14.4, 8.5Hz, 1H), 2.92-2.82 (m, 2H), 2.66-2.58 (m, 2H), 2.30-2.21 (m, 2H),
1.38 (t, J = 7.1Hz, 3H), 1.35 (td, J = 7.4, 4.3Hz, 3H). 13C-NMR (151MHz, D2O): δ
= 176.89, 175.55, 174.60 (d, J = 11.6Hz), 174.4, 165.64 (q, J = 35Hz), 154.88 (d, J =
17.9Hz), 119.06 (q, J = 292Hz, acetonitrile contamination?), 116.15 (dd, J = 148.6,
30.3Hz), 66.04 (dd, J = 10.1, 6.9Hz), 56.36 (d, J = 6.7Hz), 55.12, 43.91, 39.08 (d, J
= 11.0Hz), 33.79, 28.28 (d, J = 6.0Hz), 27.40, 18.30. 31P-NMR: (243MHz, D2O): δ =
44.90 (d, J = 9.8Hz). HR-MS (ESI+) for C16H31N3O8PS2
+ [M+H+] calcd.: 488.1285,
found: 488.1016.
Glutathione addition to vinylphosphonothiolate peptides (28-32)
HPLC-purified peptides 28-32 were dissolved in 200µL conjugation buffer (PBS pH 7.4
or 50mM NH4HCO3 pH 8.5). To start the reaction, 50µL of a 30mM solution of reduced
glutathione in conjugation buffer was added to reach a final glutathione concentration
of 6mM and peptide concentrations of 5mM. The solutions were shaken at 700 rpm at
25 ◦C. Samples were drawn in a volume of 8µL, diluted into 30µL of H2O and subjected























































tetrazole, THF, -40 °C to r.t.
1 eq.i)


















A round bottom flask was charged with 33 (201mg, 1.0mmol, 1.0 eq.), dissolved in
dry acetonitrile (10mL) and cooled to –40 ◦C. Separately, a solution of Boc-protected
ethanolamine (161mg, 1.0mmol, 1.0 eq.) and tetrazole (Sigma, 0.45M in MeCN,
4.4mL, 2.0mmol, 2.0 eq.) was prepared and added drop-wise to the first stirred
solution at –40 ◦C. The reaction mixture was stirred for 10min at –40 ◦C before allowed
to warm to r.t. and stirred for another 30min. Then, a tert-butyl hydroperoxide
solution (70 wt. % in H2O, 286µL, 1.0mmol, 1.0 eq.) was added at r.t. and stirred
for 10min. The reaction mixture was then diluted with 30mL H2O and extracted with
DCM (3 times 60mL). The combined organic layers were dried over Na2SO4, filtered
and the solvents were removed under reduced pressure. After purification by silica
gel chromatography (100% EtOAc) the titled product was obtained as a colourless oil
(168mg, 0.60mmol, 60%). 1H-NMR: (300MHz, CDCl3): δ = 4.18-3.96 (m, 4H), 3.31
(q, J = 5.5Hz, 2H), 3.06 (d, J = 13.4Hz, 1H), 1.33 (s, 9H), 1.27 (td, J = 7.1, 0.8Hz,
3H). 13C-NMR: (75MHz, CDCl3): δ = 155.78, 88.61 (d, J = 51.1Hz), 79.61, 73.69 (d,
J = 291.1Hz), 66.58 (d, J = 6.4Hz), 63.85 (d, J = 6.0Hz), 40.70 (d, J = 7.1Hz),
28.34, 16.02 (d, J = 7.0Hz). 31P-NMR: (122MHz, CDCl3): δ = -8.03. HR-MS (ESI+)
for C11H21NO5P
+ [M+H+] calcd.: 278.1157, found: 278.1149.


















































tetrazole, THF, -40 °C to r.t.
1 eq.i)


















A round bottom flask was charged with 34 (203mg, 1.0mmol, 1.0 eq.), dissolved in
dry acetonitrile (10mL) and cooled to –40 ◦C. Separately, a solution of Boc-protected
ethanolamine (177mg, 1.0mmol, 1.0 eq.) and tetrazole (Sigma, 0.45M in MeCN,
4.4mL, 2.0mmol, 2.0 eq.) was prepared and added drop-wise to the first stirred
solution at –40 ◦C. The reaction mixture was stirred for 10min at –40 ◦C before allowed
to warm to r.t. and stirred for another 30min. Then, a tert-butyl hydroperoxide
solution (70wt.% in H2O, 286µL, 1.0mmol, 1.0 eq.) was added at r.t. and stirred for
10min. The reaction mixture was then diluted with 30mL H2O and extracted with
DCM (3 times 60mL). The combined organic layers were dried over Na2SO4, filtered
and the solvents were removed under reduced pressure. After purification by silica
gel chromatography (100% EtOAc) the titled product was obtained as a colourless oil
(100mg, 0.36mmol, 36%). 1H-NMR: (300MHz, CDCl3): δ = 6.395.87 (m, 3H), 5.14
(s, 1H), 4.153.96 (m, 4H), 3.36 (q, J = 5.4Hz, 2H), 1.40 (s, 9H), 1.30 (t, J = 7.0Hz,
3H). 13C-NMR: (75MHz, CDCl3): δ = 158.89, 136.28 (d, J = 2.0Hz), 125.38 (d, J =
183.9Hz), 79.54, 65.14 (d, J = 6.0Hz), 62.26 (d, J = 5.5Hz), 41.13 (d, J = 6.0Hz),
28.43, 16.40 (d, J = 6.2Hz). 31P-NMR: (122MHz, CDCl3): δ = 17.97. HR-MS (ESI+)
for NaC11H22NO5P
+ [M+Na+] calcd.: 302.1133, found: 302.1120.
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tetrazole, THF, -40 °C to r.t.
1 eq.i)


















Boc-protected ethynylphosphonate derivative 61 was dissolved in TFA/H2O=95:5 at a
concentration of 0.1M. The solution was stirred for 10min at r.t. and then diluted with
water (1:10). The product 63 (an oil) was obtained quantitatively after lyophilization
and was directly used for subsequent reactions.



















































tetrazole, THF, -40 °C to r.t.
1 eq.i)


















Boc-protected vinylphosphonate derivative 62 was dissolved in TFA/H2O=95:5 at a
concentration of 0.1M. The solution was stirred for 10min at r.t. and then diluted with
water (1:10). The product 64 (an oil) was obtained quantitatively after lyophilization
and was directly used for subsequent reactions.



















































tetrazole, THF, -40 °C to r.t.
1 eq.i)




































A solution containing HATU (33.2mg, 0.087mmol, 1.1 eq.), EDANS-derivative 42
(32mg, 0.087mmol, 1.1 eq.) and DIPEA (47µL, 0.237mmol, 3.0 eq.) in 0.2mL DMF
was added to amine derivative 63 (14mg, 0.079mmol, 1.0 eq.) dissolved in 0.1mL
DMF and the mixture was stirred at r.t. for 30min. The solvents were then evaporated
under reduced pressure and the crude product was purified via semipreparative HPLC
(gradient: 10-50% MeCN+0.1% TFA in H2O+0.1% TFA over 50min, flow: 5mL/min)
giving product 65 (13mg, 0.0248mmol, 31%) as a white powder after lyophilization.
1H-NMR: (600MHz, DMSO−d6): δ = 8.27 (d, J = 8.6Hz, 1H), 8.13-8.04 (m, 3H), 7.95
(m, 1H), 7.40-7.29 (m, 2H), 6.76 (d, J = 7.4Hz, 1H), 4.55 (d, J = 13.5Hz, 1H), 4.08
(dq, J = 9.0, 7.1Hz, 2H), 3.99-3.95 (m, 2H), 3.39 (q, J = 6.1Hz, 2H), 3.30 (q, J = 6.3,
5.9Hz, 4H), 2.35 (s, 4H), 1.27 (t, J = 7.1Hz, 3H). 13C-NMR: (151MHz, DMSO−d6):
δ = 15.82 (d, J = 6.7Hz), 16.72, 18.07, 30.65 (d, J = 14.8Hz), 37.23, 41.84, 53.61,
64.18 (dd, J = 285.2, 5.7Hz), 72.86Hz, 74.75Hz, 92.55 (d, J = 48.8Hz), 122.61,
123.23, 124.05, 125.58, 125.94, 130.11, 144.25, 171.74, 172.16. 31P-NMR: (243MHz,























































tetrazole, THF, -40 °C to r.t.
1 eq.i)




































A solution containing HATU (30mg, 0.079mmol, 1.1 eq.), EDANS-derivative 42 (29mg,
0.079mmol, 1.1 eq.) and DIPEA (38µL, 0.215mmol, 3.0 eq.) in 0.2mL DMF was added
to amine derivative 64 (13mg, 0.072mmol, 1.0 eq.) dissolved in 0.1mL DMF and the
mixture was stirred at r.t. for 30min. The solvents were then evaporated under reduced
pressure and the crude product was purified via semipreparative HPLC (gradient: 10-
50% MeCN+0.1% TFA in H2O+0.1% TFA over 50min, flow: 5mL/min) giving product
66 (10mg, 0.0190mmol, 26%) as a white powder after lyophilization.
1H-NMR: (300MHz, DMSO−d6): δ = 8.26 (d, J = 8.6Hz, 1H), 8.18-8.01 (m, 3H), 7.95
(d, J = 7.4Hz, 1H), 7.44-7.23 (m, 2H), 6.75 (d, J = 7.6Hz, 1H), 6.30-6.04 (m, 3H),
4.03-3.93 (m, 2H), 3.87 (dt, J = 7.5, 5.7Hz, 2H), 3.38 (t, J = 5.7Hz, 2H), 3.32-3.23 (m,
4H), 2.34 (s, 4H), 1.22 (t, J = 7.0Hz, 3H). 13C-NMR: (151MHz, D2O): δ = 178.59,
177.53, 142.00, 141.10, 134.34, 131.81, 129.73, 129.49, 129.29, 128.61, 126.64, 125.50 (d,
J = 182Hz), 67.49 (d, J = 5.4Hz), 66.49 (d, J = 5.8Hz), 52.09, 42.14 (d, J = 6.7Hz),
39.01, 33.35, 18.20 (d, J = 6.2Hz). 31P-NMR: (122MHz, DMSO−d6): δ = 17.33.
HR-MS (ESI+) for C22H31N3O8PS




















































tetrazole, THF, -40 °C to r.t.
1 eq.i)


















































































































































































































To a solution of Dabcyl peptide (2.5mg, 2.35µmol, 1.0 eq.) in aqueous 50mM
NH4HCO3 buffer containing 1mM EDTA at pH 8.5 was added EDANS ethynylphos-
phonate derivative 65 (1.5mg, 2.82µmol, 1.2 eq.) dissolved in DMF (280µL). The
reaction mixture was shaken at r.t. for 1 hour and then diluted with water (4.7mL)
for purification via semipreparative HPLC (gradient: 10-50% MeCN+0.1% TFA in
H2O+0.1% TFA over 45min, flow: 16mL/min). After lyophilization, product 68 was
obtained as a red powder (3mg, 2.01µmol, 86%).
HR-MS (ESI+) for C70H94N15O22PS2
+ [M+H2+] calcd.: 795.7933, found: 795.7931.
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tetrazole, THF, -40 °C to r.t.
1 eq.i)


















































































































































































































To a solution of Dabcyl peptide (2.5mg, 2.35µmol, 1.0 eq.) in aqueous 50mM
NH4HCO3 buffer containing 1mM EDTA at pH 8.5 was added EDANS vinylphos-
phonate derivative 66 (1.5mg, 2.82µmol, 1.2 eq.) dissolved in DMF (280µL). The
reaction mixture was shaken at r.t. for 3 hours and then diluted with water (4.7mL)
for purification via semipreparative HPLC (gradient: 10-50% MeCN+0.1% TFA in
H2O+0.1% TFA over 45 min, flow: 16mL/min). After lyophilization, product 69 was
obtained as a red powder (3mg, 2.01µmol, 86%).
HR-MS (ESI+) for C70H96N15O22PS2
+ [M+H2+] calcd.: 796.8012, found: 796.8002.
Fig. 81 UPLC-UV analysis (220 nm) of compound 69.
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crude, 2 eq. P
O
DMSO + 10 eq. TFA























































































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)
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50 mM NH4HCO3




































































PBS pH 7.4 or
50 mM NH4HCO3 pH 8.5























































Scheme 60 Glutathione addition to unsaturated P(V) electrophiles.
Glutathione additions to EDANS-P(V)-electrophiles were conducted at different con-
centrations, depending on the reactivity of the compounds: For ethynylphosphonate
65, ethynylphosponamidate 67 and ethynylphosphonothiolate 43 at pH 7.4 and for
vinylphosphonothiolate 49 at pH 8.5 reactions were run at 100µM while for vinylphos-
phonothiolate 49 at pH 7.4 the conjugation with glutathione was run at 1mM. There-
fore, 2.5µL of either a 20mM or a 200mM solution of EDANS-P(V) electrophile in
DMF (for reactions at 100µM or 1mM, respectively) and 5µL of a 10mM or a 100mM
solution of unconjugated EDANS (as an internal standard) in 1:1 DMF/conjugation
buffer (PBS + 1mM EDTA pH 7.4 or 50mM NH4HCO3 + 1mM EDTA adjusted to pH
8.5 with aqueous ammonia buffer) were added to 488µL conjugation buffer. Then, 5µL
of a 10mM/100mM solution of reduced glutathione in conjugation buffer was added
to start the reaction. Samples were drawn in a volume of 2 µL (for reactions at 1mM)
or 20µL (for reactions at 100µM) and immediately diluted into 98 or 80µL of 50mM
NaOAc buffer at pH 3.5 to stop the reaction. The first sample (t = 0) was drawn
before the addition of glutathione. Samples were subjected to HPLC analysis inject-
ing 20µL (see general information in chapter 8.1 for details). In Fig. 82A, exemplary
chromatogram traces are shown for the glutatione addition to vinylphosphonothiolate
39. Signal intensities were quantified by integration of the area under the peak for
both the P(V) electrophiles and the internal standard EDANS. The concentration of re-
maining P(V) starting material (SM) at time point x ([SM]x) was calculated as follows:
[SM ]x = ((SMx/EDANSx)/(SM0/EDANS0)) ∗ [SM ]0 whereas SM and EDANS are
the measured intensities of the respective peaks at a given time point and [SM]0 is
the initial concentration of P(V) electrophiles (either 0.1mM or 100 µM). The inverse
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concentrations of remaining P(V) electrophile (1/[SM]0) were plotted against time and
second order rate constants were deduced from the slopes of the fitted curves through

































































0 500 1000 1500
10000
15000
20000 1/c(SM) = 4.456 M-1min-1 ± 0.09143t
+ 9933 ± 45













40000 1/c(SM) = 79.29 M-1min-1 ± 2.121t
+ 9634 ± 240














1/c(SM) = 8.749 M-1min-1 ± 0.5097t
+ 9995 ± 32
















1/c(SM) = 0.1209 M-1min-1 ± 0.0096t
+ 989 ± 5






Fig. 82 A) Exemplary HPLC traces (fluorescence at 490 nm) of the reaction mixture of
vinylphosphosphonothiolate 39 and glutathione. B) 1/concentration of P(V) elec-
trophiles over time for reactions with glutathione and linear plot. The slopes of the
linear plots are the second order rate constants k.
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8.2.9 Antibody labelling with unsaturated phosphonothiolates
Cetuximab labelling with phosphonothiolate-biotin derivatives 18, 45 and 46 or
maleimide-biotin derivative 58
Cetuximab11 (Erbitux R©, Merck KGaA, 1.5mg/mL, ca. 10µM in PBS buffer containing
50mM borate pH 8.0, 10µL per condition) was reduced with 1000 eq. DTT (1µL of a
100mM solution in borate PBS pH 8.0) at 37 ◦C for 30min. DTT removal and buffer ex-
change to conjugation buffer (50mM NH4HCO3, 100mM NaCl containing 1mM EDTA
pH 8.5 or PBS pH 7.4 containing 1mM EDTA) was conducted using spin desalting
columns (75µL ZebaTM, 7K MWCO, Thermo Fisher Scientific, USA) following the
manufacturers instructions. Then, ethynyl- or vinylphosphonothiolate derivatives 45,
46 or 18 or maleimide-biotin derivative 58 (Sigma Aldrich) (0.25µL of a 20mM solu-
tion in DMSO, resulting in a final reagent concentration of ca. 0.5mM (50 eq.) and
2.5% DMSO in the reaction mixture) was added quickly and the mixture was shaken
at 850 rpm and 14 ◦C for 16 h. For control reactions, compounds 45, 46, 18 or 58
were directly added to unreduced Cetuximab in conjugation buffer. After conjugation,
removal of excess reagent and buffer exchange to PBS pH 7.4 was conducted using
spin desalting columns (75µL ZebaTM, 7K MWCO, Thermo Fisher Scientific, USA).
For SDS-PAGE/Western-blot analysis, 3µL of the antibody solution after gel filtration
were mixed with 27µL of mercaptoethanol-containing Laemmli buffer and heated at
95 ◦C for 10min. Thereof, 10µL were loaded on a 12% acrylamide SDS-gel and then
then subjected to Western-blotting using the commercially available Streptavidin-POD
conjugate (Roche Diagnostics GmbH) for hybridisation to the biotin-modified antibod-
ies and indirect detection of biotin via chemiluminescence (see general information in
chapter 8.1 for details).
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BPBS, pH 8.0
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2) removal of DTT
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analysis by intact protein MS
and LC-MS/MS after tryptic digest
Scheme 61 Trastuzumab labeling with phosphonothiolates 7 and 8.
Trastuzumab12 (Herceptin, Roche, 5mg/mL, ca. 33µM in PBS buffer containing 50mM
borate pH 8.0, 20µL per condition) was reduced with 1000 eq. DTT (2µL of a 330mM
solution in borate PBS pH 8.0) at 37 ◦C for 30min. DTT removal and buffer exchange to
conjugation buffer (50mM NH4HCO3, 100mM NaCl containing 1mM EDTA pH 8.5 or
PBS pH 7.4 containing 1mM EDTA) was conducted using spin desalting columns (75 µL
ZebaTM, 7K MWCO, Thermo Fisher Scientific, USA) following the manufacturers in-
structions. Then, ethynyl- or vinylphosphonothiolate derivatives 7 or 8, respectively
(1µL of a 66mM solution in DMSO, resulting in a final concentration of 3.3mM phos-
phonothiolate derivative (100 eq.) and 5% DMSO in the reaction mixture) was added
11We thank Dr. Kai Licha and Prof. Dr. Karsten Spiekermann for the provision of Cetuximab.
12We thank Prof. Dr. Karsten Spiekermann for the provision of Trastuzumab.
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quickly and the mixture was shaken at 850 rpm and 14 ◦C for 16 h. For control reac-
tions, compounds 7 and 8 were directly added to unreduced Trastuzumab in conjugation
buffer. After conjugation, removal of excess reagent and buffer exchange to PBS pH
7.4 was conducted using spin desalting columns (75µL ZebaTM, 7K MWCO, Thermo
Fisher Scientific, USA).
For MS analysis, 10µL of the antibody solution after gel filtration (diluted to 2mg/mL
with PBS pH 7.4) was mixed with 0.5µL PNGase-F solution (Promega, Germany, re-
combinant, cloned from Elizabethkingia miricola 10 u/µL) and incubated at 37 ◦C for
2 h. Then, disulfide bridges were reduced by the addition of 1 µL DTT solution (100mM
in PBS, pH 7.4) and incubation at 37 ◦C for another 30min. Samples were diluted with
30µL distilled H2O and subjected to MS analysis with the Waters H-class system (see
general information in chapter 8.1 for details).
For MS/MS analysis, 3µL of the antibody samples after gel filtration were mixed with
10µL β-mercaptoethanol-containing Laemmli buffer, heated at 95 ◦C for 10min and run
on a 12 % SDS-gel. Bands were stained with Coomassie brilliant blue, cut out, alkylated
with chloroacetamide and subjected to tryptic digest and LC-MS/MS analysis (see gen-
eral information in chapter 8.1 for details).
For peptide identification, the RAW-files were loaded into Proteome Discoverer (v.2.4,
Thermo Scientific) and a database search was performed with MSAmanda 2.0 [312].
Files were searched against a database containing the sequences of Trastuzumab heavy
and light chain using the following search parameters: peptide mass tolerance of ±6 ppm,
fragment mass tolerance of ±20 ppm, a maximum of three missed cleavages, mini-
mum peptide length of 6 and a minimum MSAmanda score of 150. Modification with
ethynylphosphonothiolate 7 (178.022Da) or vinylphosphonothiolate 8 (180.037Da) were
considered as dynamic modifications to occur on all nucleophilic amino acids. Moreover,
cysteine carbamidomethylation (57.021Da) and methionine oxidation (15.995Da) were
considered as dynamic modifications. Spectra that identified a peptide carrying either
7 or 8 as modification were manually validated.
For each condition (labelling with either 7 or 8 at either pH 7.4 or pH 8.5 and respective -
DTT controls), the MS/MS results are shown below. Sequence coverages are highlighted
in green. A= cysteine modified with either 7 or 8, C= cysteine carbamidomethylation,
O= methionine oxidation. For peptides, which were found to be modified with either A
or C (individually), the two letters stand on top of each other. For peptides containing
several cysteines, a red bar indicates modifications that could not be unambiguously
assigned to one or the other site. Exemplary MS/MS spectra of modified peptides are
shown in the Appendix (see chapter 9.3).
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Trastuzumab light chain, labeled with ethynylphosphonothiolate 7 at pH 7.4: 
                        A 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVALLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYAQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
                               SCD  ATHTC  
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEA 




Trastuzumab heavy chain, labeled with ethynylphosphonothiolate 7 at pH 7.4: 
AVQLVESGGG LVQPGGSLRL SAAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
AVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGALVK DYFPEPVTVS  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP P SADATHTAPPPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALANAYT QKSLSLSPGK 






































Trastuzumab light chain, labeled with ethynylphosphonothiolate 7 at pH 7.4 (-DTT control): 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYAQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
                              SCD  ATHTC                  
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEA 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
Trastuzumab heavy chain, labeled with ethynylphosphonothiolate 7 at pH 7.4 (-DTT control): 
AVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGATRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP P SADATHTAPPPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LAKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALANAYT QKSLSLSPGK 




























Trastuzumab light chain, labeled with ethynylphosphonothiolate 7 at pH 8.5: 
                        A 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVALLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYAQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
                               SCD  ATHTC  
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEA 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
 
 
Trastuzumab heavy chain, labeled with ethynylphosphonothiolate 7 at pH 8.5: 
AVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS 
 WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP P SCDATHTCPPPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALANAYT QKSLSLSPGK 
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Trastuzumab light chain, labeled with ethynylphosphonothiolate 7 at pH 8.5 (-DTT control): 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYAQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
                               SCD  ATHTC                 C 
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VAACEVTHQG LSSPVTKSFN RGEA 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
 
 
Trastuzumab heavy chain, labeled with ethynylphosphonothiolate 7 at pH 8.5 (-DTT control): 
AVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGATRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP P SCDATHTCPPPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LAKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALANAYT QKSLSLSPGK 






































Trastuzumab light chain, labeled with vinylphosphonothiolate 8 at pH 7.4: 
DIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEA 
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEC 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
 
 
Trastuzumab heavy chain, labeled with vinylphosphonothiolate 8 at pH 7.4: 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALHNHYT QKSLSLSPGK 










































Trastuzumab light chain, labeled with vinylphosphonothiolate 8 at pH 7.4 (-DTT control): 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEA 
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEC 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
Trastuzumab heavy chain, labeled with vinylphosphonothiolate 8 at pH 7.4 (-DTT control): 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP P SCDATHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALHNAYT QKSLSLSPGK 












































Trastuzumab light chain, labeled with vinylphosphonothiolate 8 at pH 8.5: 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEA 
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEC 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
 
 
Trastuzumab heavy chain, labeled with vinylphosphonothiolate 8 at pH 8.5: 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP P SADATHAA PPAPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALHNAYT QKSLSLSPGK 









































Trastuzumab light chain, labeled with vinylphosphonothiolate 8 at pH 8.5 (-DTT control): 
AIQOTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP  
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ 
ESVTEQDSKD STYSLSSTLT LSKADYEKAK VYACEVTHQG LSSPVTKSFN RGEC 
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC       
Trastuzumab heavy chain, labeled with vinylphosphonothiolate 8 at pH 8.5 (-DTT control): 
 
AVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY 
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY  
LQONSLRAED TAVYYCSRWG GDGFYAODYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS  
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHAC PPCPAPELLG 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP PKSCDKTHTC PPCPAPELLG  
GPSVFLFPPK PKDTLOISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG 
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV OHEALANAYT QKSLSLSPGK 










































8.2 Experimental part for method development chapter
8.2.10 Stability studies of unsaturated phosphonothiolates



















PBS pH 7.4 or
50 mM NH4HCO3



























Scheme 62 Hydrolysis of unsaturated phosphonothiolate derivatives 39 and 43 in buffer.
Right before the measurement, vinyl- and ethynylphosphonothiolate derivatives 39 or
43 (3.0µmol, 1.0 eq.), iodoacetamide (60µmol, 20 eq.) and internal standard PMe4Br
(3.0µmol, 1.0 eq., only for experiments at pH 8.5; for experiments at pH 7.4 the phos-
phate signal originating from the PBS buffer serves as internal standard) were weighed
in as solids in an Eppendorf tube and dissolved in the test buffer solution (PBS pH7.4
or 50mM NH4HCO3 pH8.5 containing 10% D2O (540µL buffer and 60µL D2O)). The
role of iodoacetamide is to alkylate the thiolate, which gets released upon P-S bond hy-
drolysis, thereby circumventing re-attack, which would influence the experiment. The
mixtures were transferred to NMR tubes and one-dimensional 31P-NMR spectra with
continuous broadband decoupling (using 32 scans, resulting in 3min experiment time
per spectrum) were recorded for each sample in intervals of 1 h over the course of 90 h
on a Bruker AV-III 600 spectrometer. The samples were kept at either 25 ◦C or 37 ◦C
during the whole experiment. For analysis, the spectra were Fourier-transformed, base-
line corrected and the intensity of the 31P-NMR signal of either 39 or 43 was obtained
by integration.

















































































(I), (III), (IV), (V)





















































































































































































X= A, S, H, D, M
KYRCXK
aqueous buffer, 



















(II) (III) (IV) (V)
Scheme 63 Stability of vinylphosphonothiolate peptides in aqueous buffer: Hydrolysis of the
P-S bond in the vinylphosphonothiolate peptides (I) can lead to free Cys-peptides
(II) or P(V)-transfer to nucleophilic residues Y (structure IV). Peptides (II) and
(IV) can react with residual (I) to form the conjugation products (III) and (V).
HPLC-purified peptides 28-32 were dissolved in either 250µL PBS pH 7.4 or 50mM
NH4HCO3 containing 1mM triphenylphosphine oxide (PPh3O) as internal standard to
reach final peptide concentrations of 5mM. The solutions were shaken at 700 rpm at
159
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25 ◦C. At t= 0, 2, 4, 8 and 24 hours, samples were drawn in a volume of 8 µL, diluted
into 30µL of H2O and subjected to UPLC-UV/MS analyses (short gradient), injecting
5µL each. For quantification (compare Fig. 27) the ratios between the extracted ion
intensities of the doubly charged peptides (m/z: 28: 443.2; 29: 451.2; 30: 476.3; 31:
469.7; 32: 473.2) and the internal standard PPh3O (m/z: 279.1) at the given time
points were determined and normalized to the respective ratios at t= 0 h. Exemplary
LC-UV and TIC traces are shown for peptide 28 (X=A) in Fig. 83 for pH7.4 and in
Fig. 84 for pH8.5. The observations for the peptides 29-32 were similar (UPLC-UV

















































































(I), (III), (IV), (V)















































































































































































Fig. 83 A) UPLC-UV traces of peptide 28, incubated in PBS buffer at pH 7.4. Over time,
new peptide species arise, which were assigned by MS to the structures depicted
in scheme 63. Note that the P(V)-transfer product (IV) has the same m/z as the
vinylphosphonothiolate peptide (I) but runs at a different retention time. B) Corre-
sponding traces of extracted ion intensities for the doubly charged peptide 28. Triph-
enylphosphine oxide served as internal standard for quantification.
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(I), (III), (IV), (V)















































































































































































Fig. 84 A) UPLC-UV traces of peptide 28, incubated in 50mM NH4HCO3 buffer at pH 8.5.
Over time, new peptide species arise, which were assigned by MS to the structures
depicted in scheme 63. Some of these peptides co-elute. B) Corresponding traces
of extracted ion intensities for the doubly charged peptide 28. Note that product
(V) [M+4H+]4+ has the same m/z as starting material (I) [M+2H+]2+ but runs at






































































crude, 2 eq. P
O
DMSO + 10 eq. TFA














































DMSO + 10 eq. TFA, 










































i) 1 eq. EtOH, HN(i-Pr)2, Et2O, -40 °C to r.t.
ii) 2 eq. HN(i-Pr)2, Et2O, -40 °C to r.t.
iii) 1.1. eq.





















tetrazole, THF, -40 °C to r.t.
1 eq.i)













































































































































































































































































































































































































































































































































































PBS pH 7.4 or
50 mM NH4HCO3




















































Scheme 64 Assay to investigate the stability of thiol-P(V) conjugates. The structures of the
FRET pairs are depicted in the synthetic procedures.
Stability studies of Dabcyl-EDANS conjugates 59, 60, 68, and 69 were conducted in
96-well plates (Corning 3615, black with clear, flat bottom). 5 µL of a 200µM solution
of each Dabcyl-EDANS conjugate in H2O and 95µL of the respective test solutions
were mixed directly in the plate (exception: samples in 1M NaOH were kept in Eppen-
dorf tubes and only transferred to the plate after neutralization to protect equipment
from corrosion). Fluorescence was measured on a Tecan Safire plate reader (Excitation:
360 nm, emission: 508 nm, bandwidth: 5 nm at 20 ◦C) from the same plate at different
time points and corrected by the background measurement (test solution alone). Be-
tween measurements, the plate was kept at 25 ◦C. Mean values and standard deviation
of three independent experiments were calculated (n = 3). HeLa cell lysate was gener-
ated from approximately 3.9*107 cells, lysed in 2mL PBS by sonification (final protein
concentration: 1.0mg/mL). Cells were grown on three 75 cm2 cell culture plates, washed
twice with PBS and harvested with a cell scraper. Human serum was purchased from
Sigma Aldrich. Glutathione was dissolved at a concentration of 10mM in PBS and the
pH was adjusted to 7.4. 1M NaOH studies were conducted at 200 µM in Eppendorf
tubes, neutralized to pH7.4 and diluted to 10µM before fluorescence measurements.
8.2.12 Electrostatic potential maps
Note: Electrostatic potential maps were generated by Songwhan Hwang from the group
of Dr. Han Sun (FMP Berlin). Songwhan Hwang also wrote this Experimental
description.
All molecules were built using GaussView6 [313]. Geometry optimizations of the
molecules were performed using the density functional theory (DFT) method with the
aug-cc-pVTZ basis set at the B3LYP level in combination with the IEFPCM solvation
model for water [314]. The molecular electrostatic potential was evaluated at each
point on the isodensity surface with a value of 0.0004 electrons/bohr3. Gaussian 16
[315] was used for all calculations.
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8.3 Experimental part for protein-protein conjugation
chapter
Note: The experimental data shown in this chapter (8.3) was obtained to a large extent
by Sergej Schwagerus, as outlined in chapter 4. The data presented herein is published
in Ref. [316] (shared first authorship together with Sergej Schwagerus). The text of
the experimental descriptions shown in this chapter was written by Sergej Schwagerus
and the author and is taken from the published paper (Ref. [316]). Kristin Kemnitz-
Hassanin expressed and purified proteins together with Sergej Schwagerus. LC-MS/MS
measurements were performed Dr. Michal Nadler-Holly, who also wrote the accompany-
ing experimental description text. MS/MS data was analysed by Christian Stieger, who
also wrote the accompanying text.
8.3.1 Protein expression
Expression and purification of UbG76C (70), UbK48C (77) and UbK48M (81)
The ubiquitin DNA sequence was synthesized by GeneArt AG and cloned into pET28a








The mutations were introduced with classical PCR by the use of complementary primer
pairs:
UbG76C 70:
fwd: 5’ GTGCTCGAGTTAGCAACCACGCAGACG 3’
rev: 5’ CGTCTGCGTGGTTGCTAACTCGAGCAC 3’
UbK48C 77:
fwd: 5’ GCGTCTGATTTTTGCAGGTTGCCAGCTGGAAGATGGTCG 3’
rev: 5’ CGACCATCTTCCAGCTGGCAACCTGCAAAAATCAGACGC 3’
UbK48M 81:
fwd: 5’ GATTTTTGCAGGTATGCAGCTGGAAGATG 3’
rev: 5’ CATCTTCCAGCTGCATACCTGCAAAAATC 3’
The proteins were expressed in E. coli B834(DE3) using LB medium containing
30µg/mL Kanamycin (Roth). Cells were grown at 37 ◦C, 180 rpm until an OD600
of 0.6-0.8 was reached, induced with 1mM IPTG and incubated at 18 ◦C for 19 h.
Lysis was performed in Dulbecco’s PBS pH 7.4 using a high-pressure homogenizer
(Microfluidics LM10 Microfluidizer) and debris centrifuged at 50.000 g for 15min at
4 ◦C. The protein was purified with a BioRad NGC system (BioRad, USA) using a 5mL
HisTrap FF column (GE Healthcare, USA). Product-containing fractions were collected
and dialyzed (MWCO: 3.5 kDa, Spectra/Pro R©3 dialysis membrane) into the Thrombin
163
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cleavage buffer (20mM Tris-HCl pH8.5, 150mM NaCl, 2.5mM CalCl2). Then
Thrombin was added (5 u/mL) and samples were incubated at 37 ◦C for 18 h. A second
Ni-NTA purification was performed with a BioRad NGC system (BioRad, USA) using
a 5mL HisTrap FF (GE Healthcare, USA) column and the flow-through was collected
and dialyzed (MWCO: 3.5 kDa, Spectra/Pro R©3 dialysis membrane) into Dulbecco’s
PBS pH7.4. The protein concentration was determined by NanoDrop R© at 280 nm (ε
= 1490M−1 cm−1). The pure protein was isolated in a yield of 20mg/L for UbG76C,
9mg/L for UbK48C and 13.6mg/L for UbK48M. Protein aliquots were stored at –80 ◦C.
UbG76C 70:
Protein sequence: His-tag highlighted in green; protease cleavage site highlighted in blue;







































































































SS_190322_UbK48C_neu_1  301 (4.098) M1 [Ev-455821,It20] (Gs,0.600,598:1612,0.50,L33,R33); Cm (297:306)
3.92e78711.5000
39174036
Fig. 85 Raw and deconvoluted HR-MS (ESI) spectra of UbG76C 70 after DTT reduction.
Calcd.: 8782.0Da, found: 8783.0Da.
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UbK48C 77:
Protein sequence: His-tag highlighted in green; protease cleavage site highlighted in







































































































SS_190322_UbK48C_neu_1  301 (4.098) M1 [Ev-455821,It20] (Gs,0.600,598:1612,0.50,L33,R33); Cm (297:306)
3.92e78711.5000
39174036
Fig. 86 Raw and deconvoluted HR-MS spectra (ESI) of UbK48C 77 after DTT reduction.
Calcd.: 8710.9Da, found: 8711.5Da.
UbK48M 81:
Protein sequence: His-tag highlighted in green; protease cleavage site highlighted in


































The	 protein	 was	 expressed	 in	 E.	 coli	 Bl21(DE3)	 using	 LB	 medium	 containing	
100	μg/mL	ampicillin	(LBAMP).	Cells	were	grown	at	37	°C,	180	rpm	until	an	OD600	of	
0.6-0.8	was	 reached.	 Expression	was	 induced	with	 0.5	mM	 IPTG	 and	 incubated	 at	
18	°C	 for	 19	h.	 Lysis	was	performed	 in	 10	mM	Tris·HCl	 pH	8.0,	 1	mM	EDTA,	 1	mM	
PMSF	 using	 a	 high-pressure	 homogenizer	 (Microfluidics	 LM10	 Microfluidizer)	 and	
debris	 was	 boiled	 at	 95	°C	 for	 20	min,	 cooled	 down	 and	 centrifuged	 at	 50.000	g	
for	15	min	at	 4	°C.	 Streptomycin	 sulfate	 (Roth)	was	added	 to	 the	 supernatant	 to	 a	
m/z























SS_190605_UbK48M_1  313 (4.221) M1 [Ev-942064,It34] (Gs,0.900,464:2784,0.50,L33,R33); Cm (308:322)
1.30e88740.5000
130418976
Fig. 87 Raw and deconvoluted HR-MS spectra (ESI) of UbK48M 81 after DTT reduction.
Calcd.: 8738.9Da, found: 8740.5Da.
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Expression and purification of α-SynucleinK6C 79
The protein was expressed and purified similar to Ref. [317]. The following α-










The mutation was introduced with classical PCR by the use of complementary primer
pairs:
fwd: 5’ CATATGGATGTATTCATGTGCGGACTTTCAAAGG 3’
rev: 5’ CCTTTGAAAGTCCGCACATGAATACATCCATATG 3’
The protein was expressed in E. coli Bl21(DE3) using LB medium containing
100µg/mL ampicillin (LBAMP). Cells were grown at 37 ◦C, 180 rpm until an OD600
of 0.6-0.8 was reached. Expression was induced with 0.5mM IPTG and incubated at
18 ◦C for 19 h. Lysis was performed in 10mM Tris-HCl pH8.0, 1mM EDTA, 1mM
PMSF using a high-pressure homogenizer (Microfluidics LM10 Microfluidizer) and
debris was boiled at 95 ◦C for 20min, cooled down and centrifuged at 50.000 g for
15min at 4 ◦C. Streptomycin sulfate (Roth) was added to the supernatant to a final
concentration of 10mg/mL and stirred for 15min at 4 ◦C. After centrifugation at
50000 g for 15min at 4 ◦C, ammonium sulfate (Roth) was added to the supernatant to
reach a final concentration of 0.36 g/mL and stirred for 30min at 4 ◦C. The suspension
was centrifuged at 50000 g for 15min at 4 ◦C and the pellet resuspended in 25mM
Tris-HCl pH7.7. Then the protein was purified with a BioRad NGC system (BioRad,
USA) using an anion-exchange-column Resource Q (GE Healthcare, USA) column
with a NaCl gradient (0-600mM). The α-SynucleinK6C was eluted at 300mM NaCl.
Subsequently, a size-exclusion chromatography (Superdex 75 10/300 GL column
(GE Healthcare, USA) in Dulbecco’s PBS pH7.4 was performed to gel the clean
α-SynucleinK6C 79 with a yield of 12mg/L as determined by NanoDrop R© at 280 nm
(ε = 5960M−1 cm−1).
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(BioRad,	 USA)	 using	 an	 anion-exchange-column	 Resource	 Q	 (GE	 Healthcare,	 USA)	
column	with	a	NaCl	gradient	(0-600	mM).	The	α-synucleinK6C	was	eluted	at	300	mM	
NaCl.	 Subsequently,	 a	 size-exclusion	 chromatography	 (Superdex	 75	 10/300	 GL	

















































SS_190322_aSynK6C_neu_1  330 (4.386) M1 [Ev-592236,It25] (Gs,0.600,627:1884,0.50,L33,R33); Cm (325:340)
1.19e914435.5010
1186975104
Fig. 88 Raw and deconvoluted HR-MS (ESI) spectra of α-SynucleinK6C 79 after DTT reduc-
tion. Calcd.: 14435.1Da, found: 14435.5Da
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Expression and purification of eGFPC70MS147C 75
The protein was expressed and purified according to Ref. [208].
Protein sequence: His-tag highlighted in green; protease cleavage site highlighted in










t in	sequence:	His-tag	highlighted	in	gr en;	protease	cleavage	site	 lighted	in	
















































SS_180323_eGFP_2,4 mg in ml_1  315 (4.238) M1 [Ev-898843,It20] (Gs,0.650,391:1888,0.10,L33,R10); Cm (309:348)
9.76e727764.9004
55529.500027862.8008
Fig. 89 Raw and deconvoluted HR-MS (ESI) spectra of eGFPC70MS147C 75. Calcd.:
27766Da, found: 27765Da.
8.3.2 Synthesis and aqueous stability of vinylphosphonothiolate-Ub 72
Synthesis of Ellman’s activated UbG76C 71
1) 10 eq. DTT, PBS, 









71, quantitative2) 50 eq. Ellman’s reagent,     PBS pH 7.4, r.t., 2 min
1) 






















































































































































To a solution of UbG76C (mostly disulfide) (25.85mg, 2.95 µmol) in 10mL PBS pH 7.4
was added dithiothreitol (DTT) (4.5mg, 29.5µmol, 10 eq.) and the mixture was shaken
for 20min at 37 ◦C to reduce disulfides, which had formed during storage. Residual DTT
was then thoroughly washed away by means of spin-filtration (MCWO: 3 kDa, Sartorius,
Germany) using in total 50mL of PBS pH 7.4 and the solution was finally concentrated
to 2mL. Subsequently Ellman’s reagent (58.46mg, 147.5 µmol, 50 eq.) was added and
168
8.3 Experimental part for protein-protein conjugation chapter
the mixture was shaken for 2min at r.t. The reaction mixture was washed with 50mM
NH4HCO3 pH7.9 by means of spin-filtration (MCWO: 3 kDa, Sartorius, Germany) until
the excess of Ellman’s reagent was completely removed (requires approximately 50mL of







To	a	 solution	of	UbG76C	15	 (25.85	mg,	2.95	µmol)	 in	10	mL	PBS	pH	7.4	was	added	
dithiothreitol	 (DTT)	 (4.5	mg,	29.5	µmol,	10	eq.)	and	the	mixture	was	shaken	for	20	
min	at	37	°C	to	reduce	disulfides,	which	had	formed	during	storage	of	15.	Residual	
DTT	was	 then	 thoroughly	washed	away	by	means	of	 spin-filtration	 (MCWO:	3	kDa,	
Sartorius,	 Germany)	 using	 in	 total	 50	 mL	 of	 PBS	 and	 the	 solution	 was	 finally	
concentrated	to	2	mL.	Subsequently	Ellman’s	reagent	(58.46	mg,	147.5	µmol,	50	eq.)	
was	added	and	 the	mixture	was	 shaken	 for	2	min	at	 r.t.	 The	 reaction	mixture	was	
washed	with	 50	mM	NH4HCO3	pH	7.9	 	 by	means	of	 spin-filtration	 (MCWO:	3	 kDa,	
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15 16, quantitative2) 50 eq. Ellmann’s reagent,     PBS, rt, 2 min
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Fig. 90 Raw and deconvoluted HR-MS (ESI) spectra of Ellman’s activated UbG76C 71.
Calcd.: 8979.2Da, found: 8980.5Da
Synthesis of vinylphosphonothiolate-Ub 72
1) 10 eq. DTT, PBS, 









71, quantitative2) 50 eq. Ellman’s reagent,     PBS pH 7.4, r.t., 2 min
1) 





















































































































































Lyophilized Ellman’s activated UbG76C 71 (5.11mg, 0.569µmol) was dissolved in
380µL dry DMSO containing 1% TFA in an Eppendorf tube. Freshly synthesized
diethylvinylphosphonite 4 (crude, 36µL, ca. 0.8M in THF, 28.45µmol, 50 eq.) was
added and the mixture was immediately thoroughly vortexed to get the phosphonite
in solution. The reaction mixture was shaken under an argon atmosphere overnight at
r.t. ESI-MS analysis showed incomplete conversion, hence another portion of 50 eq.
diethylvinylphosphonite (36µL, 0.8M in THF, 28.45µmol) was added and the reaction
mixture was shaken for 3 h. The crude mixture was diluted with 40mL PBS pH7.4
and concentrated to 5mL by spin-filtration (MCWO: 3 kDa, Sartorius, Germany) to
remove the DMSO. Subsequently, the crude was purified by semipreparative HPLC
(Vydac protein C4 column, gradient: 30-70% MeCN + 0.1% TFA in H2O + 0.1% TFA
in 35min) and the vinylphosphonothiolate UbG76C 72 was isolated as a pure fraction
(2.43mg, 0.273µmol, 24%). The product was lyophilized and reconstituted before use



















































Fig. 91 Raw and deconvoluted HR-MS (ESI) spectra of purified vinylphosphonothiolate







Lyophilized	 Ellman’s	 activated	 UbG76C	 16	 (5.11	mg,	 0.569	µmol)	 was	 dissolved	 in	
380	µL	 dry	 DMSO	 containing	 1%	 TFA	 in	 an	 Eppendorf	 tube.	 Freshly	 synthesized	
diethylvinylphosphonite	 (36	µL,	 0.8	 M,	 28.45	 µmol,	 50	eq.)	 was	 added	 and	 the	
mixture	was	 immediately	 thoroughly	 vortexed	 to	 get	 the	 phosphonite	 in	 solution.	
The	reaction	mixture	was	shaken	under	an	argon	atmosphere	overnight	at	 r.t.	ESI-
MS	 analysis	 showed	 incomplete	 conversion,	 hence	 another	 portion	 of	 50	 eq.	
diethylvinylphosphonite	 (36	µL,	 0.8	M,	 28.45	 µmol)	 was	 added	 and	 the	 reaction	
allowed	shaking	for	3	h	until	all	Ellman’s	conjugated	protein	16	was	converted.	The	
crude	mixture	was	diluted	with	40	mL	PBS	pH	7.4	and	concentrated	to	5	mL	by	spin-
filtration	 (MCWO:	 3	kDa,	 Sartorius,	 Germany)	 to	 remove	 the	 DMSO.	 Subsequently	
the	crude	was	purified	by	semipreparative	HPLC	(Vydac	protein	C4	column,	30-70%	B	
in	 35	min)	 and	 the	 vinylphosphonothiolate	 UbG76C	 17	 was	 isolated	 as	 a	 pure	
fraction	 (2.43	mg,	 0.273	 µmol,	 24.4%).	 A	 second	 product-containing	 fraction	 with	
about	 68%	 purity	 was	 also	 isolated	 (1.71	mg,	 0.192	µmol,	 17%).	 The	 product	 was	
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Fig. 92 Raw and deconvoluted HR-MS spectra of crude vinylphosphonothiolate UbG76C 72.
Stability of vinylphosphonothiolate ubiquitin 72 in aqueous buffer
Vinylphosphonothiolate UbG76C 72 (1µg/µL) in PBS pH7.4 or in 50mM Na3PO4
pH8.5 was incubated at r.t. or at 37 ◦C. Samples were taken at 0, 24, 48 and 72 h and
analysed by SDS-PAGE.
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8.3.3 Protein conjugations to vinylphosphonothiolate-Ub 72

































To a solution of eGFPC70MS147C 75 (2µg/µL, 72 pmol, 2µL) in PBS pH7.4 or in
50mM Na3PO4 pH8.5 was added vinylphosphonothiolate UbG76C 72 (6.4µL, 1µg/µL,
719 pmol, 10 eq.) in PBS pH7.4 or in 50mM Na3PO4 pH8.5. The reactions were shaken
at 37 ◦C and samples were taken at 2, 8, 24, 48 and 72 h and analysed by SDS-PAGE
gel (see Fig. 36) and by HR-MS (ESI).
mass












Fig. 93 Deconvoluted ESI-MS spectrum of the reaction mixture between eGFP mutant 75 and
vinylphosphonothiolate ubiquitin 72 after 24 h, indicating the formation of Ub-GFP
conjugate 76: Calcd.: 36666Da, found: 36665Da.




78, 27%PBS, pH 8.0, 

















To a solution of UbK48C 77 (4.138mg, 0.475µmol, 5.0 eq.) in 2mL PBS containing
5mM EDTA at pH7.4 was added dithiothreitol (DTT) (366 µg, 2.375µmol, 25 eq.) and
the mixture was shaken for 30min at 37 ◦C. Residual DTT was washed away by means
of spin-filtration (MCWO: 3 kDa, Sartorius, Germany) using 50mL of the same buffer
and the mixture was finally concentrated to 900 µL. To this was added a solution of
vinylphosphonothiolate ubiquitin 72 (0.845mg, 0.095µmol, 1.0 eq.) in 100µL 100mM
NH4HCO3 pH8.5. The pH of the mixture was adjusted to pH8.0 and the mixture was
shaken at 37 ◦C. After 24 h the reaction mixture was treated with DTT (100 eq.) at 37 ◦C
for 40min to reduce disulfides of 77 because the latter would co-elute with the product
78. The crude product was purified by size-exclusion chromatography (Superdex 75
10/300 GL column (GE Healthcare, USA)) in PBS pH7.4. The conjugate DiUb(K48)
78 was isolated as a pure fraction (460µg, 0.026µmol, 27%). The protein concentration




















Fig. 94 Deconvoluted HR-MS spectra (ESI) of the reaction mixture of the conjugation between






















































Fig. 95 Raw and deconvoluted HR-MS (ESI) spectra of purified DiUb(K48) conjugate 78.
Calcd.: 17610Da, found: 17611Da.
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Hydrolytic stability of synthetic DiUb 78 against the DUB enzyme USP2CD
To the deubiquitinating enzyme USP2CD (1.6µg, 40 pmol) (BostonBiochem) in 50mM
HEPES pH8.0 containing 150mM NaCl, 0.1mM EDTA and 1mM DTT was added
either the DiUb(K48) 78 (1µg, 56.8 pmol) in PBS pH7.4 or wtDiUb(K48) (1µg,
58.4 pmol) (Enzo Life Sciences) in PBS pH7.4 and the mixtures were incubated for 2 h
at 37 ◦C.
CD analysis of synthetic DiUb 78
The synthesized DiUb(K48) 78 conjugate was compared to commercially available
wild-type DiUb(K48) (Enzo Life Sciences). DiUb(K48) samples were rebuffered to
50mM Na2HPO4 pH7.4 using spin filtration (MCWO: 10 kDa, Sartorius, Germany).
The protein concentrations were determined by BCA assay (synthetic DiUb(K48) 78:
9.34µg/mL, wtDiUb(K48): 5.27µg/mL). CD-Spectra were recorded at r.t. on a JASCO
J-720 spectrometer using a 0.1 cm path length quartz cells at 260-185 nm rage with a
scanning speed of 100 nm/min and 30 accumulations and a data pitch of 0.1 nm.




80, 16%PBS, pH 8.0, 













To a solution of α-SynucleinK6C (αSyn) 79 (6.86mg, 0.475µmol, 5.0 eq.) in 2mL PBS
containing 5mM EDTA at pH 7.4 was added dithiothreitol (DTT) (366 µg, 2.375µmol,
25 eq.) and shaken for 30min at 37 ◦C. Residual DTT was washed away by means of
spin-filtration (MCWO: 3 kDa, Sartorius, Germany) using approximately 50mL of the
same buffer and the mixture was concentrated to 900µL. To this was added vinylphos-
phonothiolate ubiquitin 72 (0.845mg, 0.095µmol, 1.0 eq.) dissolved in 100µL 100mM
NH4HCO3 pH8.5 and the pH of the mixture was adjusted to pH8.0. The mixture
was shaken at 37 ◦C for 24 h. Thereafter the crude product was purified by size-
exclusion chromatography (Superdex 75 10/300 GL column (GE Healthcare, USA))
in PBS pH7.4. Other than for the conjugate DiUb(K48) 78 described above, this reac-
tion mixture was not treated with DTT before size-exclusion chromatography because
αSyn 79 and the product 80 have similar retention times and it is therefore beneficial
to keep the αSyn 79 in the disulfide form for the purification in order to minimize mixed
fractions. The conjugate Ub-αSyn conjugate 80 was isolated as a pure fraction (354µg,
15.2 nmol, 16%). The protein amount was determined by a BCA assay using dilutions

























































Fig. 96 Raw and deconvoluted HR-MS (ESI) spectra of purified Ub-αSyn conjugate 80. Calcd.:
23335Da, found: 23336Da.






E1 and Ubc1 enzymes

























To a solution of UbK48M 81 (4µL, 229 pmol, 5.3 eq.) in 50mM Tris pH7.4 con-
taining 150mM NaCl and 6mM MgCl2 was added E1 enzyme (Enzo Life Sciences,
2µL, 1.8 pmol) and E2 enzyme (Ubc1) (Enzo Life Sciences, 1.2µL, 20 pmol) and ATP
(Thermo Fisher Scientific) (80 nmol, 0.8µL). The mixture was left at r.t. for 10min.
Subsequently, α-Synuclein-ubiquitin conjugate 80 (2µL, 43 pmol) in PBS pH7.4 was
added and the reaction was kept at 37 ◦C for over night. On the next day additional
ATP (1µL, 100 nmol) was added. The reaction was analysed by ESI-MS, SDS-PAGE
(silver stain) and Western blot (see Fig. 40B/C).
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E2	 enzyme	 (Ubc1)	 (Enzo	 Life	 Sciences,	 1.2	 µL,	 20	 pmol)	 and	 ATP	 (Thermo	 Fisher	
Scientific)	(80	nmol,	0.8	µL).	The	mixture	was	left	at	r.t.	for	10	min.	Subsequently	Ub-
αSyn	 conjugate	21	 (2	µL,	 43	pmol)	 in	PBS	pH	7.4	was	added	and	 the	 reaction	was	



































































































Fig. 97 Raw and deconvoluted HR-MS (ESI) spectra of the reaction mixture of UbK48M 81
and Ub-αSyn 80. Calculated mass for diubiquitinated product 82: 32056Da, found:
32057Da.
8.3.5 MS/MS analysis of phosphonothiolate-linked protein-protein
conjugates
Purified protein conjugates 78 and 80 were run on a SDS-gel, stained with Coomassie
and further processed by in-gel protein digest using trypsin. Digested peptides were
analysed by LC-MS/MS as described in the general procedure in chapter 8.1.
For peptide identification, the RAW-files were loaded into Proteome Discoverer (v.2.4,
Thermo Scientific) and a database search was performed with MSAmanda 2.0 [312].
Files were searched against a database containing the sequence of the two ubiquitin
mutants and α-Synuclein, using the following search parameters: peptide mass tol-
erance of ±5 ppm, fragment mass tolerance of ±20 ppm, a maximum of two missed
cleavages, minimum peptide length of 5 and a minimum MSAmanda score of 150. The
P(V)-electrophile (118.0189Da) and the P(V)-electrophile plus the attached ubiquitin
C-terminus (296.0596Da or 565.2448Da) were considered as dynamic modifications to
occur on all nucleophilic amino acids. Spectra that identified a peptide carrying one of
these modifications were manually validated.
In addition, the files were searched with pLink 2.3 [318], a software designed to identify
cross-linked peptides. Therefore, RAW-files were converted to MGF using Proteome
Discoverer (v.2.4, Thermo Scientific). The following search parameters were used: pep-
tide mass tolerance of ±5 ppm, fragment mass tolerance of ±20 ppm, a maximum of
4 missed cleavages, minimum peptide length of 2 and the P(V)-electrophile was set as
a non-cleavable crosslinker with all nucleophilic amino acids as possible crosslink sites.





























linked peptide of UbK48C
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Fig. 98 MS/MS analysis of phosphonothiolate-linked protein-protein conjugates after tryptic
digest for A) diubiquitin conjugate 78 and B) Ub-α-Synuclein conjugate 80. Shown are
the sequence coverages in green for the individual proteins and the MS/MS spectra of
the phosphonothiolate-linked peptides, indicating site-specific conjugation to UbC76.
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8.4 Experimental part for ADC chapter
The protocols used in this chapter are based on an adapted from Ref. [228]. Brentuximab
was kindly provided by Stefanie Boldt and Marcus Gerlach from Tubulis GmbH.
8.4.1 Brentuximab modification with 47 and 48 (DAR screens)
Procedure for the modification of brentuximab (1mg/mL) with different
equivalents of 47
5µl of a 70mM solution of DTT in 50mM sodium borate in PBS (pH8.0) was added to
50µl of a brentuximab solution (1.0mg/mL) in 50mM sodium borate in PBS (pH8.0)
and the mixture was incubated at 37 ◦C for 40min. Excess DTT removal and exchange
to the conjugation buffer (50mM Tris, 1mM EDTA, 100mM NaCl, pH 8.5 or PBS, 1mM
EDTA, pH 7.4 at 14 ◦C) was conducted afterwards using 2mL ZebaTM spin desalting
columns with 7K MWCO (Thermo Fisher Scientific, USA). The reduced antibody solu-
tions were mixed quickly afterwards with the desired amount of compound 47 dissolved
in DMSO to give a final amount of 5% DMSO. The mixture was shaken at 850 rpm and
14 ◦C for 16 hours.
Procedure for the modification of brentuximab (5mg/mL) with different
equivalents of 47 or with 48 using the full reduction protocol
5µl of a 350mM solution of DTT in 50mM sodium borate in PBS (pH8.0) was added to
50µl of a brentuximab solution (5.0mg/mL) in 50mM sodium borate in PBS (pH8.0)
and the mixture was incubated at 37 ◦C for 40min. Excess DTT removal and exchange
to the conjugation buffer (50mM Tris, 1mM EDTA, 100mM NaCl, pH 8.5 or PBS, 1mM
EDTA, pH 7.4 at 14 ◦C or at 25 ◦C) was conducted afterwards using 0.5mL ZebaTM
spin desalting columns with 7K MWCO (Thermo Fisher Scientific, USA). The reduced
antibody solutions were mixed quickly afterwards with desired amount of compound 47
or 48 dissolved in DMSO to give a final amount of 5% DMSO (or 10% DMSO when
using 100 eq. of 47). The mixture was shaken at 850 rpm and 14 or 25 ◦C for 16 hours.
Procedure for the modification of brentuximab (5mg/mL) with different
equivalents of 48 using the partial reduction protocol with TCEP
10µL of a brentuximab solution (5.0mg/mL) in conjugation buffer (50mM Tris, 1mM
EDTA, 100mM NaCl, pH8.5 at 14 ◦C) were mixed with 1µL of a TCEP solution in
conjugation buffer containing the appropriate amount of TCEP. Directly afterwards, the
desired amount of compound 48 dissolved in DMSO were added to give a final amount
of 5% DMSO. The mixture was shaken at 850 rpm and 14 ◦C for 16 hours.
Procedure for the modification of brentuximab (12mg/mL) with different
equivalents of 48 using the partial reduction protocol with TCEP
10µL of a brentuximab solution of (12mg/mL) in conjugation buffer (50mM Tris, 1mM
EDTA, 100mM NaCl, pH8.5 at 14 ◦C) were mixed with 1µL of a TCEP solution in
conjugation buffer containing the appropriate amount of TCEP. Directly afterwards, the
desired amount of compound 48 dissolved in DMSO were added to give a final amount




8.4.2 Generation and purification of ADC 85 with a DAR of 3.15
28µL of a 360mM solution of DTT in 50mM sodium borate in PBS (pH8.0) were
added to 300µL of a brentuximab solution (5.0mg/mL) in 50mM sodium borate in PBS
(pH8.0) and the mixture was incubated at 37 ◦C for 40min. Excess DTT removal and
exchange to the conjugation buffer (50mM Tris, 1mM EDTA, 100mM NaCl, pH 8.5)
was conducted afterwards using 2mL ZebaTM spin desalting columns with 7K MWCO
(Thermo Fisher Scientific, USA). The reduced antibody solution was mixed quickly
afterwards with 2.45µL of a 36mM solution of 47 dissolved in DMSO plus 14µL DMSO
to give a final amount of 5% DMSO and 8.8 eq. 47. The solution was shaken at
850 rpm and 14 ◦C for 16 hours. The reaction mixture was purified in one portion by
size-exclusion chromatography with a 25mL SuperoseTM 6 Increase 10/300GL (GE
healthcare, United States) and a flow of 0.7mL/min eluting with sterile PBS (Merck,
Germany). The antibody containing fractions were pooled and concentrated by spin-
filtration to 225µL (MWCO: 10 kDa, 6mL, Sartorius, Germany) and the concentration
was determined to 2mg/mL (see chapter 8.4.4), which corresponds to 450 µg ADC and
an overall yield of 30% based on the initial amount of brentuximab.
8.4.3 Generation and purification of ADC 86 with a DAR of 3.1
20µL of a 8.8mM solution of TCEP in conjugation buffer (50mM Tris, 1mM EDTA,
100mM NaCl, pH 8.5) were added to 200µL of a brentuximab solution (12.0mg/mL)
in conjugation buffer. Quickly afterwards, 12µL of a 72mM solution of 48 in DMSO
was added to give a final amount of 5% DMSO, 10 eq. TCEP and 50 eq. 48. The
solution was shaken at 850 rpm and 25 ◦C for 16 hours. The next day, another portion
of 10 eq. TCEP was added and quickly afterwards another portion of 25 eq. 48.
Two hours later, another portion of 10. eq. TCEP was added and the mixture was
shaken at 850 rpm and 25 ◦C for 14 hours. The next day, based on the finding the DAR
was still below 4 but free 48 was still detectable, another portion of 10 eq. of TCEP
was added and the mixture was shaken at 850 rpm and 37 ◦C for 16 hours, resulting
in a DAR of 4.36 as judged by intact protein MS from the reaction mixture. The
reaction mixture was then purified in one portion by size-exclusion chromatography
with a 25mL SuperoseTM 6 Increase 10/300GL (GE healthcare, United States) and a
flow of 0.7mL/min eluting with sterile PBS (Merck, Germany). Thereby, a significant
amount of aggregated antibody was separated from non-aggregated ADC. The latter
fractions were pooled and concentrated by spin-filtration to 530 µL (MWCO: 10 kDa,
6mL, Sartorius, Germany) and the concentration was determined to 2mg/mL (see
chapter 8.4.4), which corresponds to 1070µg ADC and an overall yield of 44% based on
the initial amount of brentuximab.
8.4.4 Analysis of ADCs
Determination of concentrations of purified ADCs
The final concentration of ADCs after purification by size-exclusion chromatography
was determined in a 96-well plate with a PierceTM Rapid Gold BCA Protein Assay Kit
(Thermo Fisher Scientific, USA) and a Bradford reagent B6916 (Merck, Germany) with
pre-diluted protein assay standards of bovine gamma globulin (Thermo Fisher Scientific,
USA). Results of both assays were arithmetically averaged.
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Procedure for DAR determination of brentuximab conjugates by intact protein MS
For intact protein MS analysis of modified brentuximab, 10 µL of a solution of bren-
tuximab (ca. 2mg/mL) in PBS pH 7.4 were mixed with 0.5 µL PNGase-F solution
(Promega, Germany, recombinant, cloned from Elizabethkingia miricola 10 u/µL) and
incubated at 37 ◦C for 2 h. Then, 1µL of DTT solution (10mM in PBS, pH7.4) was
added and the mixture was incubated at 37 ◦C for another 30min. Finally, samples
were diluted with 30µL distilled water and subjected to MS analysis with the Waters
H-class system (for details see general information in chapter 8.1).
Resazurin assay
This protocol is based on Ref. [228]. HL60 and Karpas cell lines were cultured in
RPMI-1640 supplemented with 10% FCS and 0.5% Penicillin-Streptomycin. SKBR3 and
MDAMB468 cell lines were cultured in DMEM/F12 supplemented with 10% FCS and
0.5% Penicillin-Streptomycin. Cells were seeded at a density of 5*103 cells/well (SKBR3,
HL60 and Karpas) or 1*103 cells/well (MDAMB468) in 96-well cell culture microplate.
1:4 serial dilutions of ADCs or antibodies were performed in cell culture medium starting
at 3µg/mL final concentration and transferred in duplicates to respective wells on the
microplate. Plates were incubated for 96 h at 37 ◦C 5% CO2. Subsequently, resazurin
was added to a final concentration of 50µM followed by incubation for 3–4 h at 37 ◦C,
5% CO2. Metabolic conversion of resazurin to resorufin was quantified by the fluorescent
signal of resorufin (λEx = 560 nm and λEm = 590 nm) on a Tecan Infinite M1000 micro
plate reader. Mean and standard deviation was calculated from duplicates, normalized
to untreated control and plotted against antibody concentration. Data analysis was
performed with MatLab R2016 software.
8.4.5 Stability studies of ADC 86 in rat serum
This protocol is based on Ref. [228]. In an Eppendorf-tube, 200 µL rat serum (Sigma
Aldrich, United States) was mixed with 50µL ADC 86 (2.0mg/mL) to give a final solu-
tion of 0.4mg/ml ADC in 80% rat serum. Samples were sterile filtered with UFC30GV0S
centrifugal filter units (Merck, Germany) and incubated at 37 ◦C for 7 days. Samples
for day 0 were directly processed further. Therefore, the supernatant of 50 µL anti hu-
man igG (Fc-Specific) agarose slurry (Sigma Aldrich, United States) was removed by
centrifugation and the remaining resin washed three times with 200 µL PBS. The resin
was incubated with 240µL of the serum-ADC mix for 30min at room temperature.
Afterwards, the supernatant was removed and the resin washed 5 times with 200 µL
PBS. Following by incubation for 5 minutes with 200 µL IgG elution buffer (Thermo-
Fisher, United States) at room temperature. The supernatant was then transferred
into a Spin filter (MWCO: 10 kDa, 0.5ml, Sartorius, Germany), rebuffered to PBS pH
7.4 and concentrated to 100µL. For analysis by intact protein MS, the samples were
processed further as described in chapter 8.4.4. All measurements were performed in
















































Fig. 99 Deconvoluted intact protein ESI-MS spectra of brentuximab ADC 86 after pull-down
from rat serum at day 0.
mass





































Fig. 100 Deconvoluted intact protein ESI-MS spectra of brentuximab ADC 86 after pull-down
from rat serum at day 7, indicating P-S bond hydrolysis of the conjugate. Example:
HC2-OH is a heavy chain that carried initially 2 modifications, from which one was
lost due to hydrolysis.
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mass

































































Fig. 101 Deconvoluted intact protein ESI-MS spectra of brentuximab ADC 86 after pull-down
from rat serum at day 7 (zoomed in spectrum of Fig. 100).
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8.5 Experimental part for chaperone photocrosslinking
chapter
8.5.1 Synthesis of photocrosslinkers
Tetrazole building block synthesis
2-Phenyl-2H-tetrazole-5-carboxylic acid was synthesized based on protocols described



















































tetrazole, THF, -40 °C to r.t.
1 eq.i)

























































































































































































































































50 mM NH4HCO3, 1 mM EDTA,




















































i. LiOH, MeOH/H2O, 0 °C to r.t.


































A solution of 50% ethyl 2-oxoacetate in toluene (3.042 g, 14.9mmol, 1.4 eq.) and
benzenesulfonyl hydrazide (1.72 g, 11.5mmol, 1.07 eq.) in 60mL EtOH was stirred at
r.t. for 1 h. The solvent was removed under reduced pressure, and the residue was
re-dissolved in 60mL pyridine. Separately, to a stirred suspension of aniline (0.974mL,
10.7mmol, 1.0 eq.) and 4mL concentrated HCl in 8mL H2O and 10mL EtOH was
added drop-wise a solution of NaNO2 (0.775 g, 11.2mmol, 1.05 eq.) in 3mL H2O
at 0 ◦C. After 10min, this solution was added drop-wise to the previously prepared
pyridine solution over 50min at –10 ◦C (ice/dry-ice bath). The mixture was warmed up
to r.t. over 2 h with stirring before 100mL H2O was added. The solution was extracted
with DCM (3 times 70mL), and the organic layers were collected, combined, washed
successively with 100mL 2N HCl (3 times) and 70mL brine (one time). After drying
over NaSO4, the solvent was removed under reduced pressure. The dark brown oily
residue was purified by silica gel flash chromatography (n-hexanes:EtOAc = 4:1) to
give the crude product as a brown solid (1.153 g). The crude product was recrystallized
from EtOH to give the title compound as a yellow solid (564mg, 2.57mmol, 24%).
1H-NMR: (300MHz, CDCl3): δ = 8.23-8.13 (m, 2H), 7.63-7.49 (m, 3H), 4.56 (q, J =
7.1Hz, 2H), 1.47 (t, J = 7.2Hz, 3H). 13C-NMR: (75MHz, CDCl3): δ = 157.87, 136.44,




























i. LiOH, MeOH/H2O, 0 °C to r.t.


































To a suspension of ethyl 2-phenyl-2H-tetrazole-5-carboxylate (500mg, 2.281mmol) in
26.5mL H2O was added 2.65mL of a 2M NaOH solution in EtOH (the mixture had to
be heated and sonicated to get everything in solution). The solution was stirred at r.t.
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for 2 hours, then acidified to pH = 2 by the addition of 2N HCl and extracted with
DCM (3 times with 30mL). The combined organic layers were dried over Na2SO4 and
filtered. The solvents were removed under reduced pressure to give the titled compound
as a slightly pink solid (330mg, 1.74mmol, 76%). 1H-NMR: (300MHz, DMSO−d6): δ
= 8.18-8.02 (m, 2H), 7.77-7.56 (m, 3H). 13C-NMR: (75MHz, DMSO−d6): δ = 158.66,
































































30% isolated yield after HPLC
photocrosslinker 88, 52% isolated yield after HPLC
2
















Scheme 65 Synthesis of photocrosslinker 88. CL= photocrosslinker.
Photocrosslinker 88 was synthesized manually according to scheme 65 in a 50µmol scale
on a Rink amide resin with a loading of 0.47mmol/g. Generally, the resin was washed
with DMF, DCM and DMF again after amino acid couplings and Fmoc-deprotections.
The amino acids G, K(Alloc) and K(Mtt) were coupled with single couplings (5 eq.
amino acid for 1 h) with Oxyma and HCTU (5 eq. each) and DIPEA (10 eq.) in
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DMF. The amino acid X (TCI, Fmoc-NH-PEG2-CH2COOH) was coupled in a single
coupling (3 eq. for 1 h) with HATU (3 eq.) and DIPEA (6 eq.). Fmoc-deprotections were
performed with piperidine/DMF (20:80; v:v, 3 times for 3min). The Fmoc-protecting
group on the last amino acid X was kept on during lysine modification with biotin. For
K(Mtt) deprotection, the resin was first equilibrated in DCM and then treated with
TFA/TIS/DCM (2:5:93; v:v:v, 3 times for 5min). Biotin was then coupled in DMF
in a single coupling (5 eq. biotin) with HATU (5 eq.) and DIPEA (10 eq.). Now
the Fmoc-protecting group on the last amino acid (X) was removed by treatment with
piperidine/DMF (20:80; v:v, 3 times for 3min) and subsequently, Boc-protected glycine
was coupled to the N-terminus (5 eq. Boc-glycine for 1 h) with Oxyma/HCTU (5 eq.
each) and DIPEA (10 eq.). For K(Alloc) deprotection, the resin was first equilibrated in
DCM and then treated with a solution of phenylsilane (0.025 eq.) and Pd(PPh3)4 (0.05
eq.) in DCM (2 times for 1 h with fresh solutions). The diazirine carboxylic acid was
coupled to the deprotected lysine in a single coupling (3 eq. for 2 h) with HATU (3 eq.)
and DIPEA (6 eq.). The final cleavage from resin was achieved by incubation with a mix-
ture of TFA/TIS/H2O (95:2.5:2.5; v:v:v) for 1.5 hours followed by precipitation in cold
diethylether. The crude peptide was purified by semipreparative reverse-phase HPLC
(gradient: 5-40% MeCN+0.1% TFA in H2O+0.1% TFA over 40min, flow: 16mL/min)
and the intermediate peptide was gained as a white powder (21mg, 15 µmol, 30%) after
lyophilization.
This purified intermediate peptide (10mg, 7.2µmol, 1.0 eq.) was dissolved in DMF
(250µL) and mixed with NHS derivative 38 (3.4mg, 10.8µmol, 1.5 eq.) and DIPEA
(3.8µL, 21.6µmol, 3.0 eq.) and the mixture was shaken at r.t. for 15min. The mixture
was then diluted with water (4.5mL) and the crude product was purified by semiprepar-
ative reverse-phase HPLC (gradient: 5-40% MeCN+0.1% TFA in H2O+0.1% TFA over
40min, flow-rate: 16mL/min) to give photocrosslinker 88 (6.1mg, 3.76µmol, 52%) as
a white powder after lyophilization.
HR-MS (ESI+) for C66H107F3N15O22PS2
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Fig. 102 UPLC-UV analysis (220 nm) of compound 88.
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photocrosslinker 90: 4% isolated yield after HPLC





















Scheme 66 Synthesis of photocrosslinkers 90 and 91. CL= photocrosslinker.
Photocrosslinkers 90 and 91 were synthesized manually according to scheme 66 in a
130µmol scale on a Rink amide resin with a loading of 0.40mmol/g. Generally, the
resin was washed with DMF, DCM and DMF again after amino acid couplings and
Fmoc-deprotections. The amino acids G, K(Alloc) and K(Mtt) were coupled with
single couplings (5 eq. amino acid for 1 h) with Oxyma and HCTU (5 eq. each) and
DIPEA (10 eq.) in DMF. The amino acid X (TCI, Fmoc-NH-PEG2-CH2COOH) was
coupled in a single coupling (3 eq. for 1 h) with HATU (3 eq.) and DIPEA (6 eq.).
Fmoc-deprotections were performed with piperidine/DMF (20:80; v:v, 3 times for
3min). The Fmoc-protecting group on the last amino acid X was kept on during lysine
modification with biotin. For K(Mtt) deprotection, the resin was first equilibrated
in DCM and then treated with TFA/TIS/DCM (2:5:93; v:v:v, 3 times for 5min).
Biotin was then coupled in DMF in a single coupling (5 eq. biotin) with HATU (5
eq.) and DIPEA (10 eq.). For K(Alloc) deprotection, the resin was first equilibrated
in DCM and then treated with a solution of phenylsilane (0.025 eq.) and Pd(PPh3)4
(0.05 eq.) in DCM (2 times for 1 h with fresh solutions). The diazirine carboxylic
acid (TCI) or tetrazole carboxylic acid (ethyl 2-phenyl-2H-tetrazole-5-carboxylate,
see procedure above) was coupled to the deprotected lysine in a single coupling (3
eq. each for 2 h) with HATU (3 eq.) and DIPEA (6 eq.). Then, the N-terminal
185
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Fmoc-protecting group was removed by treatment with piperidine/DMF (20:80; v:v, 3
times for 3min) and subsequently, the ethynylphosphonamidate building block13 (see
scheme 66 for structure) was coupled on resin (1.5 eq. for 1 h) with HATU (1.5 eq.)
and DIPEA (3.0 eq.). The final cleavage from resin was achieved by incubation with
a mixture of TFA/TIS/H2O (95:2.5:2.5; v:v:v) for 1 hour followed by precipitation in
cold diethylether. The crude peptides were purified by semipreparative reverse-phase
HPLC (gradient: 10-50% MeCN+0.1% TFA in H2O+0.1% TFA over 30min, flow:
16mL/min) and the photocrosslinkers 90 (3.7mg, 2.3µmol, 4%) and 91 (6.0mg,
3.9µmol, 6%) were gained as white powders after lyophilization.
Photorosslinker 90: LR-MS (ESI+) for C68H103F3N15O21PS
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Fig. 103 UPLC-UV analysis (220 nm) of compound 90.
Photorosslinker 91: LR-MS (ESI+) for C67H104N17O21PS
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Fig. 104 UPLC-UV analysis (220 nm) of compound 91.
13The ethynylphosphonamidate building block was kindly provided by Dr. Marc-André Kasper, who
synthesized it as described in Ref. [208].
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8.5.2 Conjugation of anti-chaperone antibodies with photocrosslinkers
Proteins and antibodies
The proteins HSP-1, DNJ-12 and DNJ-13 were expressed and purified by the Kirstein
group. Polyclonal anti-HSP-1 and anti-DNJ-12 antibodies, provided by the Kirstein
group, were generated by immunizing rabbits with purified chaperone proteins (Charles
River, Germany) [286]. The immunized sera were tested against purified chaperone
proteins and against wild-type C. elegans lysates. Anti-HSP-1 and anti-HSP-12 anti-
bodies were purified by Manuel Iburg using immobilized target proteins on Sulflolink
resin (Thermo Fisher Scientific, Waltham, USA). Briefly, 2mL of the serum containing
the antibodies (anti-HSP-1 or anti-DNJ-12) were added onto the column with the im-
mobilized target proteins (HSP-1 or DNJ-12, respectively) and incubated over night at
4 ◦C. The next day, the resin was washed with washing buffer (20mM Tris-HCl, 500mM
NaCl, 0.2% Triton X-100, pH=8.0), before eluting bound antibodies with elution buffer
(150mM glycine-HCl, 100mM NaCl, pH= 2.5). Fractions were immediately neutralized
by adding 50µL of Tris-HCl pH=9.0 and samples were taken for analysis by SDS-PAGE.
Before conjugations to photocrosslinkers, the purified antibodies were rebuffered to the
desired conjugation buffer via spin filtration. Concentrations were determined with a
BCA assay using BSA at defined concentrations as a standard.
Conjugation of anti-HSP-1 antibody with photocrosslinker 88
To the polyclonal anti-HSP-1 antibody (1µM in 50mM borate PBS pH 8.0, 50µL)
was added DTT (10mM in BPBS buffer, 5µL, final concentration in mixture: 1mM)
and the mixture was shaken at 37 ◦C and 800 rpm for 30min. Removal of DTT and
rebuffering to conjugation buffer (50mM NH4HCO3, 100mM NaCl, 1mM EDTA)
was achieved by means of gel filtration (Zeba spin column). Quickly afterwards,
photocrosslinker 88 (2mM in DMSO, 1.25µL, final concentration in mixture: approx.
50µM) was added and the mixture was shaken at 800 rpm for 16 hours at 14 ◦C.
Removal of excess photocrosslinker and rebuffering to PBS pH 7.4 was achieved
via spin-filtration and the antibody solution was concentrated to 1 µM. From this
solution, 15µL were mixed with 5µL Laemmli buffer containing β-mercaptoethanol
(4 times concentrated), heated at 95 ◦C for 15min and run on a SDS-gel (12% SDS).
For subsequent Western-blot analysis, the commercially available Streptavidin-POD
conjugate (Roche Diagnostics GmbH) was used for hybridisation and indirect detection
via chemiluminescence.
In order to test whether HSP-1-crosslinker conjugate 89 retained the ability to bind
its target protein HSP-1, recombinant HSP-1 protein was blotted on a cellulose mem-
brane and incubated with the anti-HSP-1-photocrosslinker conjugate 88 or unmodified
anti-HSP-1 antibody as a control. Antibodies bound to target protein HSP-1 were sub-


















1) reduction with DTT
2) 50 eq. photocrosslinker 88,
    50 mM NH4HCO3, pH 8.5, 
    1mM EDTA, 2 % DMSO, 

















































1: HSP-1 blotted, incubated with native anti-HSP-1, 
detected with anti-rabbit-HRP or streptavidin-HRP
2: HSP-1 blotted, incubated with anti-HSP-1-
photocrosslinker conjugate 89, 







Fig. 105 Western-blots showing that anti-HSP-1-photocrosslinker conjugate 89 recognizes its
target protein HSP-1. The intense band at ca. 70 kDa corresponds to anti-HSP-1
antibody bound to blotted HSP-1 protein.
Conjugation of anti-DNJ-12 antibody with photocrosslinker 90 and 91
To the polyclonal anti-DNJ-12 antibody (2µM in 50mM borate PBS pH 8.0, 300µL)
was added DTT (250mM in BPBS buffer, 2.4µL, final concentration in mixture:
2mM) and the mixture was shaken at 37 ◦C and 800 rpm for 30min. Removal of
DTT and rebuffering to conjugation buffer (50mM NH4HCO3, 100mM NaCl, 1mM
EDTA) was achieved by means of gel filtration (Zeba spin column). Quickly afterwards,
photocrosslinker 90 or 91 (5mM in DMSO, 6µL, final concentration in mixture:
approx. 100µM) was added and the mixture was shaken at 800 rpm for 16 hours at
14 ◦C. Removal of excess photocrosslinker and rebuffering to PBS pH 7.4 was achieved
via spin-filtration and the antibody solution was concentrated to 5 µM. From this
solution, 10µL were mixed with 10µL Laemmli buffer containing β-mercaptoethanol
(2 times concentrated), heated at 95 ◦C for 15min and run on a SDS-gel (12% SDS).
For subsequent Western-blot analysis, the commercially available Streptavidin-POD
conjugate (Roche Diagnostics GmbH) was used for hybridisation and indirect detection
via chemiluminescence.
8.5.3 Photocrosslinking
Anti-DNJ-12-conjugates 92 and 93 and DNJ-12
Anti-DNJ-12-antibody-photocrosslinker conjugates 92 and 93 (5µM in PBS pH 7.4,
40µL) were each mixed with recombinant DNJ-12 protein (5 µM in PBS pH 7.4, 40µL).
For control reactions without DNJ-12, the conjugates 92 and 93 (40µL) were diluted
with 40µL PBS pH 7.4 buffer instead. From these solutions, 40 µL were directly mixed
with 14µL β-mercaptoethanol containing Laemmli buffer (4 times concentrated) and
heated at 95 ◦C for 15min (non-irradiated control samples). The remaining volumes
were shaken at 800 rpm at r.t. for 1 hour in the dark and then irradiated with UV-light
(at 365 nm for conjugate 92 (diazirine) and at 302 nm for conjugate 93 (tetrazole)) for
15min on ice. Afterwards, 14µL of β-mercaptoethanol containing Laemmli buffer (4
times concentrated) was added and the samples were heated at 95 ◦C for 15min and
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subjected to SDS-PAGE (4-12.5% gradient gels), followed by Western-blot analysis us-
ing the commercially available Streptavidin-POD conjugate (Roche Diagnostics GmbH)
for hybridisation and indirect detection via chemiluminescence. For additional control
reactions (see Fig. 50C/D), the same procedure was followed using native anti-DNJ-
12 antibody alternatively and two SDS-gels were run. One was used for Western-blot
against biotin as described above and the other one was used for silver-stain (see general
information for details).
Anti-HSP-1-conjugate 89 and HSP-1
Anti-HSP-1-antibody-photocrosslinker conjugate 89 (1µM in PBS pH 7.4, 20µL) was
mixed with recombinant HSP-1 protein (1µM in PBS pH 7.4, 20µL). For control re-
actions without 89 or HSP-1 protein, the respective volume was replaced with buffer.
From these mixtures, 5µL were directly mixed with 5µL β-mercaptoethanol containing
Laemmli buffer (2 times concentrated) and heated at 95 ◦C for 15min (non-irradiated
control samples). The remaining volumes were shaken at 800 rpm at r.t. for 1 hour
in the dark and then irradiated with UV-light at 365 nm for 30min on ice. Samples
of 5µL were drawn after 5, 15 and 30min, diluted with β-mercaptoethanol containing
Laemmli buffer (2 times concentrated), heated at 95 ◦C for 15min and subjected to
SDS-PAGE (4-12.5% gradient gels, two identical SDS-gels were run) and subsequent
Western-blot analysis. For one blot, the commercially available Streptavidin-POD con-
jugate (Roche Diagnostics GmbH) was used for hybridisation and indirect detection via
chemiluminescence. For the other blot, first native rabbit anti HSP-1 antibody was used
for hybridisation followed by detection with anti-rabbit-HRP (chemiluminescence).
Anti-HSP-1-conjugate 89 and HSP-1 + DNJ-13
Recombinant HSP-1 protein (final concentration: 1 µM), recombinant DNJ-13 protein
(final concentration: 0.5µM) and heat-denaturated recombinant luciferase (final con-
centration: 0.5µM) were preincubated at r.t. for 1 hour, before anti-HSP-1-antibody-
photocrosslinker conjugate 89 was added (final concentration: 0.5µM) to give a final
volume of 20µL in PBS pH 7.4. This mixture was shaken at r.t. in the dark for
1 hour. 5µL of this mixture were directly mixed with 5µL β-mercaptoethanol containing
Laemmli buffer (2 times concentrated) and heated at 95 ◦C for 15min (non-irradiated
control sample). The remaining volume was irradiated with UV-light at 365 nm for
30min on ice. After 30min, 5µL of this mixture was diluted with β-mercaptoethanol
containing Laemmli buffer (2 times concentrated) and heated at 95 ◦C for 15min. The
remaining volume was mixed with magnetic beads loaded with protein A/G (PierceTM
Protein A/G magnetic beads Thermo Fisher Scientific, washed three times with TBST,
one time with PBS). After incubation for 90min, the beads were washed with TBST
three times and samples were eluted by boiling in 2x SDS sample buffer. Separation of
magnetic beads from liquid phase was carried out using a magnetic reaction vessel rack
(GE Healthcare). Flow-through (wash fractions) and elution samples were mixed with
Laemmli buffer, heated at 95 ◦C for 15min and subjected to SDS-PAGE (4-12.5% gra-
dient gel). For subsequent Western-blot analysis, native anti-DNJ-13 antibody was used
for hybridisation and an anti-rabbit-HRP conjugate for indirect detection via chemilu-
minescence (see general information in chapter 8.1 for details).
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8.6 Experimental part for DUB photocrosslinking chapter
8.6.1 Conjugation of DUBs to photocrosslinkers
In 0.5mL Eppendorf tubes, USP2CD (R&D Systems, catalogue number E-504,
50µM, 5µL) or UCHL3 (R&D Systems, catalogue number E-325, 80µM, 3.125µL)
plus 1.875µL conjugation buffer (50mM NH4HCO3 pH 8.5) were mixed with either
compound 54 or 55 (1.25mM in conjugation buffer containing 2.5% DMSO, 5µL)
resulting in DUB concentrations of 25µM and crosslinker concentrations of 625µM
(= 25 eq.). The mixtures were shaken at 14 ◦C and 800 rpm for 16 hours. Removal
of excess free crosslinker and rebuffering to PBS was then performed by gel filtration
(Zeba Spin, with PBS). For MS/MS analysis, 2 µL of the mixtures after gel filtration
were diluted with 10µL Laemmli buffer containing β-mercaptoethanol, boiled at 95 ◦C
for 5min and subjected to SDS-PAGE (15% SDS). For tryptic digest and LC-MS/MS
procedure, see general information in chapter 8.1.
8.6.2 MS/MS analysis of DUB-photocrosslinker conjugates
For peptide identification, the RAW-files were loaded into Proteome Discoverer (v.2.4,
Thermo Scientific) and a database search was performed with MSAmanda 2.0 [312].
Files were searched against a database containing the sequences of the two DUBs using
the following search parameters: peptide mass tolerance of ±8 ppm, fragment mass
tolerance of ±20 ppm, a maximum of two missed cleavages, minimum peptide length
of 5 and a minimum MSAmanda score of 150. Diazirine derivative 54 (407.068Da)
and tetrazole derivative 55 (370.098Da) (both indicated with A) were considered as
dynamic modifications to occur on cysteine. Moreover, cysteine carbamidomethylation
(57.021Da) (indicated with C) and methionine oxidation (15.995Da) (indicated with
O) were considered as dynamic modifications. Spectra that identified a peptide carrying
54 or 55 as modification were validated manually.
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for conjugation see p. 56 biobook2























































































NH4HCO3 buffer, pH 8.5
14 °C, 16 h




SKSAQGLAGL RNLGNTCFON SILQCLSNTR ELRDYCLQRL YORDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
SKSAQGLAGL RNLGNTCFMN SILQCLSNTR ELRDYCLQRL YMRDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
KTQIQRYAPR FVGYNQQDAQ EFLRFLLDGL HNEVNRVTLR PKSNPENLDH LPDDEKGRQM WRKYLEREDS RIGDLFVGQL 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODCO RLFTKEDVLD GDEKPTAARC RGRKRCIKKF SIQRFPKILV
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODCO RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLMDCM RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
LHLKRFSESR IRTSKLTTFV NFPLRDLDLR EFASENTNHA VYNLYAVSNH SGTTMGGHYT AYCRSPGTGE WHTFNDSSVT 
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SKSAQGLAGL RNLGNTCFON SILQCLSNTR ELRDYCLQRL YORDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
SKSAQGLAGL RNLGNTCFMN SILQCLSNTR ELRDYCLQRL YMRDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
KTQIQRYAPR FVGYNQQDAQ EFLRFLLDGL HNEVNRVTLR PKSNPENLDH LPDDEKGRQO WRKYLEREDS RIGDLFVGQL
KTQIQRYAPR FVGYNQQDAQ EFLRFLLDGL HNEVNRVTLR PKSNPENLDH LPDDEKGRQM WRKYLEREDS RIGDLFVGQL 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODAO RLFTKEDVLD GDEKPTAARC RGRKRCIKKF SIQRFPKILV
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODCO RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLMDCM RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
LHLKRFSESR IRTSKLTTFV NFPLRDLDLR EFASENTNHA VYNLYAVSNH SGTTMGGHYT AYCRSPGTGE WHTFNDSSVT 















































NH4HCO3 buffer, pH 8.5
14 °C, 16 h
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OEGQRWLPLE ANPEVTNQFL KQLGLHPNWQ FVDVYGMDPE LLSMVPRPVC AVLLLFPITE KYEVFRTEEE EKIKSQGQDV
MEGQRWLPLE ANPEVTNQFL KQLGLHPNWQ FVDVYGMDPE LLSMVPRPVC AVLLLFPITE KYEVFRTEEE EKIKSQGQDV 
TSSVYFOKQT ISNAAGTIGL
TSSVYFOKQT ISNACGTIGL IHAIANNKDK OHFESGSTLK KFLEESVSOS PEERARYLEN YDAIRVTHET SAHEGQTEAP 
TSSVYFMKQT ISNACGTIGL IHAIANNKDK MHFESGSTLK KFLEESVSMS PEERARYLEN YDAIRVTHET SAHEGQTEAP 
SIDEKVDLHF IALVHVDGHL YELDGRKPFP INHGETSDET LLEDAIEVAK KFERDPDEL RFNAIALSAA
SIDEKVDLHF IALVHVDGHL YELDGRKPFP INHGETSDET LLEDAIEVCK KFOERDPDEL RFNAIALSAA             
SIDEKVDLHF IALVHVDGHL YELDGRKPFP INHGETSDET LLEDAIEVCK KFMERDPDEL RFNAIALSAA
MEGQRWLPLE ANPEVTNQFL KQLGLHPNWQ FVDVYGMDPE LLSMVPRPVC AVLLLFPITE KYEVFRTEEE EKIKSQGQDV 
TSSVYFOKQT ISNAAGTIGL
TSSVYFOKQT ISNACGTIGL IHAIANNKDK OHFESGSTLK KFLEESVSOS PEERARYLEN YDAIRVTHET SAHEGQTEAP 
TSSVYFMKQT ISNACGTIGL IHAIANNKDK MHFESGSTLK KFLEESVSMS PEERARYLEN YDAIRVTHET SAHEGQTEAP 
SIDEKVDLHF IALVHVDGHL YELDGRKPFP INHGETSDET LLEDAIEVAK KFERDPDEL RFNAIALSAA
SIDEKVDLHF IALVHVDGHL YELDGRKPFP INHGETSDET LLEDAIEVCK KFOERDPDEL RFNAIALSAA             





Fig. 106 A) Conjugation of USP2CD with photocrosslinker 54. B) Amino acid sequence of
USP2CD. MS sequence coverage is highlighted in green (84%). MS/MS recorded pep-
tide is highlighted in orange. A= cysteine modified with crosslinker 54, C= cysteine
carbamidomethylation, O= methionine oxidation. C) Peptide spectrum match of the
modified peptide LFTKEDVLDGDEKPTC(A/C)C(A/C)R (HCD spectrum). Both





























NH4HCO3 buffer, pH 8.5
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SKSAQGLAGL RNLGNTAFAHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
SKSAQGLAGL RNLGNTCFON SILQCLSNTR ELRDYCLQRL YORDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
SKSAQGLAGL RNLGNTCFMN SILQCLSNTR ELRDYCLQRL YMRDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
KTQIQRYAPR FVGYNQQDAQ EFLRFLLDGL HNEVNRVTLR PKSNPENLDH LPDDEKGRQO WRKYLEREDS RIGDLFVGQL
KTQIQRYAPR FVGYNQQDAQ EFLRFLLDGL HNEVNRVTLR PKSNPENLDH LPDDEKGRQM WRKYLEREDS RIGDLFVGQL 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODAO RLFTKEDVLD GDEKPTAARC RGRKRCIKKF SIQRFPKILV
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODCO RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLMDCM RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
LHLKRFSESR IRTSKLTTFV NFPLRDLDLR EFASENTNHA VYNLYAVSNH SGTTMGGHYT AYCRSPGTGE WHTFNDSSVT 
POSSSQVRTS DAYLLFYELA SPPSRO                                                           
PMSSSQVRTS DAYLLFYELA SPPSRM
95
Fig. 107 A) Conjugation of USP2CD with photocrosslinker 55. B) Amino acid sequence of
USP2CD. MS sequence coverage is highlighted in green (85%). MS/MS recorded pep-
tides are highlighted in orange. A= cysteine modified with crosslinker 55, C= cysteine
carbamidomethylation, O= methionine oxidation. C) Peptide spectra matches of the
modified peptides, from top to bottom: LFTKEDVLDGDEKPTC(A/C)C(A/C)R;
RGYPEVTLM(O)DC(A/C)M(O)R; NLGNTC(A/C)FM(O)NSILQC(C)LSNTR.
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SKSAQGLAGL RNLGNTCFMN SILQCLSNTR ELRDYCLQRL YMRDLHHGSN AHTALVEEFA KLIQTIWTSS PNDVVSPSEF 
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KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODCO RLFTKEDVLD GDEKPTAARC RGRKRCIKKF SIQRFPKILV
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLODCO RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLMDCM RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
LHLKRFSESR IRTSKLTTFV NFPLRDLDLR EFASENTNHA VYNLYAVSNH SGTTMGGHYT AYCRSPGTGE WHTFNDSSVT 
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KSSLTCTDCG YCSTVFDPFW DLSLPIAKRG YPEVTLMDCM RLFTKEDVLD GDEKPTCCRC RGRKRCIKKF SIQRFPKILV 
LHLKRFSESR IRTSKLTTFV NFPLRDLDLR EFASENTNHA VYNLYAVSNH SGTTMGGHYT AYCRSPGTGE WHTFNDSSVT 















































NH4HCO3 buffer, pH 8.5
14 °C, 16 h
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OEGQRWLPLE ANPEVTNQFL KQLGLHPNWQ FVDVYGMDPE LLSMVPRPVC AVLLLFPITE KYEVFRTEEE EKIKSQGQDV
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Fig. 108 A) Conjugation of UCHL3 with photocrosslinker 54. B) Amino acid sequence of
UCHL3. MS sequence coverage is highlighted in green (80%). MS/MS recorded pep-
tides are highlighted in orange. A= cysteine modified with crosslinker 54, C= cysteine
carbamidomethylation, O= methionine oxidation. C) Peptide spectra matches of the
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Fig. 109 A) Conjugation of UCHL3 with photocrosslinker 55. B) Amino acid sequence of
UCHL3. MS sequence coverage is highlighted in green (82%). MS/MS recorded pep-
tides are highlighted in orange. A= cysteine modified with crosslinker 55, C= cysteine
carbamidomethylation, O= methionine oxidation. C) Peptide spectra matches of the
modified peptides, from top to bottom: KPFPINHGETSDETLLEDAIEVC(C/A)K;
QTISNAC(C/A)GTIGLIHAIANNKDK
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8.6 Experimental part for DUB photocrosslinking chapter
8.6.3 Photocrosslinking
DUB-conjugates 94-97 and mono-ubiquitin
In lids of Eppendorf tubes, DUB-photocrosslinker conjugates 94-97 (25µM in PBS pH
7.4, 2µL) were mixed with wild-type ubiquitin (Ub wt) (100 µM in PBS pH 7.4, 2µL)
and GFP (50µM in PBS pH 7.4, 4µL) resulting in the following final concentrations:
DUB-photocrosslinker conjugates: 6.25µM; Ub wt: 25µM; GFP: 25µM. For control
samples without ubiquitin or GFP, the respective volume was replaced with PBS pH 7.4.
Without additional incubation time, the mixtures were directly irradiated with UV-light
for 10min at r.t at either 365 nm (diazirine conjugates 94 and 96) or 302 nm (tetrazole
conjugates 95 and 97) in a distance of approximately 2 cm to the UV-lamp (see general
procedure in chapter 8.1 for details). The samples were then diluted with 4 µL Laemmli
buffer containing β-mercaptoethanol, boiled for 5min at 95 ◦C and subjected to SDS-
PAGE (15% SDS gels).
DUB-conjugates 94-97 and diubiquitins
In lids of Eppendorf tubes, DUB-photocrosslinker conjugates 94-97 (25µM in PBS pH
7.4, 1µL) were mixed with diubiquitins (DiUb(K63): Enzo, 1mg/mL, ca. 55 µM, 1µL
or DiUb(K48): Enzo, 4.2mg/mL, ca. 240µM, 0.25µL) and 6µL PBS pH 7.4 resulting in
the following final concentrations: DUB-photocrosslinker conjugates: ca. 3 µM; DiUbs:
ca. 6-7µM. Without additional incubation time, the mixtures were directly irradiated
with UV-light for 10min at r.t at either 365 nm (diazirine conjugates 94 and 96) or
302 nm (tetrazole conjugates 95 and 97) in a distance of approximately 2 cm to the
UV-lamp (see general procedure in chapter 8.1 for details). The samples were then
diluted with 4µL Laemmli buffer containing β-mercaptoethanol, boiled for 5min at








































































































































































Fig. 125 31P-NMR spectrum of compound 6 in CDCl3 (122MHz).
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Fig. 128 31P-NMR spectrum of compound 7 in CDCl3 (122MHz).
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Fig. 137 31P-NMR spectrum of compound 10 in CDCl3 (122MHz).
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Fig. 151 13C-NMR spectrum of compound 16 in CDCl3 (75MHz).
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Fig. 154 31P-NMR spectrum of compound 17 in CDCl3 (122MHz).
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Fig. 157 31P-NMR spectrum of compound 18 in DMSO−d6 (243MHz).
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Fig. 174 31P-NMR spectrum of compound 34 in CD3CN (122MHz).
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Fig. 177 31P-NMR spectrum of compound 35 in CDCl3 (122MHz).
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Fig. 180 31P-NMR spectrum of compound 36 in CDCl3 (243MHz).
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Fig. 183 31P-NMR spectrum of compound 37 in CDCl3 (122MHz).
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Fig. 186 31P-NMR spectrum of compound 38 in CDCl3 (243MHz).
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Fig. 189 31P-NMR spectrum of compound 39 in DMSO−d6 (243MHz).
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Fig. 192 31P-NMR spectrum of compound 43 in DMSO−d6 (243MHz).
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Fig. 195 31P-NMR spectrum of compound 44 in DMSO−d6 (243MHz).
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Fig. 198 31P-NMR spectrum of compound 45 in DMSO−d6 (243MHz).
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Fig. 201 31P-NMR spectrum of compound 47 in DMSO−d6 (243MHz).
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Fig. 205 1H-NMR spectrum of compound 53 in CDCl3 (300MHz).
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Fig. 208 31P-NMR spectrum of compound 54 in CDCl3 (122MHz).
295
9 Appendix































































































Fig. 214 31P-NMR spectrum of compound 56 in D2O (122MHz).
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Fig. 217 31P-NMR spectrum of compound 57 (Z -isomer) in D2O (243MHz).
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Fig. 220 31P-NMR spectrum of compound 57 (E -isomer) in D2O (243MHz).
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Fig. 223 31P-NMR spectrum of compound 61 in CDCl3 (122MHz).
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Fig. 226 31P-NMR spectrum of compound 62 in CDCl3 (122MHz).
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Fig. 229 31P-NMR spectrum of compound 65 in DMSO−d6 (243MHz).
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Fig. 232 31P-NMR spectrum of compound 66 in DMSO−d6 (122MHz).
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Fig. 234 Raw intact protein ESI-MS spectrum of ADC 86 (compare Fig. 44).
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9.2 Intact protein MS spectra
mass






























































































Fig. 235 Deconvoluted intact protein ESI-MS spectra of a brentuximab ADC generated with
ethynylphosphonothiolate 47 with an initial DAR of 5.70. A) After incubation at
25 ◦C (A) and 37 ◦C (B) for 16 hours at pH7.4, 25% and 35% of toxins were lost re-
spectively as a consequence of the P-S bond cleavage in the ADC (compare scheme 52).
Example: HC2-OH is a heavy chain that initially carried two toxins, from which one
was lost due to hydrolysis.
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9.3 Peptide MS/MS spectra of phosphonothiolate-labeled
trastuzumab
The spectra (HCD MS/MS) shown in the following belong to the trastuzumab labelling
experiment shown in Fig. 47 and described in the Experimental section 8.2.9.
Trastuzumab	heavy	chain:		
LSC(7)AASGFNIKDTYIHWVR	
Fig. 236 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C3. Labelling conditions: pH 7.4.
Trastuzumab	light	chain:		
ADYEKH(7)K	
Fig. 237 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position H6. Labelling conditions: pH 7.4.
Trastuzumab	light	chain:		
ADYEKHKVYAC(7)EVTHQGLSSPVTK	
Fig. 238 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C11. Labelling conditions: pH 7.4.
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9.3 Peptide MS/MS spectra of phosphonothiolate-labeled trastuzumab
Trastuzumab	heavy	chain:	
SC(7)DKTHTC(7)PPCPAPELLGGPSVFLFPPKPK	
Fig. 239 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at the positions C2 and C8. Labelling conditions: pH 7.4.
Trastuzumab	heavy	chain:	
STSGGTAALGC(7)LVK	
Fig. 240 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C11. Labelling conditions: pH 7.4.
Trastuzumab	light	chain:		
HKVYAC(7)EVTHQGLSSPVT	
Fig. 241 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-





Fig. 242 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C8. Labelling conditions: pH 7.4.
Trastuzumab	light	chain:	
SGTDFTLTISSLQPEDFATYYC(7)QQHYTTPPTFGQGTK	
Fig. 243 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C22. Labelling conditions: pH 7.4.
Trastuzumab	light	chain:	
VTITC(7)R	
Fig. 244 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C5. Labelling conditions: pH 7.4.
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9.3 Peptide MS/MS spectra of phosphonothiolate-labeled trastuzumab
Trastuzumab	light	chain:		
SFNRGEC(7)	
Fig. 245 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position C7. Labelling conditions: pH 8.5.
Trastuzumab	heavy	chain:		
IYPTNGY(7)TR	
Fig. 246 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-
iolate 7 at position Y7. Labelling conditions: pH 8.5 (-DTT control).
Trastuzumab	light	chain:		
VY(7)ACEVTHQGLSSPVTK	
Fig. 247 Peptide spectrum match of the indicated peptide modified with ethynylphosphonoth-





Fig. 248 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at position C7. Labelling conditions: pH 7.4.
Trastuzumab	heavy	chian:		
WQQGNVFSCSVMHEALHNH(8)YTQK	
Fig. 249 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at position H19. Labelling conditions: pH 7.4 (-DTT control).
Trastuzumab	heavy	chain:		
THT(8)CPPCPAPELLGGPSVFLFPPKPK	
Fig. 250 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at position T3. Labelling conditions: pH 8.5.
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9.3 Peptide MS/MS spectra of phosphonothiolate-labeled trastuzumab
Trastuzumab	heavy	chain:		
SC(8)DKTHTC(8)PPC(8)PAPELLGGPSVFLFPPKPK	
Fig. 251 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at the positions C2, C8 and C11. Labelling conditions: pH 8.5.
Trastuzumab	light	chain:		
ADYEKH(8)K	
Fig. 252 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at position H6. Labelling conditions: pH 8.5.
Trastuzumab	light	chain:	
(N-ter:8)DIQMTQSPSSLSASVGDR	
Fig. 253 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-





Fig. 254 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at position T7. Labelling conditions: pH 8.5 (-DTT control).
Trastuzumab	heavy	chain:	
(N-ter:8)EVQLVESGGGLVQPGGSLR	
Fig. 255 Peptide spectrum match of the indicated peptide modified with vinylphosphonothio-
late 8 at the N-terminus. Labelling conditions: pH 8.5 (-DTT control).
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